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Abbreviations 
°C   Degrees Celsius     
%   Percent 
FA   Fusidic acid 
BV   Betamethasone valerate 
MRSA   Methicillin-Resistant Staphylococcus aureus 
EF-G   Elongation factor G 
GCC   Glucocorticoid 
C-n   Carbon atom number n 
GCC-R  Glucocorticoid receptor 
TLC   Thin Layer Chromatography 
GC   Gas Chromatography 
LC   Liquid Chromatography 
HPLC   High Performance Liquid Chromatography 
UPLC   Ultra-High Performance Liquid Chromatography 
RP-HPLC  Reversed-Phase High Performance Liquid Chromatography 
N   Number of theoretical plates   
α   Selectivity factor 
k   Capacity factor 
Rs   Resolution 
w1/2   Peak width at half peak height 
HETP   Height equivalent of a theoretical plate   
A   Eddy diffusion term 
B   Longitudinal diffusion term 
u   Linear velocity in m s
-1
 
C   Mass transfer term 
m/sec
  
 Metres per second 
ml/min  Millilitres per minute 
t0   Dead time 
tR   Retention time 
RRT   Relative retention time 
UV-Vis  Ultra–violet / visible 
RI   Refractive index 
DAD   Diode Array Detector 
ELSD   Electronic Light Scattering Detector 
5 
MS   Mass spectrometry 
XRD   X-Ray Diffraction 
XRPD   X-Ray Powder Diffraction 
λ   Wavelength 
CCD   Charged Coupled Device 
mg/min  Milligrams per minute 
mg/min/cm
2
  Milligrams per minute per square centimetre 
Ph. Eur.   European Pharmacopeia 
Rpm   Revolutions per minute 
ml   Millilitre 
µl   Microliter 
mg   Milligram 
µm   Micrometre 
d   Density 
g/L   Grams per litre 
M   Molarity of a solution 
nm   Nanometre 
PL   Polylactide 
PCL   Poly(caprolactone) 
PLGA   Poly (lactic-co-glycolic acid) 
Mn   Molecular mass range 
w/w   Weight per weight in % 
Ga.   Gauge 
kV   Kilovolt 
IDR   Intrinsic Dissolution Rate 
API   Active Pharmaceutical Ingredient 
pKa   Acid dissociation constant 
LOD   Limit of detection 
LOQ   Limit of quantitation 
L   Length 
ID   Internal diameter 
C18   Octadecylsilyl silica gel 
O/W   Oil-in-Water Emulsion System 
ICH   International Conference on Harmonisation 
r   Correlation coefficient 
6 
r
2
   Coefficient of determination 
S-20   Macrogolstearylether-20 
S-21   Macrogolstearylether-21 
CSA   Cetostearyl alcohol 
HPMC   Hydroxypropylmethyl cellulose 
RH   Relative Humidity 
HLB   Hydrophilic Lipophilic Balance 
Σ   Sum of 
®   Registered Trade Mark 
ATR-FTIR  Attenuated Total Reflectance Fourier Transform Infrared  
   Spectroscopy 
PA   Peak Area 
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Abstract 
The research work presented in this thesis describes studies concerning the stability of 
the drug substances betamethasone 17-valerate and fusidic acid hemihydrate in topical 
pharmaceutical formulations. In particular, the work concentrates on formulation factors 
affecting the intra-molecular isomerisation of betamethasone 17-valerate to 21-valerate 
in a developmental topical cream for treatment of atopic dermatitis and psoriasis. 
Appropriate analytical tools for the simultaneous analysis of both drug substances have 
been developed and their suitability for use in the study demonstrated by validation 
experiments. The results of the isomerisation study indicate that the concentration of the 
emulsifier macrogolstearylether-21 significantly influences the isomerisation rate of the 
glucocorticoid. 5 % (w/w) of this substance in the formulation resulted in complete 
isomerisation within a number of months, whereas 1.5 % (w/w) gave rise to less than 3 
% isomerisation after 3 years storage. The study data was used to develop a new topical 
drug formulation containing both betamethasone 17-valerate and fusidic acid which 
went to market in early 2017. Additionally, the influence of the polymorphic form of 
fusidic acid on its stability was investigated. Fusidic acid is known to exist in 4 
polymorphic modifications and this study has shown that polymorphic forms I and III 
are currently available on the commercial market. Intrinsic dissolution – and in-vitro 
permeation studies demonstrate that both polymorphs have similar intrinsic dissolution 
rates, as well as comparable in-vitro release rates from the developmental cream. This 
indicates that both forms may be used interchangeably without affecting the safety and 
efficacy of concerned drug products. Finally, the plausibility of incorporating both drug 
substances into electrospun poly(caprolactone) (PCL) microfibers for potential use as an 
occlusive medicated dressing was examined. The effect of addition of the novel low 
molecular weight gelator, Fmoc-OH-C18, on the manufacture of the microfibers as well 
as on their in-vitro drug release rates was studied. The gelator was found to have a 
profound effect on the morphology of the resulting fibers but had little effect on the 
release rate of the active drug substances. The results suggest that the use of a medicated 
electrospun dressing containing betamethasone valerate and fusidic acid might be a 
viable treatment alternative to the current topical dosage forms. However, significant 
further work is needed in this regard. 
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CHAPTER 1 
 
Introduction 
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The purpose of pharmaceutical stability testing is to investigate how the quality of 
a drug substance or drug product varies over time under the influence of a variety 
of environmental factors such as temperature, light, and humidity; and to use this 
data to establish a suitable retest period for the drug substance or appropriate shelf-
life and storage conditions for the drug product under study 
1
. Stability testing 
therefore forms an integral part of the product development process, beginning 
with the manufacture of the very first trial formulations and continuing to the stage 
of marketing authorization and beyond. The stability data generated during the 
development phase forms a major part of the product quality dossier, and indeed, 
even after marketing authorization has been granted, the stability of the product 
must be monitored on an on-going basis, in order to ensure consistent product 
safety and efficacy. 
The goal of any drug product development is to obtain a stable product 
which does not degrade to a significant degree upon storage. Drug degradation may 
have several unwanted effects on the finished product, including loss of active 
substance leading to a corresponding loss of potency of the drug product; 
generation of potentially toxic impurities; changes to the aesthetic characteristics of 
the product, such as colour or odour; or degradation of preservatives, possibly 
leading to microbial contamination.  The degradation of drug substances in finished 
product formulations is usually the result of undesired chemical reactions. Such 
reactions include hydrolysis of esters; reaction of amines with reducing sugars 
(Maillard reaction); as well as transesterification and oxidation reactions, to name 
but a few. Examples of such unwanted side-reactions are described in the following 
3 real-life case studies from the pharmaceutical industry.  
Case 1: Dexpanthenol, a wound healing compound, is susceptible to 
hydrolysis in tablet formulations and degrades to form pantoic acid and 3-
aminopropanol 
2
 (Figure 1). If the pH conditions are suitable then pantoic acid may 
subsequently undergo an intra-molecular lactonisation forming pantolactone. This 
degradation reaction is extremely sensitive to the water content of the tablets and 
degradation rates of up to 10 % have been observed by this author in tablets stored 
 CHAPTER I – Introduction 1
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over 36 months at 25 °C/60 % relative humidity. The rate of degradation may be 
minimized by controlling the content of water in the product at the granulation and 
drying stages of manufacture. 
 
 
 
Figure 1 Schematic of the degradation of Dexpanthenol in Panthenol tablets 
 
Case 2: The analgesic compound acetylsalicylic acid, commonly sold under 
the brand name Aspirin®, is available in tablet form for the treatment of mild to 
acute pain. Stability studies have shown that if the water content of the tablets is 
sufficiently high, then the drug substance may be hydrolysed to salicylic- and 
acetic acid 
3
 (Figure 2) and it is not uncommon for aspirin tablets to smell of acetic 
acid after long-term storage.  
 
 
Figure 2 Hydrolysis of acetylsalicylic acid in a tablet formulation 
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Case 3: An example of a drug substance/excipient interaction involves the 
anti-viral compound acyclovir which is known to undergo a Maillard-type-reaction 
in tablet formulations containing the reducing sugar lactose 
4
. The interaction of 
both of these compounds results in the formation of an acyclovir-lactose 
condensation product (Schiff’s Base, Figure 3). 
 
 
Figure 3   Reaction of acyclovir with lactose in a tablet formulation 
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performance of drug-excipient interaction studies, whereby mixtures of the active 
drug substances and selected excipients are prepared and stressed in such a manner 
as to determine their likely compatibility in potential formulation candidates.  
In Europe, Japan and the United States the requirements for the design and 
implementation of stability studies is governed by ICH Guideline Q1A (R2) 
5
. 
Stability studies of drug substances in new drug products are classified into long-
term, intermediate and accelerated studies. In general cases, where studies are 
being performed in climatic zones I and II, long term stability studies should be 
performed at 25 °C/60 % relative humidity, intermediate studies at 30 °C/65 % 
relative humidity and accelerated studies at 40 °C/75 % relative humidity. For 
some products for which special storage conditions are required, e.g. refrigeration, 
the stability conditions may vary from those described above.  
 General Characteristics 1.2.1
Fusidic acid (FA) is a tetracyclic triterpenoid antibiotic chemically related to the 
steroids 
6,7
  but not showing any of the corticosteroid like activity associated with 
the former compounds 
8
. It was first isolated from the fermentation broth of the 
microorganism Fusidium coccineum by Godfredsen et al. at Leo Pharmaceutical 
Products in the early 1960s 
9–11
 and belongs to the small class of antibiotic 
substances known as the Fusidanes
 12
. These compounds are of fungal origin and 
are characterized by a common 29-nor Protostane structure (Figure 4)
 12
. To date, 
18 naturally occurring Fusidanes have been reported 
12
 with FA being the only 
representative of this group to have been used clinically 
13
. The substance has a 
limited spectrum of activity but is particularly effective for treatment of Gram-
positive bacterial infections; particularly those caused by Staphylococcus species 
14–16
. In-vitro experiments have also shown it to be effective against co-agulase 
negative staphylococci, cornyebacteria and gram-positive anaerobes 
10,17
. It shows 
little activity against streptococci and enterococci  and most Gram-negative species 
show complete resistance 
18
. 
 
 
 Fusidic acid – an antibiotic agent 1.2
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Figure 4 Chemical structure of 29-nor Protostane 
 
 
 Clinical use and side-effects 1.2.2
FA is primarily used for the treatment of Gram-positive bacterial infections 
10,19
 
and may be administered through several different routes. Available dosage forms 
include: creams and ointments for topical treatment of secondary skin infections 
13,16,20
;  tablets for the systemic treatment of conditions such as prosthetic joint- and 
bone infections 
21–23
, septic arthritis 
24
 or Staphylococcal bacteraemia 
25
; as well as 
parenteral dosage forms, e.g. for the treatment of Staphylococcal endocarditis 
26,27
.  
Eye drops are also available for the treatment of ocular infections caused by FA 
sensitive microbes 
28
.  
FA is licenced for use in Europe but has never been approved in the United 
States 
29
, although there are currently on-going efforts to attain its approval, given 
the ever growing problem of bacterial resistance to older antibiotics and the lack of 
new alternatives coming out of the development pipeline 
30
. The substance has 
regained popularity in recent years due to its low toxicity 
31,32
 and effectiveness in 
the treatment of methicillin-resistant Staphylococcus aureus (MRSA) 
14,15,17,33
, 
which is becoming and will continue to become a major problem in both clinical 
and community care in future years 
34,35
. In contrast to the high levels of resistance 
observed for many of the other widely used antibiotics, such as vancomycin and 
daptomycin 
36
, only relatively low levels of resistance to FA has been observed 
thus far in Staphylococcal isolates 
8,13
. This can be partially attributed to the low 
level use of this antibiotic since its discovery and its administration together with 
other anti-Staphylococcal agents, helping to minimize the formation of resistant 
clones 
17
. Recent studies however indicate that resistance is on the increase, 
partially due to the inappropriate use of FA in topical ointments and creams as a 
monotherapy for the treatment of acute skin infections 
17,37
.   
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Side effects of fusidic acid treatment may include jaundice due to impaired liver 
function 
25
, as well as upper gastrointestinal discomfort and diarrhoea when 
administered orally. Several case studies have reported the development of 
sensitisation during topical administration 
31,38
.  
 
 Mechanism of action and Structure-activity  1.2.3
  relationships 
FA blocks bacterial protein synthesis by binding to prokaryotic elongation factor G 
(EF-G) on the bacterial ribosome 
19,39
. This binding prevents the subsequent release 
of the EF-G complex  which results in the stalling of the elongation process, 
leading to a shut-down of the protein synthesis machinery of the bacterial cell 
40–42
. 
Structure-activity studies (Figure 5) have demonstrated that a number of structural 
features of the fusidic acid molecule are critical for its antimicrobial activity. It has 
been shown that, for example, the correct geometry of the Δ17(20) double bond 43, 
the presence of hydroxyl groups at both C-3 and C-11 as well as the presence of an 
ethoxy group at C-16 are required, since modification of these groups leads to a 
much reduced activity 
44
. Simultaneous oxidation of the hydroxyl groups at C-3 
and C-11 to form keto moieties leads to a reduction in activity to 1% of the original 
structure 
44
.  It has also been shown that a free carboxylic acid group is essential 
since derivatization of this group leads to a complete loss of activity 
44
. In contrast, 
the lipophilic side chain seems to be least sensitive to modifications, e.g. reduction 
of the Δ24 double bond leads to compounds with a similar activity to FA 44. FA is 
metabolised and excreted in the liver 
45
. 
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Figure 5 Essential features of the Fusidic acid molecule required for its antimicrobial 
activity 
 General Characteristics and History 1.3.1
Glucocorticoids (GCCs) are substances of both natural and synthetic origin which 
are considered to be chemical analogues of cholesterol 
46
 and whose existence in 
nature can be traced as far back as the pre-Cambrian period around 2.7 billion years 
ago 
47
. They have strong immunosuppressive, anti-mitotic and anti-inflammatory 
actions 
48–50
 and all possess a common cyclopentahydrophenanthrene skeleton, 
differing only in the substituents linked to the 17 carbon atoms, or in their 
stereochemical configuration. Miniscule quantities of active steroids were first 
isolated in the 1930s from adrenal glands 
51
. Among the isolated substances were 
the hormones cortisone and cortisol (hydrocortisone, Figure 6) which were later 
demonstrated by Hench et al. 
47
 to possess strong anti-arthritic properties. After this 
discovery many medicinal chemistry groups immediately sought suitable starting 
materials and synthetic processes that could be used for producing large amounts of 
cortisone, which went on to become the first steroid hormone to be produced on a 
large scale commercial basis 
51
 . The early success of cortisone was however short 
lived since it was subsequently discovered that long-term use led to severe side-
effects, including increased sodium retention, muscular atrophy, osteoporosis and 
hypertension 
52–55
.  
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In subsequent years attempts were made to synthesise new steroid variants 
with increased glucocorticoid and reduced mineral-corticoid activity, but no 
synthetic glucocorticoid more active than cortisone was discovered in the early 
years. This led to the widely held perception that it would be impossible to improve 
on the potency of the naturally occurring substances 
56
. In later years, however, 
several synthetic glucocorticoids were produced which showed much superior 
efficacy to cortisone.  
 
 Structure-Activity Relationships 1.3.2
After many years of experimentation it was discovered that modification of the 
type and stereochemistry of the substituents of the steroid backbone could lead to 
vastly improved glucocorticoid potency (Figure 7). In particular, it was found that 
modification of the C 1,2 single bond to a double bond led to a 4-fold increase in 
potency and reduced unwanted side-effects 
51
. This eventually led to the 
development of the compounds prednisone and prednisolone which quickly 
became the drugs of choice for the systemic treatment of inflammatory disease and 
remain so today. Addition of a C-16-α-hydroxyl- and a C9-α-fluoro group 
increased potency by a factor of 5 and helped to reduce the unwanted sodium 
retention properties. This variant was successfully marketed as triamcinolone 
51
. 
Replacing the C-16-α hydroxyl group with an α-methyl group further increased 
anti-inflammatory effects, leading to the eventual development of dexamethasone 
51
.  
Surprisingly, many of the newly synthesised steroids, although possessing 
potent systemic action, were found to be topically inactive 
47,51
. It was later 
recognized that in addition to biological activity the drug substances needed to 
have the appropriate physical properties such as solubility and lipophilicity in order 
to penetrate the skin and be topically effective 
51
.   
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Figure 6 Chemical structures of some common glucocorticoids  
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Experiments showed that a C-16, C-17 acetonide group was found to 
dramatically reduce the unwanted electrolyte retention properties of the fluorine 
groups and was subsequently discovered to increase skin permeability properties, 
resulting in improved percutaneous absorption 
51
. Further substitution of the 
hydroxyl group at C-21 by an acetate led to substances with even greater potential, 
e.g. hydrocortisone acetate. These esters were more resistant to hydrolysis and 
showed increased activity 
51
. Modern structure-activity models indicate that 
glucocorticoid binding affinity is dramatically increased by 6-α or 9-α halogenation 
and tends to increase with increasing lipophilicity 
51
. Fluorination also tends to 
protect the steroid ring from metabolic conversion. Models show good fitting of 
glucocorticoid 17-esters and unfavourable stearic interactions for C-21 esters with 
substituents larger than propionate 
51
.  
 
 
Figure 7 Essential features of glucocorticoids required for their gluco- and 
mineralcorticoid activity 
 
 Mechanism of Action 1.3.3
In vivo, approximately 95 % of GCCs are bound to plasma proteins including the 
specific steroid binding globulin, transcortin, which facilitates the transfer of 
GCCs to target tissues via the blood stream or tissue fluids 
57
. Once they have 
entered the target tissue GCCs function by binding to the glucocorticoid receptor 
(GCC-R) which belongs to the steroid-hormone-receptor family of proteins and 
which is found in the cytoplasm of almost all cell types
 58
.  Once bound, the GCC-
R-complex is translocated to the nucleus where it binds to specific target sites on 
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the genome, thereby initiating the synthesis of various proteins responsible for the 
observed anti-inflammatory effect. GCCs decrease the initial anti-inflammatory 
action by reducing capillary permeability, resulting in less leakage of proteins and 
fluids into the affected tissue and consequently less swelling. Exudation of 
macrophages and various other immune cells is also reduced by altering the 
endothelial sticking properties of these cells and reducing their ability to move 
through the capillary wall. 
 
 Betamethasone-17-valerate 1.3.4
Betamethasone is a synthetic glucocorticoid which is topically inactive and must 
therefore be administered in the form of one of its esters, such as betamethasone-
17-valerate (BV, Figure 8) or betamethasone-17,21-dipropionate.  The esterified 
forms generally have increased lipophilic nature allowing for better penetration of 
the drug molecule across the lipid membranes of the skin, thus enhancing the local 
bioavailability of the substance 
59
. BV was discovered in the 1960s using the 
McKenzie-Stoughton vasoconstriction assay 
60
, which is a screening method which 
classifies steroid potency based on their ability to cause vasoconstriction, i.e. 
narrowing of the blood vessels in the skin. BV has a potency of approximately 25 – 
30 times that of cortisol (hydrocortisone) and is classified as a moderate to high 
potency glucocorticoid depending on how it is formulated 
61
. When formulating 
BV the choice of vehicle used is extremely important since the substance is 
susceptible to an acid and base catalysed isomerisation in aqueous and semi-solid 
formulations, resulting in an acyl group migration from position C-17 to the more 
stable C-21 position of the steroid ring system 
62–64
. This isomerisation process is 
clinically relevant since betamethasone-21-valerate demonstrates only a fraction 
the potency of its 17-valerate counterpart 
60
.  
 
 
Figure 8 Chemical structure of betamethasone 17-valerate 
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 Psoriasis 1.4.1
Psoriasis is a lifelong, chronic, immune-mediated skin disease (Figure 9) which is 
auto-inflammatory in nature and affects approximately 1- 3 % of the Caucasian 
population 
55
.  It may appear at any age but appears before the age of 40 in an 
estimated 75% of affected individuals 
65
. The disease occurs to a similar degree in 
both men and women
 
and symptoms generally include itchy, round or oval scaly 
plaques frequently located on the scalp, lower back, umbilical region, intergluteal 
cleft, knees and elbows
 66
. Contributing factors to the disease include predisposing 
genetic factors,  stress, excessive alcohol consume, smoking and obesity 
65
.
 
 Some 
medications, such as ß-blockers, malaria tablets and lithium may cause the 
condition to flare 
65
. 
 
 
Figure 9 (a)  Example of psoriasis of the elbow showing the characteristic plaque formation; 
(b) graphical representation of the histopathology of psoriasis  
 
 
 
 
 Psoriasis and Atopic Dermatitis  1.4
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 Atopic Dermatitis  1.4.2
Atopic dermatitis, otherwise known as atopic eczema, is a complex skin disorder 
(Figure 10) caused by the interplay between multiple genetic and environmental 
factors 
67
. The term atopic is used to describe a group of conditions including 
asthma, eczema and hay-fever which show increased activity of the allergic 
component of the condition 
68
. It is caused by several factors including defects in 
the skin barrier and abnormalities in the normal inflammatory and allergic 
responses 
69
. The disease has a large genetic component and is linked to a defect in 
a gene responsible for producing the protein filaggrin, which is responsible for 
providing structural stability to the skin and thereby helping to ensure that the skin 
barrier remains intact 
70,71
. When defects in the skin barrier occur, the immune cells 
of the dermis are exposed to external antigens and initiate an anti-inflammatory 
response. The condition occurs in up to 20 % of children 
72
 and 1 % - 3 % of adults, 
with 40 % - 60 % of patients also having respiratory allergies 
69
. Due to the genetic 
involvement of the condition, atopic dermatitis tends to run in families. It is usually 
detected before the age of 2, with only 10 % of cases being detected after the age of 
5. 
 
 
Figure 10   (a) Example of atopic dermatitis of the hand in a young child; (b) micrograph of 
healthy skin showing the staining of filaggrin compared to diseased skin such as found in atopic 
dermatitis [reproduced from Irvine et al 
70
] 
 
Symptoms include extremely itchy, scaly skin lesions often located on the 
flexural surfaces of the body. In severe cases weeping and blistering of lesions may 
occur
 73
. Picking and scratching of the skin may lead to scarring and/or to 
secondary infections, for which an antibiotic such as fusidic acid may need to be 
prescribed 
69
. The condition is often associated with sleep disturbances. 
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 Treatments and Associated Side-Effects 1.4.3
The first line of treatment for both psoriasis and atopic dermatitis is topical therapy, 
including the application of emollients (e.g. E45 cream), calcineurin inhibitors (e.g. 
tacrolimus), keratolytics (e.g. salicylic acid), topical vitamin D analogues (e.g. 
calcipotriol) as well as topical corticosteroids, which are by far the most common 
treatment for both conditions. Such treatments may also be used complimentary to 
any systemic treatment, e.g. together with oral prednisone or dexamethasone.  
In Europe, glucocorticoids are classified into 4 sub-groups depending on 
their relative potencies. Low potency steroids are suitable for application to 
sensitive areas such as the face, armpits, and groin as well as being suitable for use 
by infants and children. Compounds belonging to this group include hydrocortisone 
and hydrocortisone acetate. Superpotency GCCs on the other hand (e.g. clobetasol 
17-propionate) are used for stubborn, cutaneous plaques or lesions on the palms, 
soles and scalp. Moderate potency (e.g. prednicarbate) and high potency GCCs 
(e.g. mometasone furoate) are generally used for the remaining areas of the body in 
adult patients. 
Long-term glucocorticoid treatment is associated with a number of severe 
side-effects which include skin- and muscle atrophy (Figure 11), the formation of 
cutaneous striae, cataracts as well as the development of osteoporosis and 
hypertension 
53,52
.  The skin- and muscle atrophy can be attributed to the reduced 
vascular blood supply and anti-mitotic effects of GCCs, whereas hypertension is 
exacerbated by the sodium retaining properties of some of the non-fluorinated 
steroid compounds, such as prednisolone and prednisone. GCCs also tend to 
increase intra-ocular pressure which may result in damage to the optic nerve, 
potentially leading to the development of glaucoma 
52
.   
 
Figure 11 Atrophic skin caused by the long-term use of topical steroids 
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The primary aim of the work in this thesis is to study the influence of drug product 
formulation on the stability of the drug substances betamethasone 17-valerate (BV) 
and fusidic acid hemihydrate (FA) in a developmental semi-solid cream 
formulation. In particular, the work will focus on factors affecting the intra-
molecular isomerisation of BV, since this process presents a significant challenge 
to the formulation chemist and the influence of the formulation on this process is 
not fully understood for such systems. The isomerisation of the 17-valerate ester is 
of clinical significance since the corresponding 21-valerate ester demonstrates only 
approximately 1/15
th 
of the potency of the C-17 ester 
60
. Much of the literature on 
this topic tends to concentrate solely on the role of pH in the isomerisation process. 
The work in this thesis studies the influence of factors other than formulation pH, 
such as for example, (i) the types and concentrations of excipients; (ii) the 
influence of oxidative processes and (iii) the effect of trace metals. 
Appropriate analytical tools for the simultaneous characterization of BV 
and FA in semi-solid formulations have not been published in the current literature. 
These must first be developed and their appropriateness for use in the study 
demonstrated by suitably designed validation experiments. These analytical 
procedures will then be employed to investigate the formulation factors influencing 
the stability of the aforementioned drug substances in semi-solid formulations. The 
ultimate goal is to use the knowledge gained through the study to develop a stable 
and marketable drug product formulation containing both FA and BV for the 
topical treatment of infected inflammatory skin conditions, including atopic 
dermatitis and psoriasis. 
Additionally, the influence of the polymorphic form of FA on its stability in 
bulk form will be investigated. FA is known to exist in 4 polymorphic 
modifications 
74
 and at least 2 of these polymorphs are currently available on the 
commercial market. The influence of the polymorphic form of commercially 
available FA on the intrinsic dissolution rate of the bulk substance as well as its 
release rate from a topical cream formulation will be investigated. 
Finally, the release rates of both BV and FA from electrospun 
poly(caprolactone) (PCL) microfibers will be studied with a view to investigating 
the plausibility of incorporating these drug substances into an electrospun bandage 
 Aims of Research 1.5
26 
for use in the treatment of patients for which a cream or ointment may not be 
practicable. The release characteristics of fibres with different drug loadings and 
with or without chemical modifiers will be investigated.  
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This thesis has been structured such that each chapter has its own short introduction and 
experimental section. Consequently, the main experimental chapter focuses 
predominantly on the theory and application of the analytical methods employed in the 
research and the analytical equipment used for the respective measurements. 
 Introduction 2.1.1
In an analytical chemistry setting it is often necessary to separate mixtures of chemical 
substances in order to identify, quantify or isolate one or more of the components of the 
mixture. The analytical discipline concerned with chemical separation is termed 
‘chromatography’, derived from the Greek ‘chroma’, meaning colour, and ‘graphein’, 
meaning to-write. The field of chromatography encompasses several different 
chromatographic techniques, including paper chromatography, thin-layer 
chromatography (TLC), gas chromatography (GC) and liquid chromatography (LC). 
Despite these different classifications, all chromatographic techniques are essentially 
based on a similar principle, which involves a mixture of analytes being transferred via 
a carrier through a stationary phase which retards the movement of the analyte in some 
fashion. Through the retardation of analytes, differences in both their physical and 
chemical characteristics are exploited. This results in analytes travelling at different 
rates through the stationary phase and leads to their separation. The degree of separation 
is dependent on the analyte-, stationary phase- and mobile-phase characteristics, e.g. 
hydrophobicity, pH or particle size.  
 In gas chromatography, for example, the mobile phase is a high-purity inert gas, 
usually Helium or Nitrogen, with the stationary phase being a solid coated with a thin 
layer of a high boiling-point liquid, e.g. dimethylpolysiloxane, which is responsible for 
retardation of the analytes. In the case of liquid chromatography, the stationary phase 
comprises of a solid substance, often porous silanised silica gel, and the carrier (mobile-
phase) is a liquid. The mobile phase may be aqueous, organic or a mixture of both, 
depending on the mode of chromatography being used, i.e. normal or reversed-phase. 
Many chromatographic techniques are performed at atmospheric pressure; High-
Performance Liquid Chromatography (HPLC), however, is a high pressure analytical 
technique operating at pressures of up to 400 bar. A modern variant of HPLC, namely 
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UPLC (ultra-high-pressure liquid chromatography), can be operated at even higher 
pressures of up to 1000 bar or more. Operating at high pressure results in faster and 
more efficient separations and it is for this reason that HPLC is the most widely used 
chromatographic technique in modern analytical laboratories. A high-performance 
liquid chromatograph comprises essentially of a mobile phase, a pumping system, a 
degassing unit, an injection system, an analytical column and its associated thermostatic 
oven, a detector, and a data management system. The function of each of these 
components is described in Table 1. 
 
Table 1  Basic components of a modern high-performance liquid chromatograph 
 
Component Function 
Mobile phase transfers the analyte through the chromatographic system 
Pump 
pumps the mobile phase at a constant rate through the chromatographic 
system 
Degassing unit removes dissolved gases from the mobile phase 
Injection system transfers an exact volume of the analyte solution into the chromatograph 
Analytical column retards the movement of the analyte 
Column-oven heats the analytical column to a required temperature 
Detector measures the analyte signal 
Data Management 
System 
converts the electrical signal coming from the detector to a visual output 
 
 
Figure 12  Basic components of a high-performance liquid chromatograph 
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 The objective of any HPLC separation is to obtain the best resolution between 
peaks in the shortest possible time. The resolution (Rs) between 2 peaks is governed by 
Equation 1 below, where N is the theoretical plate count, α is the selectivity factor and k 
is the retention factor. 
 
Equation 1 Rs = 
1
4
√N x (
∝-1
∝
)  x (
k
1+k
) 
 
 The theoretical plate count, N, is a measure of the efficiency of a 
chromatographic separation. In simple terms it is the relationship between the retention 
time (tR) and the width of the analyte peak measured at half peak height (w1/2). Efficient 
separations are those which give rise to sharp, narrow peaks. The theoretical plate count 
can be calculated using Equation 2.  
 
Equation 2  N = 5.54 (
tR
w1/2
)
2
 
 
 
Figure 13 Peak width at base and half peak height 
[1]
 
 
 When an aliquot of sample is injected into the HPLC system it is distributed on 
the stationary phase as a narrow band which gradually broadens as it travels through the 
analytical column. The degree of broadening may be modelled according to the Van-
Deemter equation, which describes the relationship between the height equivalent of a 
theoretical plate (HETP) and the linear velocity of the mobile phase. The equation is 
made up of the terms A, B, C and u (Equation 3, Figure 14), where the A term is known 
as the eddy-diffusion term, the B term is known as the longitudinal diffusion term, the C 
term is the mass transfer term and u is the linear velocity of the mobile phase in m s
-1
. 
 
Equation 3  H = A + (
B
u
)  + (C . u) 
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Figure 14 Van-Deemter Plot showing the influence of the A, B and C terms 
[2]
 
 
 The eddy diffusion term is related to the fact that not all analyte molecules take 
the same path through the stationary phase. Some molecules take a longer path and 
others a shorter path (Figure 15 a).  Eddy diffusion leads to a broadening of analyte 
peaks because molecules that travel a shorter path through the stationary phase reach the 
detector quicker than those which take a longer path. This term is independent of the 
mobile phase flow rate.  
 The B term represents longitudinal diffusion within the stationary phase. Since 
analyte molecules are free to move both with and against the direction of mobile phase 
flow, they may move in opposite directions resulting in peak broadening (Figure 15 b). 
The contribution of the B term is more significant at very low flow rates and decreases 
with increasing linear velocity. The B term does not make a significant contribution to 
peak broadening at normal flow rates, i.e. above 0.5 ml/min. 
 
 
 
Eddy diffusion 
 
 
Longitudinal 
Diffusion 
 
Figure 15  Eddy-diffusion (a) and Longitudinal-diffusion (b) 
 
 The C term is the mass transfer coefficient and describes the actual 
chromatographic process within the stationary phase, i.e. the interactions between the 
analyte molecules and the bonded phase. These interactions are enhanced at low flow 
rates because the analyte molecules have longer to interact with the stationary phase. 
a) b) 
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This suggests that lowering the flow rate should increase the plate count and provide a 
better resolution. However, the benefit obtained at lower linear velocity through an 
increased mass transfer coefficient is often offset by an increase of the diffusion term B, 
which increases significantly at very low flow rates.   
 The retention factor (capacity factor), k, is a measure  of the degree to which the 
analyte interacts with the stationary phase. If k is a low value then the analyte does not 
interact significantly with the stationary phase. In contrast, if k is a large value the 
interaction between the analyte and stationary phase is strong. Generally, 
chromatographers aim for a k value of between 2 and 5 for a target analyte. k values 
below 2 will not provide sufficient separation of analyte components and values above 5 
will unnecessarily increases the analysis time without bringing a significant 
improvement in resolution. The capacity factor is described by Equation 4, where tR is 
the retention time of the analyte and t0 is the dead time, i.e. the time required for an 
unretained substance, e.g. uracil, to travel through the HPLC system. 
 
Equation 4   k =  
tR – t0
t0
 
 
 The selectivity factor, α, is a measure of the ratio of the retention factors of 2 
substances in a HPLC separation. A selectivity factor of 1 indicates co-elution of both 
analytes. The larger the α-value, the further away the apices of both peaks are from each 
other. It may, however, not be presumed that both peaks are baseline resolved, since this 
is also dependent on the peak width, and therefore on the theoretical plate count. 
 
Equation 5  α =  
k2
k1
=  
tR2 - t0
tR1 - t0
 
 
 On examination of Equation 1 it is clear that doubling the theoretical plate count 
(N) will not double the resolution between 2 peaks, since the efficiency is governed by 
the term √N/4. In practical terms this means that the resolution cannot be doubled by 
doubling the length of the analytical column. It is also clear that doubling the retention 
factor (k) brings increasingly less benefit with each doubling of the retention time. The 
most efficient way to increase the resolution between 2 peaks is to increase the 
selectivity factor, α, by altering analyte/stationary phase chemistry. This may be 
achieved by employing an alternative stationary phase or by modifying the composition 
of the mobile phase.  
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 After separation of the analyte peaks in the stationary phase the analytes are 
carried via the mobile phase to the detector. The most commonly used detector is the 
UV-Vis detector which detects analytes based on their absorption of electromagnetic 
radiation of ultra-violet and/or visible wavelength (190 - 800 nm). For compounds 
which do not sufficiently absorb such wavelengths, a fluorescence detector may provide 
an alternative, provided that the compounds of interest fluoresce.  Fluorescence 
detectors may be several orders of magnitude more sensitive than standard UV-Vis 
detectors. Some analyte molecules do not contain a chromophore and can’t be detected 
using either UV-visible or fluorescence spectrophotometry. In such cases it may be 
possible to use a non-specific detector, such as a refractive-index (RI), light-scattering 
(ELSD), conductivity, electro chemical (ECD), or mass spectrometry (MS) detector.  
 
 
 General Procedures 2.1.2
 Sample preparation 2.1.2.1
The following procedure was employed for the preparation of cream samples: 
1 Weigh 1.00g of cream into a 50.0 ml volumetric flask 
2 Add 30 ml of acetonitrile and shake vigorously by hand. Suspend thoroughly using a vortexer 
3 Place in a water bath at 65°C for 5 minutes, shaking at regular intervals 
4 Shake for 10 minutes on a flat-bed mechanical shaker and make up to volume with acetonitrile 
5 Place in a freezer at approx. -20°C for 20 minutes 
6 
Centrifuge approx. 15 ml of the cold solution at ca. 3000 rpm for 5 minutes and transfer a portion 
of the cold supernatant to a volumetric flask. Allow to warm to room temperature 
7 Make a 1:2 (v/v) dilution with purified water, e.g. 5.0 ml to 10.0 ml 
8 Filter a portion of the solution through a 0.45 µm regenerated cellulose filter into a HPLC vial 
 
 Stress-testing of BVand FA 2.1.2.2
The procedures described below were used for stressing BV. In the case of FA the 
procedure remained largely unchanged with only the sample weight being increased 
from 5.0 mg to 80 mg. 
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Preparation of the analysis solution – Acidic Stress 
- Weigh 5.0 mg of the BV into a 50.0 ml volumetric flask 
- Add 30.0 ml of acetonitrile, 5.0 ml water and 1.0 ml of 1.0 M HCl 
- Shake on a flat-bed mechanical shaker for 4 hours 
- Adjust the pH to 7.0 ± 0.2 with 1.0 M NaOH and make up to volume with 
purified water 
- Dilute 1:2 (v/v) with purified water 
 
Preparation of the analysis solution – Alkaline Stress 
- Weigh 5.0 mg of BV into a 50.0 ml volumetric flask 
- Add 30.0 ml of acetonitrile, 5.0 ml of purified water and 1.0 ml of 1.0 M NaOH 
- Shake on a flat-bed mechanical shaker for 4 hours 
- Adjust the pH to 7.0 ± 0.2 with 0.1 M HCl and make up to volume with purified 
water 
- Dilute 1:2 (v/v) with purified water 
 
Preparation of the analysis solution – Oxidative stress 
- Weigh 5.0 mg of BV into a 50.0 ml volumetric flask 
- Add 30 ml of acetonitrile, 5 ml water and 0.5 ml of 30 % H2O2 
- Shake on a flat-bed mechanical shaker for 4 hours and make up to volume with 
purified water 
- Dilute 1:2 (v/v) with purified water 
 
Preparation of the analysis solution – Influence of Ultrasonic Treatment 
- Weigh 5.0 mg of BV into a 50.0 ml volumetric flask and add 35 ml of 
acetonitrile 
- Shake on a flat-bed mechanical shaker for 20 minutes and place in a USB bath 
for 1 hour (35 Hz, 120 W), making sure to change the water at regular intervals 
to compensate for temperature increases 
- Make up to volume with acetonitrile 
- Dilute 1:2 (v/v) with purified water 
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Preparation of the analysis solution – Temperature Stress 
- Heat a 1 g sample of bulk BV for 24 hours at 105 °C in an appropriate oven 
- Weigh 5.0 mg of the stressed BV into a 50.0 ml volumetric flask and add 35 ml 
of acetonitrile 
- Shake on a flat-bed mechanical shaker for 20 minutes 
- Make up to volume with acetonitrile 
- Dilute 1:2 (v/v) with purified water 
 
Preparation of the analysis solution – Daylight Stress 
- Transfer 1 g of BV into a clear glass GC vial, cover the sample with argon and 
leave standing on a window sill in direct sunlight for 72 hours 
- Weigh 5.0 mg of the stressed sample into a 50.0 ml volumetric flask and add 35 
ml of acetonitrile 
- Shake on a flat-bed mechanical shaker for 20 minutes and make up to volume 
with acetonitrile 
- Dilute 1:2 (v/v) with purified water 
 
Preparation of the analysis solution – Stability in solution 
- Weigh 5.0 mg of BV into a 50.0 ml volumetric flask and add 35 ml of 
acetonitrile 
- Shake on a flat-bed mechanical shaker for 20 minutes 
- Make up to volume with acetonitrile and dilute 1:2 (v/v) with purified water 
- Allow to stand at room temperature and for 7 days 
 
Preparation of the analysis solution – UV 254 nm 
- Place 1 g of BV on an appropriate petri-dish and spread thinly over the complete 
surface 
- Place the sample under a UV lamp set at 254 nm for 72 hours 
- Weigh 5.0 mg of the stressed BV into a 50.0 ml volumetric flask and add 35 ml 
of acetonitrile 
- Shake on a flat-bed mechanical shaker for 20 minutes and make up to volume 
with acetonitrile 
- Dilute 1:2 (v/v) with purified water 
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Preparation of the analysis solution – Control 
- Weigh 5.0 mg of unstressed BV into a 50.0 ml volumetric flask and add 35 ml 
of acetonitrile 
- Shake on a flat-bed mechanical shaker for 20 minutes and make up to volume 
with acetonitrile 
- Dilute 1:2 (v/v) with purified water 
 
Preparation of the analysis solution – pH-Stability 
- Weigh 25.0 mg of the active into a 50.0 ml volumetric flask 
- Add 15.0 ml of acetonitrile and 35.0 ml of the appropriate buffer solution  
- Measure the pH-value and, if necessary, adjust with dilute phosphoric acid or 
potassium hydroxide solution 
- Allow to stand at room temperature for 48 hours (protected from light) 
- Dilute 1:10 (v/v) with 50:50 acetonitrile/purified water (v/v) 
-  
 Preparation of Buffer Solutions used for Stress 2.1.2.3
Testing 
The buffer solutions employed in the pH-stability tests were prepared as described 
below using the following stock solutions: 
- 0.2 M hydrochloric acid solution / 0.2 M sodium hydroxide solution 
- 0.2 M potassium biphthalate comprising of 40.85 g of potassium biphthalate 
dissolved in 1000 ml of purified water 
- 0.2 M potassium monophosphate comprising of 22.22 g of potassium 
dihydrogen phosphate dissolved in 1000 ml of purified water 
- 0.2 M boric acid solution comprising of 12.37 g of boric acid + 14.91 g of 
potassium chloride dissolved in 1000 ml of purified water 
- 0.2 M potassium chloride solution comprising of 14.91 g of potassium chloride 
dissolved in 1000 ml of purified water 
 
 
Buffer pH 1.2 
Transfer 50 ml of 0.2 M potassium chloride solution to a 200.0 ml volumetric flask and 
add 85 ml of 0.2 M hydrochloric acid solution. Make up to volume with purified water. 
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Buffer pH 2.2 
Transfer 500 ml of 0.2 M potassium chloride solution to a 200.0 ml volumetric flask 
and add 7.8 ml of 0.2 M hydrochloric acid solution. Make up to volume with purified 
water. 
 
Buffer pH 3.2 
Transfer 50 ml of 0.2 M potassium biphthalate solution to a 200.0 ml volumetric flask 
and add 15.7 ml of 0.2 M hydrochloric acid solution. Make up to volume with purified 
water. 
 
Buffer pH 4.2 
Transfer 50 ml of 0.2 M potassium biphthalate solution to a 200.0 ml volumetric flask 
and add 3.0 ml of 0.2 M hydrochloric acid solution. Make up to volume with purified 
water. 
 
Buffer pH 5.2 
Transfer 50 ml of 0.2 M potassium biphthalate solution to a 200.0 ml volumetric flask 
and add 28.8 ml of 0.2 M hydrochloric acid solution. Make up to volume with purified 
water. 
 
Buffer pH 6.2 
Transfer 50 ml of 0.2 M potassium dihydrogen phosphate solution to a 200.0 ml 
volumetric flask and add 8.1 ml of 0.2 M sodium hydroxide solution. Make up to 
volume with purified water. 
 
Buffer pH 7.2 
Transfer 50 ml of 0.2 M potassium biphthalate solution to a 200.0 ml volumetric flask 
and add 34.7 ml of 0.2 M hydrochloric acid solution. Make up to volume with purified 
water. 
 
Buffer pH 8.2 
Transfer 50 ml of 0.2 M boric acid/potassium chloride solution to a 200.0 ml volumetric 
flask and add 6.0 ml of 0.2 M hydrochloric acid solution. Make up to volume with 
purified water. 
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 Equipment 2.1.2.4
All HPLC experiments described in this thesis were performed on Shimadzu 
Prominence HPLC systems (Shimadzu, Tokyo, Japan). The systems were equipped 
with a binary pump (LC-20AD), a temperature-controlled auto-sampler (SIL-20ACHT), 
a temperature-controlled column compartment (CTO-20AC) as well as an on-line 
degasser (DGU-20A5). A SPD-M20A diode-array detector (DAD) was employed for 
detection. The software packages used were SHIMADZU LCsolution version 1.24 SP1 
and SHIMADZU Class-VP version 6.14 SP2A. 
 
 
 Introduction 2.2.1
X-ray diffraction, commonly abbreviated as XRD, is an analytical technique used to 
obtain information about the structural arrangement of atoms and molecules within a 
crystal lattice. Comprehensive structural data may be obtained using the single-crystal 
x-ray diffraction technique which involves irradiation of a high quality crystal of the 
analyte with a beam of x-rays and recording the resulting diffraction pattern. Since the 
x-ray diffraction pattern is highly correlated with the 3 dimensional arrangements of 
atoms within the crystal lattice, it can be used to determine the particular crystal class 
and space group of the crystal lattice and can even be used to determine the exact 
molecular structure and stereochemistry of chemical substances. In many cases, 
however, it may be extremely difficult, or impossible, to obtain crystals of suitable 
quality and as such this technique is often not practicable for routine analysis in a 
pharmaceutical setting.  
 X-ray powder diffraction, or XRPD, provides a much quicker and routine-
friendlier alternative to single-crystal XRD. An XRP diffractometer comprises in 
principle of an x-ray source, a sample holder, a detector, and a goniometer for rotation 
of the sample within the x-ray beam (Figure 16 a). X-rays are produced by application 
of a 15 – 60 kV potential to a tungsten filament (cathode) within a sealed tube under 
vacuum. Electrons are ejected from the filament and strike an Anode producing x-rays 
according to an “inverse” photoelectric effect. The Anode is made of either Cr, Fe, Co, 
Cu, Mo or Ag; with Cu and Mo being the most common materials. The resulting x-rays 
are generally not monochromatic, instead comprising of both kα und kβ radiation 
(Figure 17). A beta filter, often comprising of an element just below the target material 
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on the periodic table, can be used to remove unwanted x-ray wavelengths. For example, 
if using a Copper anode, a Nickel beta filter may be used which has the potential to 
remove 50 % of kα and 99 % of the kβ radiation. Further selection may be obtained 
using a monochromator. 
 The sample is irradiated with a beam of monochromatic x-rays at an angle, θ, to 
the sample surface and the scattered x-rays are detected at an angle equivalent to 2θ of 
the angle of the incident beam (Figure 16 b). XRPD is based on the premise that a 
powder sample will present an infinite and entirely random selection of all possible 
crystal faces at the powder interface. In order to observe all potential lattice planes the 
sample is rotated within the x-ray beam whilst maintaining the detector angle 2θ to the 
incident beam. In single-crystal measurements x-rays are diffracted by the individual 
atoms in the crystal, with each atom being represented by a single point. In powder 
diffraction, however, x-rays are scattered not from a single crystal but from a 
theoretically infinite number of crystallites. This leads to the formation of a 
characteristic diffraction cone as illustrated in Figure 18 b. 
 
 
 
Figure 16 Example of the construction of a typical XRP diffractometer (a); illustration of the 
incident angle, θ, and diffraction angle, 2θ, of the employed x-ray beam  relative to the sample [3] 
 
 The reflected x-rays can be interpreted according to Bragg’s law provided 
below, where n is an integer (= 1,2,3,…) related to the order of the diffracted beam, λ 
represents the wavelength of the incident x-ray beam, d is the interplanar distance 
between lattice planes (d-spacing) and θ is the angle of the incident x-ray beam. 
 
Equation 6  nλ = 2d sinθ 
 
Bragg’s law allows for the calculation of the angle where constructive interference from 
x-rays scattered by parallel planes of atoms will produce a diffraction peak. Since the 
(a) (b) 
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wavelength λ is fixed, a family of planes produces a diffraction peak only at a specific 
angle 2θ. The resulting diffracted x-ray intensity is measured using a suitable detector 
and the resulting signals undergo mathematical treatment, including Fourier 
transformation. The mathematical calculations used to obtain a diffractogram from the 
detected signals are complex and must be performed by a computer. The end result is a 
typical diffractogram as exemplified in Figure 19. 
 
 
Figure 17 Spectrum of x-rays produced by bombardment of a copper anode with high energy 
electrons 
[4] 
 
 XRP detectors may be of the point- or position sensitive type. Point detectors 
observe one point in space at a time whereas position sensitive detectors cover a wider 
2θ range. Position sensitive detectors include charged coupled devices (CCD) and solid 
state semiconductor strips which observe all photons over a certain range. In practice, a 
single point scintillation detector is most commonly used. Such detectors work by 
converting diffracted x-rays to visible light by fluorescence. This is achieved with the 
aid of a NaI or YAP (Yttrium Aluminum Perovskite) crystal. The resulting light 
impulses are then detected and enhanced using a photomultiplier.  
 
 
Figure 18 Typical diffraction patterns of a single-crystal (a) and powder sample (b) 
[5]
 
  
 Powder diffractograms can provide information about the phase identity, phase 
composition and degree of crystallinity of a powder sample and this technique is the 
“gold standard” for the determination of polymorphism in pharmaceutical substances. 
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 Polymorphism can be described as the occurrence of different physical 
modifications of the same chemical substance which differ in the 3 dimensional packing 
of atoms and/or molecules within the crystal lattice. Nowadays, regulatory authorities 
place particular emphasis on the study of polymorphism in pharmaceutical substances 
since experience has shown that different polymorphs of the same substance very often 
possess different chemical and physical characteristics which can lead to a different “in-
vivo” performance of a drug product.  
 
 
Figure 19 Example XRD diffractogram of a powder sample 
 
 Since the XRP diffraction pattern of a substance is correlated to the 3 
dimensional arrangements of atoms and molecules within its crystal lattice, different 
polymorphs will inherently produce different XRP diffraction patterns. This property is 
made use of in the pharmaceutical industry as a tool to compare the crystalline 
structures of different batches of a chemical substance in order to ensure consistent 
batch-to-batch reproducibility.  
 An amorphous substance is a substance which, in contrast to a crystalline 
substance, does not possess any long-range structural order of atoms and/or molecules. 
For this reason, amorphous compounds do not produce diffraction peaks in XRD. 
Instead, they give rise to a characteristic “halo”, as illustrated in Figure 20 below. This 
fact is useful when determining the crystallinity of a substance using XRPD data. 
 
 
Figure 20 Characteristic “halo” in the XRP diffractogram of an amorphous substance 
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By obtaining both purely amorphous and purely crystalline samples of the substance of 
interest and preparing mixtures with different ratios of amorphous to crystalline 
substance, a calibration curve of the sum of the area of the diffraction peaks versus 
crystalline content can be generated. Pure crystalline substance can be obtained through 
recrystallisation and amorphous substance could be generated, for example, through 
freeze-drying of a solution of the substance.  
 
 General Procedures 2.2.2
All XRD experiments presented in this thesis were performed by the company Jesalis 
Pharma GmbH (Jena, Germany) using a Bruker D8 Advance (Bruker, Massachusetts, 
USA) diffractometer with parallel beam geometry; a Cu/Cu kα radiation source; and a 
LynxEye position sensitive detector with silicon strip detection technology. 
 
 Introduction 2.3.1
The solubility of pharmaceutical drug substances may be influenced by several factors 
including: the degree of crystallinity, the particle size and/or the specific surface area of 
the drug substance. The presence of polymorphism and pseudopolymorphism is another 
critical aspect to be considered; and it has been extensively documented in the literature 
that different polymorphs of a substance may possess different solubility properties, 
which may give rise to differences in their in-vivo bioavailability.  During drug product 
development it is often necessary to compare the relative solubilities of several 
polymorphs of a substance so that an informed decision can be made regarding the 
polymorph to be used in the final drug product formulation, so far as different 
polymorphs exist. The goal of such experiments is to compare the intrinsic solubility of 
the different polymorphs independent of any differences in their specific surface area 
and particle size distribution. Both these characteristics are unlikely to be identical 
between polymorphs and may have a large effect on the dissolution rate. It must be 
ensured in all experiments that the influence of surface area and particle size on the 
dissolution rate is the same for all polymorphs; since only then can a true comparison of 
the intrinsic solubility differences between polymorphs be made.  
 The intrinsic solubility of a substance may be evaluated by measuring its 
intrinsic dissolution rate. The intrinsic dissolution rate is defined as the rate of 
dissolution of a pure, compacted sample of a substance from a defined surface area. The 
procedure involves preparation of a compact of the substance in a hydraulic press 
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(Figure 21 A, B) and measurement of the dissolution rate of this compact in a suitable 
fluid medium at a specific pH, ionic strength, rotation speed and temperature, which are 
chosen based on the physico-chemical characteristics of the drug molecule. Since not all 
powders are suitable for compaction, the compactability and required press tonnage 
must be investigated individually for each substance prior to any quantitative 
measurement. The preparation of a compact ensures that neither the particle size nor the 
surface area have an influence on the dissolution rate, since inter-particle spaces are 
removed on compaction. When choosing a suitable dissolution medium for the test, it 
must be ensured that sink conditions are present. Sink conditions are said to be present 
if a maximum of 1/3 of the saturation concentration of the analyte were reached, if the 
complete sample of the drug substance were dissolved in the required volume of 
dissolution medium. The choice of the pH value of the dissolution medium is likely to 
be critical for ionisable substances. The intrinsic dissolution rate (mg/min/cm
2
) is 
calculated as the slope of the regression line (mg/min) obtained by plotting the amount 
of dissolved drug substance versus time; divided by the exposed surface area of the drug 
substance compact, which is a constant 0.5 cm
2
.  
 
 General Procedures 2.3.2
Intrinsic dissolution experiments described in this thesis were performed using an 
ERWEKA DT800 dissolution apparatus (ERWEKA, Germany) equipped with 6 
rotating cylinders as described in Ph. Eur. 2.9.29.  A rotation speed of 50 rpm and a 
medium comprising of 500 ml of 0.01M sodium hydroxide were used. Each compact 
was prepared by compacting 100 mg of sample at a force of 5 tonnes using a suitable 
hydraulic press. The experiment was performed at 37 °C. Preliminary experiments were 
performed in order to investigate the effect of rotation speed (50, 100 and 150 rpm) and 
press tonnage (3, 5 and 7 tonnes) on the release rate of the substance. The rotation speed 
was found to have a significant effect; with an increased rotation speed leading to a 
more rapid release rate.  The press tonnage had no effect on the release rate. Suitable 
conditions were chosen which would lead to approximately 10 - 20 % release of the 
drug substance over a reasonable time period. For the final analysis, samples were taken 
at 10, 20, 30, 40, 50 and 60 minute intervals with a total release of ca. 15 % of the drug. 
Samples were measured by UV-visible spectrophotometry at a wavelength of 240 nm 
using a Specord205 spectrophotometer (AnalytikJena, Germany).  
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Figure 21 Hydraulic press and utensils for compact preparation (a), sample holder (b), 
dissolution set-up (c) 
 
 
 
 
 Introduction 2.4.1
A membrane permeation study is an in-vitro study designed to mimic the diffusion of a 
drug substance out of topically applied pharmaceutical drug products, such as creams 
and ointments, across the epidermal-barrier to the target skin layers. Such tests are 
primarily used to compare the release rates of drug substances from different 
formulation candidates during product development and also as a quality control tool to 
monitor the batch-to-batch reproducibility of the release rate. The most common 
apparatus used for this test is the so-called “Franz-Cell” apparatus which is a vertical 
diffusion cell as shown in Figure 22/ Figure 23. The Franz-cell apparatus comprises of 6 
jacketed, diffusion cells connected by suitable tubing to a heated reservoir of fluid kept 
at a constant temperature of 32 °C using a suitable temperature bath.  A sample of the 
cream or ointment to be measured is placed in a specially designed donor compartment 
above the synthetic membrane (or skin sample). The reverse side of the membrane is in 
contact with the receptor medium, the composition of which is chosen based on the 
solubility properties of both the drug substance and drug product matrix. The receptor 
cell contains a magnetic stirrer which ensures that the correct hydrodynamic 
environment is present for an optimal drug diffusion rate. Samples are removed at 
predefined intervals through a sampling port and measured using an appropriate 
analytical procedure, e.g. HPLC.  
 
 
   
 
A B C 
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 General Procedures 2.4.2
For the experiments performed in this thesis a Franz cell apparatus (Hanson Research, 
Chatsworth, USA) comprising of 6 vertical diffusion cells was employed. Each 
diffusion cell contained a magnetic stirring bar and approximately 7 ml of a collector 
medium comprising of a mixture of 50:50 methanol/water (v/v). Porafil
®
 membranes 
(Macherey-Nagel, Germany) made from regenerated cellulose and having a porosity 
and diameter of 0.45 µm and 25 mm, respectively, were employed in all tests. 300 mg 
of the cream sample were used for each diffusion cell.  Sampling was performed at 
intervals of 60, 120, 180, 240 and 300 minutes and the samples were measured by 
HPLC. The HPLC method comprised of a Spherisorb ODS 2, 150 x 4.6 mm column 
packed with 5 µm particles and a mobile phase comprising of methanol, 10 g/L 
phosphoric acid, purified water and acetonitrile at a ratio of 10:20:20:50 v/v/v/v. The 
flow-rate, column-oven temperature and detector wavelength were 2.0 ml/Min, 25 °C 
and 235 nm, respectively. The method was run isocratically for 15 minutes and an 
injection volume of 15 µl was used. 
 
 
Figure 22 Franz-cell apparatus with thermostat and stirring unit (a), single vertical diffusion cell 
(b), and artificial membrane (c) 
 
 
 
 
Figure 23  Detailed illustration of a vertical diffusion cell 
[6] 
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 Introduction 2.5.1
Laser diffractometery is an analytical technique designed to measure the size 
distribution of particles in a given sample matrix, e.g. solid particles suspended in a 
liquid; where a particle may include: drops in a gas or liquid, solid particles in a gas or 
liquid, or gas bubbles in a liquid medium. Since individual particles may possess very 
different morphologies, e.g. spherical, plate or long needle-like forms, it is not possible 
to define the exact size of a real particle with a single number. Instead, particle size 
measurements are reported, not as absolute values, but as sphere-equivalent results, e.g. 
sphere equivalent volume. This is illustrated in Figure 24 a, where both the cylinder and 
sphere have the same volume but different morphologies. It is clear that at least 2 values 
are required to describe the size of the cylinder, but only 1 value is required to describe 
the sphere, namely the diameter. Particle size results are always to be understood as 
sphere equivalent approximations, regardless of the morphology of the particular 
particles. 
 A laser diffractometer works by illuminating a sample of particles with light 
from a laser source (HeNe gas laser, 466 / 633 nm) and measuring the scattering angles 
of that light after interaction with the particles (Figure 24 b). The optical system is 
constructed in such a manner that particles with the same size will scatter light onto the 
same position of the detector (Figure 24 c). In general, smaller particles give rise to 
larger scattering angles than larger particles; and it is this property which allows the 
scattering angle to be used to estimate the particle size. The detector is made up of 
multiple detection modules which are arranged such that a wide range of scattering 
angles may be detected, e.g., in the case of the Mastersizer 2000, which was used for 
experiments in this thesis, there are 52 detection modules. Subsequent to detection, the 
measured detector intensities are Fourier transformed and fitted to a suitable 
mathematical model.  
 There are currently 2 popular models in use which describe the light scattering 
characteristics of particles; these are the Fraunhofer- und the Mie Model. The 
Fraunhofer model is an approximation and is generally considered to be less accurate 
than Mie model. Mie theory provides a more accurate prediction of the scattering 
intensities for all incident wavelengths and scattering angles than the Fraunhofer model, 
particularly when dealing with particles below 50 µm in size. Particle size results are 
generally reported in the form of a particle size distribution (see Figure 24 d) which 
plots the volume percent (y-axis) against the particle size (x-axis, µ). 
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 General Procedures 2.5.2
All particle size measurements in this thesis were performed using a Malvern 
Mastersizer 2000 laser diffractometer with a Hydro 200S wet dispersion unit (Malvern 
Instruments Limited, UK). Purified water was obtained from the in-house purification 
system at mibe GmbH (Brehna, Germany). Fusidic acid hemihydrate was of Ph. Eur. 
grade and was obtained from OJSC Biosintez (Penza, Russia) and Ercros SA (Madrid, 
Spain). Betamethasone valerate was obtained from Crystal pharma (Valladolid, Spain). 
Polysorbat 80 was of synthesis grade and was purchased from Merck (Darmstadt, 
Germany). 
 
 Preparation of the sample solution – betamethasone 2.5.2.1
valerate 
Weigh 100 mg of sample into a suitable glass beaker and add 3 drops of polysorbate 80. 
Mix with the aid of a spatula until no further dry particles are observed and slowly add 
10 ml of purified water. Mix with the aid of a vortexer and sonicate for 60 seconds in an 
ultrasonic bath. Transfer the sample dropwise with the aid of a Pasteur pipette to the 
dispersion unit until an obscuration value of between 10 and 20 is reached.  Start the 
measurement. The mean value of 6 single measurements should be reported. The results 
should be reported as a % volume distribution.   
 
 
 Preparation of the sample solution – fusidic acid 2.5.2.2
hemihydrate 
Weigh 100 mg of sample into a suitable glass beaker and add 3 drops of polysorbate 80. 
Mix with the aid of a spatula until no further dry particles are observed and slowly add 
10 ml of purified water. Mix with the aid of a vortexer and sonicate for 60 seconds in a 
ultra-sonic bath. Transfer the sample dropwise with the aid of a Pasteur pipette to the 
disperging unit until an obscuration value of between 10 and 20 is reached. Start the 
measurement. The mean value of 6 single measurements should be reported. The results 
should be reported as a % volume distribution.  
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Figure 24 (a) Sphere equivalent volume, (b) diffractometer setup, (c) all particles of the same size 
are focused onto the same detector cell by the fourier lens, (d) example of particle size volume distrib-
ution 
 
 
 
 
 
(a) 
(b) 
(c) 
(d) 
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 Introduction 2.6.1
Electrospinning is a procedure for producing spun polymer threads or membranes, by 
application of a high voltage electric field to a drop of polymer fluid, usually 
comprising of a mixture of the required polymer, such as Polylactide (PLA) or 
Poly(caprolactone) (PCL), in a suitably volatile solvent. Application of the electric field 
causes the solution to become charged which in turn leads to droplet deformation 
(Taylor-cone formation). A charged jet is ejected from the tip of the cone which 
accelerates towards the counter electrode, leading to the formation of continuous fibers. 
Electrospun fibres have huge potential for use in biomedical applications, including 
tissue engineering and as bioresorbable wound dressings. One particularly interesting 
potential use of electrospun microfibers is in the topical- and systemic delivery of drug 
substances. Electrospun fibres have a large surface area allowing for relatively high 
drug loading capacities and have the added advantage of being modifiable, i.e. fibre 
thickness, solubility and pore size may be modified allowing for a tailored release rate 
of the drug substance.   
 
 General Procedures 2.6.2
 Drug-Polymer Solution Preparation 2.6.2.1
Electrospun fibres were prepared by dissolving the required quantity of drug substance 
in chloroform (HPLC grade, Sigma-Aldrich) and diluting this solution to the required 
concentration with a pre-prepared PCL solution comprising of 1 g of PCL (Mn 70.000 – 
90.000, Sigma-Aldrich) in a mixture of 7.5 ml of chloroform and 2.5 ml of ethanol 
(HPLC grade, Sigma-Aldrich). For example, co-loaded fibres containing 20 % FA 
(w/w) and 1.21 % BV (w/w) were prepared by dissolving 200 mg of FA in 1.0 ml of 
chloroform and mixing this solution with 1.0 ml of a solution comprising of 12.1 mg 
BV in 1.0 ml of chloroform. This mixture was then diluted to 10.0 ml with PCL 
solution. For fibres containing the gelator, Fmoc-C18-OH, an extra solution comprising 
of 1.5 mg gelator in 1.0 ml of ethanol was prepared, mixed with both drug substance 
solutions, and then made up to 10.0 ml with 7.0 ml of PCL solution. Appropriate control 
samples were also prepared.  
 
 Electrospinning 2.6
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  Electrospinning Set-Up 2.6.2.2
The electrospinning set up employed in all experiments consisted of a 10 ml syringe and 
stainless steel blunt-ended needle (18 Ga. 51 mm / pst3. Hamilton), a syringe pump 
(IVAC P3000) with a variable flow rate from 1 ml to 6 ml, a ground electrode and a 
high voltage power supply (0-20 kV, (PLS K007-20, Spraybase, Ireland)) 
 
 
Figure 25 Schematic of the electrospinning set-up used in this study 
 
 
 Analysis of the release rate of drug substance  2.6.2.3
The analysis of the release rates of FA and BV from the electrospun fibres was 
performed using the same Franz-Cell apparatus, experimental setup and analysis 
procedure as described in section 2.4.  
 
Agar diffusion experiments were performed using the Staphylococcus aureus bacterial 
strains: ATCC 6538P, ATCC 6538 and ATCC 29213. Additional tests were performed 
using the ATCC 12228 strain of Staphylococcus epidermidis. These strains were chosen 
because they are the designated reference strains as required by the European 
Pharmacopeia and used frequently in relevant literature 
26
. For safety reasons it was not 
possible to use clinical strains of MRSA. All microorganisms were obtained from the 
Leibnitz-Institut DSMZ - German collection of Microorganisms and Cell Cultures 
GmbH (Braunschweig, Germany). The test was performed by placing small discs of 
electrospun membrane, as well as diverse controls, on the surface of 4-5 mm thick agar 
plates (Tryptic Soy Agar, Merck/Millipore, pH 7.3 ± 0.2) inoculated with 24 hour 
cultures of the test microorganisms. Each strain was inoculated separately. Reference 
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solutions of fusidic acid prepared in buffer pH 6.0, which were required for comparative 
purposes, were placed in 6 mm cavities on separate agar plates which had been pre-
prepared using an appropriate sterile, stainless-steel punch. The concentration of fusidic 
acid applied to these cavities was equivalent to the concentration present in the 
equivalent area of electrospun disc and based on the minimum inhibitory concentration 
(MIC) of 1 mg/L for Staphylococcus sp. as detailed in the literature 
26,27
. Zones of 
inhibition were evaluated using a calibrated calliper (INSIZE, China) after incubation of 
the plates at 37 °C for 24 hours. 
 
Table 2  Overview of samples employed in the Agar Diffusion Test  
 
FUSIDIC ACID - Sample: Fusidic acid (Mic.); OJSC Biosintez; Lot: 831113 
FA, Filterpaper saturated with 25 µl of solution 50 µl FA solution filled into cavity 
Sample 
Name 
Quantity of Fusidic 
acid 
Quantity  
comparable  
with 
Sample 
Sample Name 
Quantity of Fusidic 
acid 
Quantity 
comparable 
with  
Sample 
G 200 µg B K 200 µg B 
H 350 µg C L 350 µg C 
I 450 µg D M 450 µg D 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N 0.25 µg < B, C & D 
O 2.5 µg < B, C & D 
P 25 µg < B, C & D 
R:  
Control Buffer pH 
6.0 
0 µg 
 
 
 
 
 
 
 
 
 
 In-Vitro Antimicrobial Efficacy Testing 2.7.1
Numerous methods are described in the literature for determining the antimicrobial 
efficacy of wound bandages 
23,28–37
. On review of this literature it was decided to 
employ 2 separate procedures (Methods A and B) to evaluate the antimicrobial 
effectiveness of the electrospun membranes. The procedures were designed to mimic 
the conditions present in an infected wound, i.e. moderate temperature and high 
humidity. All microbiological experiments were performed in the microbiology 
laboratory of mibe GmbH Arzneimittel by Ms. Sylvia Noll. The procedures were as 
follows: 
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 Method A (Membrane Filtration Method) 2.7.1.1
Three 2 x 2 cm pieces of each of the electrospun membranes to be examined (n=3, B, C 
and D) were placed on sterile petri dishes and 20 µl of inocula (equivalent to 10
9
 CFU), 
prepared using Staphylococcus aureus strains ATCC 6538 and ATC 29213 as well as 
Staphylococcus epidermidis strain ATCC 1228, were placed in the middle of each piece 
of membrane.  Each membrane was subsequently covered with a 1.5 x 1.5 cm piece of 
parafilm (microbiologically inert) in order to prevent it from drying out. The petri 
dishes were incubated at 20 – 25 °C in an 80 % humidity environment in order to 
simulate wound conditions 
38
.  After 24 hours the number of viable microorganisms was 
determined by transfer of the membrane samples into 100 ml of a recovery diluent and 
extracting by shaking and vortexing followed by appropriate serial decimal dilution. 
The membrane filtration method (according to Ph. Eur.2.6.12) was used to count the 
number of surviving bacteria (CFU/ml). The decimal log reductions in the number of 
viable micro-organisms were calculated against the value for the inoculum. The above 
mentioned diluent was phosphate buffer saline pH 7.2 with 3 % polysorbate. 
 
 Method B (Pour Plate Method) 2.7.1.2
Small discs of the electrospun membranes containing fusidic acid as well as diverse 
controls (diameter ca. 5 mm) were cut aseptically from the bulk material. Each piece of 
membrane was incubated for 48 hours at 35 – 37 °C with 1 ml of inoculum (equivalent 
to 10
10
 CFU)   in 48 well cell culture multiwall plates (CellStar, Greiner Bio-One).  The 
number of viable microorganisms was determined after 5, 24 and 48 hours by 
transferring 0.2 ml aliquots of the incubated inoculum into 1.8 ml of a phosphate 
buffered saline pH 7.2 recovery diluent and performing serial decimal dilution. The 
pour plate method (Ph. Eur., 2.6.12) was used for counting the number of surviving 
microorganisms (CFU/ml). The decimal log reductions in the number of viable micro-
organisms were calculated after 24 hours against the value for the inoculum. 
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In order for active drug substances to reach their target sites they need to be formulated 
and administered in a suitable pharmaceutical vehicle, e.g. cream, tablet or injection 
solution. Two requirements of any drug vehicle are (i) that the drug substance is 
sufficiently stable in the chosen vehicle and (ii) that the drug substance is released at an 
appropriate rate so as to guarantee that the efficacy of the drug product is acceptable and 
reproducible. The development of an appropriate formulation requires the employment 
of a stability-indicating analytical procedure which can quantify the active substances 
and preservatives, as well as impurities and degradation products, in relevant 
formulation candidates.   
Current international guidelines 
1,2
 require that the content and purity of active 
pharmaceutical ingredients (API) are analysed during both release and shelf-life testing 
of marketed drug products. This requirement ensures that the API does not degrade to 
such an extent that the efficacy of the product is diminished and also, that the levels of 
potentially toxic impurities, arising through degradation of the API, are maintained 
below specified limits 
3
. 
In the past, it was common in analytical laboratories to have several individual 
HPLC procedures for the separate analysis of APIs and preservatives in the same 
finished formulation. In recent times, however, there appears to be a trend towards 
developing a single procedure for the analysis of all components in a single 
chromatographic run. Examples include Shaikh et al 
4
, who developed a procedure for 
the simultaneous quantitation of chlorocresol, mometasone furoate and fusidic acid in a 
topical cream, and Goswami et al  
5
, who developed a procedure for the analysis of 
halometasone, fusidic acid, methyl paraben and propyl paraben in a single run. This 
trend has most likely been driven by advances in analytical technology such as Ultra-
Performance Liquid Chromatography (UPLC), as well as the availability of modern 
stationary phases with multiple selectivity modes and increased efficiency, e.g. mixed 
mode phases and sub 3 µm shell-core particle technologies. Cost efficiency and 
environmental awareness issues are also likely to have played a significant role.  
 
 
 CHAPTER 3 - Development of Analytical Procedures 3
 Introduction 3.1
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The principle objective of the work in this chapter was to develop analytical procedures 
based on HPLC and a suitable detection method (e.g. UV, ELSD, MS, RI) which could 
be employed for the stability-indicating content and purity analysis of formulation 
candidates of a developmental cream containing the drug substances BV and FA. The 
procedures were required to be based on HPLC since this technique is the most widely 
used for the analysis of pharmaceutical compounds and is available in most analytical 
laboratories, making transfer of the procedures between laboratories significantly easier.  
From the outset the objective was to employ a single assay procedure for the selective 
quantitative analysis of the two drug substances BV and FA as well as the preservative 
compounds methyl paraben, propyl paraben and potassium sorbate. The simultaneous 
measurement of all analytes of interest in a single HPLC run would enable a more cost-
effective assay analysis of formulation candidates. It was also envisaged to develop a 
separate procedure for the purity analysis of both APIs.  
The development of a single procedure for both assay and purity was initially 
considered but not deemed practicable since it was clear, due to the complexity of the 
samples, that a relatively long run time would be needed for the purity measurement. A 
long run-time for assay would, however, have been counterproductive, since in-process 
samples need to be measured quickly so that the manufacturing process can continue on 
to the next phase. It was envisaged that the developmental cream would be an oil-in-
water based emulsion system and contain the drug substances BV and FA suspended in 
a matrix of excipients, such as vaseline, liquid paraffin, gelling agents, emulsifiers and 
preservatives. 
The initial physico-chemical characterisation and early analytical development were 
performed using a model cream which had the same qualitative formulation as the final 
product but whose quantitative formulation was chosen based on the experience of the 
formulation chemist rather than on relevant stability data (see Chapter 5), i.e. the active 
substances and excipients were known but the quantities of each required to achieve a 
stable formulation were not. Nothing was known about the stability of the APIs in the 
cream base. The first task was to develop a basic sample preparation procedure. In order 
to do this, the solubility of the active substances and the cream base in different solvents 
used routinely in HPLC analysis was first investigated.  
 Aim 3.2
 Results and Discussion 3.3
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 Investigation of the Solubility of the Active Substances 3.3.1
The solubility of the active substances was investigated by adding 20 mg of each 
substance to 50.0 ml of selected solvents or solvent mixtures in an appropriate glass 
beaker and stirring for 10 minutes using a magnetic stirrer. The solubility was then 
determined visually at room temperature. The degree of solubility was assessed using 
criteria such as ‘completely dissolved after X minutes’, ‘does not dissolve well’ and 
‘insoluble’. The dissolution time was recorded as well as any relevant observations, e.g. 
aggregation, flocculation. The above procedure can be viewed as a “Quick-Test” which 
allows for a fast qualitative analysis of the solubility but without actual quantitative 
data. In most cases this test is sufficient to obtain a basic idea of the solubility of the 
API and/or drug product. The results indicated that both active substances are insoluble 
in purified water and soluble in common high polarity organic solvents such as 
methanol and acetonitrile which are relatively cheap solvents used frequently in RP-
HPLC analysis. A summary of the data is provided in Table 3. 
 
 Investigation of the Solubility of the Cream Base 3.3.2
The solubility of BV/FA cream base was investigated by suspending 500 mg of the 
cream in 20.0 ml of solvent and stirring for 10 minutes at room temperature. The same 
solvents as used for testing the solubility of the APIs were employed. The results were 
again evaluated visually. The purpose of the experiment was to gain information about 
which solvents were likely to be suitable for extracting the active substance from the 
cream base without dissolving unwanted matrix components.  From the data presented 
in Table 3 and Table 4 it was concluded that acetonitrile was a suitable solvent 
candidate since both active substances dissolve well in this solvent but the matrix 
components remain largely undissolved. This is to be preferred since large quantities of 
dissolved matrix components could potentially cause problems, such as peak tailing, 
double- or extraneous peaks, during HPLC analysis. 
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Table 3  Solubility of the active substances in selected solvents 
Solvent 
Observation 
BV 
Observation 
FA 
Purified water Insoluble Insoluble 
Methanol Completely dissolved after 2 minutes Completely dissolved after 3 minutes 
Acetonitrile Dissolved immediately Completely dissolved after 3 minutes 
2-Propanol Completely dissolved after 3 minutes Completely dissolved after 2 minutes 
Ethanol Completely dissolved after 2 minutes Completely dissolved after 2 minutes 
Ethanol/1-Butanol 
(50:50 v/v) 
Completely dissolved after 3 minutes Completely dissolved after 3 minutes 
Dichloromethane Dissolved immediately Dissolved immediately 
Ethanol/ 
Dichloromethane 
(50:50 v/v) 
Dissolved immediately Dissolved immediately 
 
 
Table 4  Solubility of BV/FA cream in selected solvents 
Solvent Observation 
Purified water Milky, well dispersed suspension without agglomerates 
Methanol Slow, incomplete dissolution 
Acetonitrile Does not dissolve well 
2-Propanol Slow, incomplete dissolution 
Ethanol Dissolves completely 
Ethanol/1-Butanol 
(50:50 v/v) 
Slow, incomplete dissolution 
Dichloromethane Fast, complete dissolution 
Ethanol/Dichloromethane 
(50:50 v/v) 
Fast, complete dissolution 
 
 
 Sample Preparation Procedure 3.3.3
Using the information obtained from the solubility tests and experience with other semi-
solid dosage forms, the initial sample preparation procedure provided in Table 5 was 
devised. 
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Table 5  Sample preparation procedure 
 
 Procedure Purpose of step 
1 Weigh 1.00g of cream into a 50.0 ml 
volumetric flask 
Weighing of sample 
2 Add 30 ml of acetonitrile and shake 
vigorously by hand. Suspend thoroughly 
using a vortexer 
Suspension of sample 
3 Place in a water bath at 65°C for 5 minutes, 
shaking at regular intervals 
The increased temperature allows for complete 
suspension of the sample by facilitating the melting 
of the fatty components, e.g. vaseline 
4 Shake for 10 minutes on a flat-bed 
mechanical shaker and make up to volume 
with acetonitrile 
Extraction of the analytes from the matrix 
5 Place in a freezer at approx. -20°C for 20 
minutes 
‘Freezing out’ of any partially soluble matrix 
components which may have dissolved on heating of 
the sample 
6 Centrifuge approx. 15 ml of the cold 
solution at ca. 3000 rpm for 5 minutes and 
transfer a portion of the cold supernatant to 
a volumetric flask. Allow to warm to room 
temperature 
The cold solution is centrifuged in order to remove 
unwanted matrix components. The cold solution is 
used because the unwanted matrix components are 
less soluble at lower temperature. Allowing the 
supernatant to warm to room temperature before 
dilution helps to prevent temperature-related 
dilution errors 
7 Make a 1:2 dilution with purified water, 
e.g. 5.0 ml to 10.0 ml 
This step is performed in order to increase the 
polarity of the sample solution. This ensures good 
peak shape during HPLC analysis. The injection of 
a sample in pure acetonitrile combined with an 
aqueous mobile phase would lead to severe peak 
fronting. The dilution with purified water also helps 
to remove unwanted matrix components  
8 Filter a portion of the solution through a 
0.45 µm regenerated cellulose filter into a 
HPLC vial 
Filtration of the sample to remove unwanted 
particulates. A regenerated cellulose filter was used 
because it is standard in the laboratory and is 
compatible with the employed solvents. Recovery 
rates were acceptable. 
 
 
 Development – Purity Method 3.3.4
As previously mentioned, current guidelines governing the quality of marketed drug 
products require that the degradation of active drug substances is monitored throughout 
the shelf-life of the product. A literature search of published analytical methods which 
might be suitable for the required analysis was performed but none of the reported 
methods were suitable for the simultaneous analysis of impurities of both BV and FA in 
a single chromatographic run.                
Analytical procedures have been published for the analysis of the single APIs in 
topical formulations. For example, Po et al. 
6
 developed a HPLC procedure for the 
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analysis of BV and its degradation products in topical preparations. However, the vast 
majority of published methods were only suitable for the analysis of the main 
component, i.e. the API, and did not consider potential impurities. Furthermore, many 
of the published procedures were often poorly selective, i.e. could not measure the 
analyte of interest unequivocally without interferences from other sample components. 
Such methods were often based on UV-Vis spectrophotometry 
7
 or atomic absorption 
spectrometry 
8
 which are no longer considered to be state-of-the-art or stability-
indicating. Shaikh et al.  
4
 published a method for the simultaneous quantitation of 
chlorocresol, mometasone furoate and FA in creams which is capable of separating and 
quantifying the impurity 3-didehydrofusidic acid (3-ketofusidic acid), which is one of 
the main impurities of FA. However, 14 other impurities related to FA have been 
described, many of which are potential degradation products 
9
 (Figure 26). These 
impurities have not been considered in any of the peer-reviewed literature methods 
found. Consequently, it was necessary to develop a novel procedure for the selective 
analysis of impurities of both active substances. 
 
 Initial Chromatographic Conditions 3.3.5
FA has a single carboxylic acid functional group which has a pKa of 5.3 
10
. 
Consequently, the retention time of FA in an RP-HPLC system will be influenced by 
the pH of the mobile phase 
11
. A suitable mobile phase should have a pH of 2 units 
below the pKa of the acidic group 
12
, ensuring that the molecule remains completely 
protonated in solution and therefore enhancing hydrophobic interactions between the 
analyte and the stationary phase. The impurities of fusidic acid (see Table 8) are either 
acidic, as FA, or neutral compounds. For this reason a mobile phase acidified with 
phosphoric acid was chosen. BV and its impurities betamethasone and betamethasone 
21-valerate are neutral compounds and their retention on the analytical column should 
not be affected by pH. 
 The chosen starting conditions comprised of mobile phase A made up of a 
20:20:40:40 (v/v/v/v) mixture of methanol, acetonitrile, purified water and a 10 g/L 
solution of phosphoric acid (85 % w/w) and mobile phase B comprising of a 22:70:4:4 
(v/v/v/v) mixture of the same solvents. The gradient program started with 100 % mobile 
phase A held for 3 minutes followed by an increase to 100 % mobile phase B over the 
next 25 minutes. 100 % B was then held for a further 10 minutes before returning to the 
start conditions. The total run time was 60 minutes. The initial flow-rate was 1.0 ml/min 
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and 20 µl of sample were injected. Detection was performed at 235 nm using a UV-Vis 
detector. 
 
Figure 26  Structures of some of the major degradation products of BV and FA 
 
 
Through column screening experiments it was found that a YMC-Pack Pro C18, 
150 mm x 4.6 mm column with 3.5 µm particles provided the best overall separation of 
all impurities, although several impurities were still not satisfactorily separated. In order 
to achieve an acceptable separation, the gradient program, column-temperature, flow-
rate and mobile phase composition required optimisation.  
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 Optimisation 3.3.6
 Optimisation – Gradient program 3.3.6.1
A combination of modification of the initial part of the gradient program from 100 % A 
for 3 minutes to 95:5 (v/v) A/B for 20 minutes and reduction of the flow rate to 0.7 
ml/min was found to increase resolution between all of the peaks eluting in the early 
part of the chromatogram. It was also found that reducing the quantity of methanol in 
mobile phase A from 200 ml to 170 ml per litre enabled a better separation between the 
impurities betamethasone-21-valerate and 26-oxofusidic acid  as well as between the 
impurities (24R)-24,25-dihydroxyfusidic acid-21,24-lactone and 26-hydroxyfusidic 
acid. The above optimisation steps enabled an acceptable separation of the 2 previously 
co-eluting peak pairs as demonstrated by Figure 27 and Figure 28. 
 
 Optimisation - Sample weight / injection volume 3.3.6.2
Very early on during method development it became apparent that an injection volume 
of 20 µl was not sufficient to achieve a limit of quantitation (LOQ) of below 0.1 %, 
which is the reporting threshold required by the relevant guideline 
3
. The injection 
volume was increased to 150 µl and the limits of detection and quantitation were re-
calculated using Equation 7 and Equation 8. The LOQ may be defined as the lowest 
concentration of analyte which can be accurately and precisely quantified by the 
analytical system and is related to the limit of detection (LOD) which is the lowest 
quantity of analyte which can be detected by the analytical system.  
 
Equation 7  LOD = 
H(N) x 3 x c(S)
H(S) x 2  
 
Equation 8  LOQ = 
H(N) x 10 x c(S)
H(S) x 2
 
 
Where,  
H(N) = Height of noise in millivolts (mV) or  absorption units (AU) 
c(S) = Concentration of test solution in % 
H(S) = Height of signal in mV or AU 
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Figure 27  Chromatogram of BV/FA cream measured using the initial procedure and 
demonstrating the co-elution of peaks 5 and6 as well as 8 and 9. The HPLC conditions are provided in 
section . The sample was prepared as described in Table 5. 
 
 
Figure 28  Chromatogram of BV/FA cream measured with the optimized procedure. The peak 
pairs which were co-eluting in Figure 27 are now separated. The HPLC conditions are provided in 
section 3.3.6.1. The sample was prepared as described in Table 5. 
 
1. Betamethasone    8.   Betamethasone-21-valerate  15. Deacetylfusidic acid-21,16-lactone 
2. 24,25-dihydro-24,25-dihydroxyfusidic acid  9.   26-oxofusidic acid   16. 11-deoxyfusidic acid               
3. 24,25-dihydro-24,25-dihydroxyfusidic acid-21,25-lactone 10. 3-didehydrofusidic acid   U = unknown impurity  
4. Betamethasone-17-valerate   11. 11-didehydrofusidic acid   
5. (24R)-24,25-dihydro-24,25-dihydroxyfusidic acid 21,24-lactone  12. 16-epideacetylfusidic acid   
6. 26-hydroxyfusidic acid    13. Fusidic acid    
7. (24S)-24,25-dihydro-24,25-dihydroxyfusidic acid 21,24-lactone 14. 16-epideacetylfusidic acid-21,16-lactone 
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Table 6  LOD and LOQ values with 1 g of sample and 150 µl injection volume 
Substance LOD, % LOQ, % 
FA 0.0079 0.0264 
BV 0.0633 0.2110 
 
The LOQ value of 0.21 % for BV did not meet the required specification of ≤ 0.1 %. 
There were 2 practicable solutions for decreasing the LOD, i.e. the sensitivity, of the 
procedure. These were 1) to further increase the injection volume and/or 2) to increase 
the analyte concentration in the sample solution. The injection volume of 150 µl was 
already too large for many of the HPLC instruments in the laboratory, which were only 
fitted with 50 µl sample loops. A reduction of the injection volume to 50 µl had 
previously been envisaged in order to increase flexibility within the laboratory by 
enabling the method to be run on all HPLC systems. Additionally, a further increase of 
injection volume was likely to lead to peak deformation due to overloading of the 
HPLC column, leaving an increase of the analyte concentration in the sample solution 
as the only practicable option.  
The analytical procedure was modified by increasing the sample weight from 1.0 
g to 5.0 g and reducing the injection volume from 150 µl to 50 µl.  The LOD and LOQ 
values were recalculated under the optimised conditions (Table 7). With the revised 
sample weight and injection volume the required LOQ level of ≤ 0.1 % was obtained. 
 
Table 7  LOD and LOQ values with 5 g of sample and 50 µl injection volume 
Substance LOD, % LOQ, % 
FA 0.0033 0.0109 
BV 0.0291 0.0972 
 
 
 Identification of Impurities 3.3.7
The available impurities of BV (namely, betamethasone and betamethasone 21-valerate) 
were identified by dissolving an appropriate quantity of each compound in the sample 
solvent and injecting them into the HPLC. Their respective retention times and relative 
retention times were recorded and compared to the peaks in the sample solution. For the 
known impurities of FA, which were not available as pure substances, the EP standards 
fusidic acid for peak identification CRS and fusidic acid impurity mixture CRS were 
used. EP and CRS refer to European Pharmacopeia and Chemical Reference Substance, 
respectively. A summary of the investigated relative retention times (rrt) of the BV and 
FA impurities is provided in Table 8.  
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Table 8  Nomenclature and rrt values of BV and FA impurities 
Nomenclature according to the                                         
current Ph. Eur. monograph 
 
Impurity Label rrt value  
(relative to the 
fusidic acid peak) 
Betamethasone - 0.11 
Betamethasone-17-valerate API - 
Betamethason-21-valerate - 0.43 
24,25-dihydro-24,25-dihydroxyfusidic acid Impurity A 0.26 
24,25-dihydro-24,25-dihydroxyfusidic acid 21,25-lactone Impurity B 0.31 
(24R)-24,25-dihydro-24,25-dihydroxyfusidic acid 21,24-
lactone 
Impurity C 0.36 
26-hydroxyfusidic acid Impurity E 0.38 
(24S)-24,25-dihydro-24,25-dihydroxyfusidic acid 21,24-
lactone 
Impurity D 0.41 
Impurity N Impurity N 0.42 
26-oxofusidic acid Impurity F 0.46 
3-didehydrofusidic acid Impurity G 0.68 
11-didehydrofusidic acid Impurity H 0.73 
16-deacetylfusidic acid Impurity O 0.84 
16-epideacetylfusidic acid Impurity I 0.92 
Fusidic acid API - 
16-epideacetylfusidic acid 21,16-lactone Impurity J 1.19 
Deacetylfusidic acid 21,16-lactone Impurity K 1.25 
9,11–anhydrofusidic acid Impurity L 1.31 
11-deoxyfusidic acid Impurity M 1.36 
 
 Final HPLC Method 3.3.8
After the method optimisation studies, the conditions used in the final HPLC method for 
the analysis of BV/FA Cream are detailed in Table 9. 
 
 Table 9  Final HPLC Conditions 
 
 
HPLC Column  - YMC-Pack Pro C18, 150 mm L x 4.6 mm ID, 3 µm particles 
Guard Column - C18,  4.0 mm L x 3.0 mm ID  
Flow rate ml/min 0.7 
Mobile Phase A 170 ml methanol + 215 ml 10 g/L H3PO4 + 215 ml purified water + 400 
ml acetonitrile 
B 220 ml methanol + 40 ml 10 g/L H3PO4 + 40 ml purified water + 700 
ml acetonitrile 
Wavelength nm 235 
Column temperature °C 40 
Auto-sampler 
temperature 
°C 4 
Gradient  - Time Event  % A % B 
0 Pump A B 95 5 
20 Pump A B 95 5 
45 Pump A B 0 100 
50 Pump A B 95 5 
60 Pump A B 95 5 
Injection volume µl 50 
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 Example Chromatograms 3.3.9
 Placebo (cream without  the active substances)  3.3.9.1
 
 
 BV/FA Cream 3.3.9.2
 
 
Figure 29  (a) Placebo without the active substances (b) Chromatogram of a degraded cream 
sample analysed after stressing under the conditions of 40 °C/75 % RH at pH 7 for 2 months. The sample 
demonstrated significant degradation. HPLC conditions as provided in section 3.3.8. Peak 3 was not 
present in this particular sample 
 
1. Betamethasone    8.   Betamethasone-21-valerate  15. Deacetylfusidic acid-21,16-lactone 
2. 24,25-dihydro-24,25-dihydroxyfusidic acid  9.   26-oxofusidic acid   16. 11-deoxyfusidic acid               
3. 24,25-dihydro-24,25-dihydroxyfusidic acid-21,25-lactone 10. 3-didehydrofusidic acid   U = unknown impurity  
4. Betamethasone-17-valerate   11. 11-didehydrofusidic acid   
5. (24R)-24,25-dihydro-24,25-dihydroxyfusidic acid 21,24-lactone  12. 16-epideacetylfusidic acid   
6. 26-hydroxyfusidic acid    13. Fusidic acid    
7. (24S)-24,25-dihydro-24,25-dihydroxyfusidic acid 21,24-lactone 14. 16-epideacetylfusidic acid-21,16-lactone 
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The target analytes for the assay method were the 2 active substances BV and FA as 
well as the preservative compounds potassium sorbate, methyl paraben and propyl 
paraben. The chemical structures of theses analytes are provided in Figure 30. 
 
 
Figure 30 Chemical structures of methyl paraben (a), propyl paraben (b), potassium sorbate (c), 
BV (d) and FA (e) 
 
 The first step of the development process involved a search of the current 
literature for appropriate published methods which could be used or adapted to tackle 
the current analysis needs. No analytical procedures were found which were suitable for 
the simultaneous analysis of all 5 analytes of interest in a single chromatographic run. 
As already mentioned in section 3.3.4, the majority of reported methods were only 
suitable for the analysis of a maximum of 1 or 2 of the compounds of interest 
6,7,8,13
 and 
were often based on poorly selective procedures 
7,8
. It was therefore necessary to 
develop a novel procedure specific to the required analysis. 
As previously discussed, the acidic nature of FA means that its retention on the 
HPLC column will be influenced by the pH of the mobile phase. To achieve an 
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acceptable retention of this compound on a C18 column, it needs to remain in its 
protonated form in solution so that it can interact sufficiently with the stationary phase. 
BV, as well as methyl- and propyl paraben are neutral compounds whose retention 
times will remain largely unaffected by pH. Potassium sorbate is the potassium salt of 
sorbic acid and may be present in either ionised- or non-ionised form in aqueous 
solution. The retention time of the dissociated form will be influenced by the pH of the 
mobile phase since the sorbate anion may become protonated depending on its pKa 
value and on the pH of the sample solution/mobile phase 
11,12
. The compound will only 
be reproducibly retained in its protonated form, i.e. as sorbic acid, which has a pKa 
value of 4.8 
14
, necessitating the use of a mobile phase with a pH of 2.8 or lower, i.e. 2 
pH units below the pKa of the strongest acidic group in the analytes of interest. 
 
 Initial Chromatographic Conditions  3.4.1
After consideration of the points discussed in the previous section, an acidic mobile 
phase containing 10 g/L phosphoric acid (85 % w/w) and having a pH of approximately 
1.6 was chosen as mobile phase A. Mobile Phase B comprised of an 83:17 (v/v) mixture 
of acetonitrile and methanol. For the initial experiments a Nucleosil
®
 C18 100-5, 250 
mm L x 4.6 mm ID column with 5 µm particles was chosen. The oven-temperature; 
detector wavelength; and injection volume used were 25 °C; 240 nm and 50 µl, 
respectively.  
It was considered unlikely that an isocratic run with the above mobile phases 
would be sufficient to provide a stability-indicating separation of such a highly complex 
mixture of analytes with very different polarities (2 APIs + 3 preservatives + 16 main 
impurities + matrix). It was decided to perform an initial 60 minute gradient run 
beginning with a high proportion of aqueous phase followed by a gradual increase of 
the proportion of organic solvent. The initial conditions chosen  for the gradient 
program were 60 % mobile Phase A (aqueous) and 40 % mobile phase B (organic) held 
for 10 minutes, after which the percentage of B was increased to 100 over the next 30 
minutes and held at this concentration for a further 10 minutes. After returning to the 
initial conditions over a period of 5 minutes, the system was equilibrated for a further 5 
minutes giving a total run time of 60 minutes. The initial flow rate was 1.0 ml/min 
(Table 10). 
 A sample of BV/FA cream was prepared according to the procedure described in 
section 3.3.3 and analysed according to the described method.  As demonstrated by 
Figure 31, all target peaks eluted before 30 minutes, indicating that a run time of 60 
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minutes was unnecessarily long. It was also evident that several of the early eluting 
peaks were insufficiently resolved (0 - 10 minutes), as in the case of potassium sorbate 
and methyl paraben which were co-eluting. The same experiment was repeated with a 
more hydrophobic Gemini C18 column (250 mm L x 4.6 mm ID, 5 µm) and a more 
polar Spherisorb ODS 2 (250 mm L x 4.6 mm ID, 5 µm) column, but neither column 
provided an acceptable separation.  
 
Table 10 Initial chromatographic conditions 
 
 
Figure 31  Chromatogram of BV/FA cream spiked with the impurities betamethasone, 
betamethasone-21-valerate and 3-didehydrofusidic acid. Chromatographic conditions as provided in 
Table 10. Peak assignment: coelution of potassium sorbate and methyl paraben (1), betamethasone (2), 
Unknown (3), Unknown (4), BV (5), betamethasone 21-valerate (6), 3-didehydrofusidic acid (7) and FA 
(8) 
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Column description - Nucleosil C18 100-5 (250 mm L x 4.6 mm ID) 
Flow rate ml/min 1.0 
Mobile Phase A 500 ml 10 g/L phosphoric acid  + 500 ml purified water 
B 833 ml Acetonitrile + 167 ml Methanol 
Wavelength nm 240 
G
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Time (Min.) Event  % A % B 
START Pump A B  60 40 
10.0 Pump A B  60 40 
40.0 Pump A B  0 100 
50.0 Pump A B  0 100 
55.0 Pump A B  60 40 
60.0 STOP - - 
Injection volume µl 50 µl 
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 Optimisation  3.4.2
 Optimisation – Run time 3.4.2.1
The initial experiments showed that a run time of 60 minutes was not necessary since all 
target analytes eluted within 30 minutes. The mobile phase flow-rate and gradient 
program were therefore optimised as detailed in Table 11 with the aim of reducing the 
run time. 
 
Table 11 Modified Gradient I 
 
 
 
 
 
 
 
 
 
 Using the modified gradient program a sample of BV/FA cream, which had been 
spiked with the impurities betamethasone, betamethasone-21-valerate and 3-
didehydrofusidic acid, was analysed. All peaks of interest eluted within 27 minutes. To 
aid identification of the impurities, active substances and preservatives, standard 
solutions of the substances were also injected. The results indicated that the potassium 
sorbate and methyl paraben peaks continued to co-elute.  
 
 Optimisation - Column temperature 3.4.2.2
In an attempt to enhance analyte-stationary phase interactions, the column-oven 
temperature was reduced from 25 °C to 20 °C. This would normally lead to a longer 
retention time of the analyte which can, in some circumstances, help to improve 
resolution. On this occasion it proved to be unsuccessful. An increase of the column 
temperature was not considered at this point because this would have reduced the level 
of interaction between analyte and stationary phase, leading to shorter retention times 
and reduced selectivity. 
Flow rate ml/min 1.5 
G
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Time (Min.) Event % A % B 
START Pump A B. 60 40 
20.0 Pump A B. 10 90 
25.0 Pump A B. 10 90 
27.0 Pump A B. 60 40 
35.0 Pump A B. 60 40 
35.0 STOP - - 
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 Optimisation – Gradient program 3.4.2.3
The above experiments indicated that a significant change of chemistry would be 
required to separate the potassium sorbate and methyl paraben peaks. The analytes were 
not being retained sufficiently long on the analytical column to allow for interaction 
with the stationary phase, indicating that the mobile phase composition was too strong, 
i.e. too much organic solvent was being employed at the beginning of the gradient 
program. There were 2 possible approaches to solve this problem. The first approach 
was to select an alternative column with a more hydrophobic character, which would 
help to increase the strength of the analyte-stationary phase interaction of the early 
eluting substances. This option was considered unlikely to bring improvement.  
Alternatively, the gradient program could be modified by increasing the proportion of 
aqueous phase at the beginning of the program, leading to an increased affinity of the 
analytes for the C18 phase. The later approach was chosen. The proportion of mobile 
phase A was increased from 60 % to 70 % and a standard solution containing potassium 
sorbate, methyl paraben and propyl paraben was analysed with the gradient program 
detailed in Table 12. 
 
Table 12 Modified Gradient II 
 
 
 
 
 
 
 
 
 
The potassium sorbate and methyl paraben peaks began to separate at a mobile phase 
composition of 70:30 (v/v) A/B. Further increasing the percentage of A to 82 % 
provided a complete baseline separation of both peaks (Rs = 1.5).  At 85 % A the 
resolution between the 2 peaks increased further to 1.8 (Figure 32). An increased 
proportion of aqueous phase lead to an increased system pressure which was 
counteracted by increasing the column oven temperature from 25 °C to 30 °C. The 
increased temperature did not adversely affect the peak resolution. 
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Time (Min.) Event  % A % B 
START Pump A B.  70 30 
16.0 Pump A B.  70 30 
25.0 Pump A B.  10 90 
27.0 Pump A B.  70 30 
35.0 Pump A B.  70 30 
35.0 STOP - - 
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 Optimisation - Column dimensions and flow rate 3.4.2.4
Since it had been observed that the separation of potassium sorbate and methyl paraben 
was more dependent on the polarity of the mobile phase and the structure of the gradient 
program than on the minor selectivity differences between different C18 stationary 
phases (i.e. the mobile phase chemistry plays a more significant role than the column 
chemistry), it was attempted to reduce the column dimensions and optimise the flow 
rate in order to save mobile phase and make the separation more cost effective. For this 
purpose a Supelco Ascentis
® 
column packed with 2.7 µm fused core particles and 
having the dimensions 100 mm L x 3.0 mm ID was chosen. This column was relatively 
new on the market and the fused core technology provided high column efficiency 
(theoretical plate count) with a relatively low backpressure (≈ 200 – 300 bar) at normal 
flow-rates (≈ 1 – 2 ml/min). This allows the column to be used with conventional HPLC 
systems (up to ca. 400 bar) whilst providing an efficiency approaching that of UPLC 
15
. 
 
 Optimisation of the injection volume 3.4.2.5
On injecting 50 µl of a mixed standard solution, poor peak shape for the early eluting 
compounds was observed due to overloading of the smaller HPLC column which had an 
ID of 3 mm as opposed to 4.6 mm for the original column. Reduction of the injection 
volume from 50 µl to 20 µl and then to 10 µl resulted in a significant improvement of 
peak shape (Figure 33). An injection volume of 10 µl was chosen for the final method. 
 
 79 
 
Figure 32  (a), (b) and (c)  Optimisation of the separation of potassium sorbate and methyl 
paraben. Baseline separation (resolution, Rs = 1.5) is obtained with 82 % buffer. Peak assignment:        
PS (1), MP (2) and PP (3) 
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 Final HPLC Method 3.4.3
After the method optimisation studies, the conditions used in the final HPLC method for 
the analysis of BV/FA Cream are detailed in Table 13 
 
Table 13 Final HPLC Conditions 
 
Column description - Supelco Ascentis C18, 100 mm x 3.0 mm with 2.7 µm 
Fused Core™ particles 
Guard column - C18,  4.0 mm L x 3.0 mm ID with 
Phenomenex
®
 Security Guard™ Cartridge system 
Flow rate ml/min 0.75 
Mobile Phase A 833 ml acetonitrile + 167 ml methanol 
B 10 g phosphoric acid (85 % m/m) in 1000 ml of purified 
water 
Wavelength nm 240 
Column temperature °C 30 
Auto-sampler 
temperature 
°C 25 
Gradient  - Time Event  % A % B 
0.0 Pump A B.  18 82 
16.0 Pump A B.  48 52 
25.0 Pump A B.  90 10 
27.0 Pump A B.  90 10 
27.1 Pump A B. 18 82 
35.0 STOP - - 
Injection volume µl 10 
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Figure 33  Effect of injection volume on the peak symmetry of early eluting compounds. A 
(50 µl) = complete peak deformation leading to double peaks, B (20 µl) = broad, deformed peaks, C (10 
µl) = sharp, symmetrical peaks. Peak assignment: PS (1), MP (2), betamethasone (3), PP (4), BV (5), 
betamethasone-21-valerate (6) and FA (7). 
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 Example Chromatograms 3.4.4
 Placebo (cream without active substances) 3.4.4.1
 
 
 BV/FA Cream 3.4.4.2
 
Figure 34  (a) Placebo (b) A chromatogram of topical cream after storage at 40 °C/75 % relative 
humidity for 9 months. The HPLC conditions are the same as those provided in Table 13. Peak 
assignment: PS (1), MP (2), PP (3), BV (4), Degradant betamethasone-21-valerate (5) and FA (6) 
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  Introduction 3.5.1
Stress testing is an important part of both the analytical- and formulation development 
processes. It is primarily used as a tool to investigate the intrinsic stability of a drug 
substance, thus providing information about likely degradation pathways for this 
substance in the finished product. It is also used to check the stability-indicating 
properties of an analytical procedure in respect of likely degradation products of the 
active substances 
16,17
.  Stress-testing  of FA and BV was performed under the following 
conditions: 
 
1. Acidic (hydrochloric acid) 
2. Basic (sodium hydroxide) 
3. Oxidative (hydrogen peroxide) 
4. Ultrasonic bath 
5. Temperature (105 ºC) 
6. Exposure to daylight 
7. Stability in solution (acetonitrile/water) 
8. Exposure to UV radiation (254 nm) 
9. Control (non-stressed) 
10. pH profile (pH 1 – pH 8) 
 
The acidic, basic and oxidative stress-tests were performed using dilute solutions 
of hydrochloric acid, sodium hydroxide and hydrogen peroxide, respectively. In each 
case, an initial investigation was performed in order to determine the concentration of 
each reagent required to provide sufficient, but not complete, degradation of the active 
compounds. A description of the sample preparation procedure is provided in Chapter 2. 
Only then could useful information be attained which would allow identification of 
likely degradation products/mechanistic pathways of degradation for the active 
substances. Under some conditions little or no degradation was observed. In such cases, 
it was not attempted to increase the harshness of the stress conditions further, since any 
impurities generated were unlikely to be relevant for finished product analysis since the 
cream would never be exposed to such harsh conditions during manufacture, packaging 
or storage. The percentage of impurities arising through the stressing procedures was 
measured according to the HPLC method described in section 3.3.8. 
 
 Stress-Testing of the APIs 3.5
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 Results 3.5.2
 Fusidic acid hemihydrate 3.5.2.1
As demonstrated by the results presented in Table 14 and Figure 37, FA degrades 
significantly under basic pH and high temperature conditions and to a lesser extent 
under acidic and oxidative conditions. The substance is relatively stable at pH values 
between 3 and 7, having a pH optimum of approximately 4.2 in this experiment. At pH 
values below 3, FA begins to degrade rapidly (see Figure 35). 
 
 
Figure 35 pH stability profile of FA over the range 1.2 – 7.2 
 
 
 Betamethasone-17-valerate 3.5.2.2
BV is extremely sensitive to basic pH conditions. In the presence of the prescribed 
volume of 1.0 M sodium hydroxide there was complete degradation of the active 
substance as well as of its primary degradation products betamethasone-21-valerate and 
betamethasone (Table 15 (a)).  On employing an equal volume of a weaker 0.1 M 
sodium hydroxide solution, complete degradation was also observed with 
betamethasone as the main degradation product (≈ 70 %). A further reduction of the 
base concentration to 0.001 M resulted in a lower degree of degradation of 
approximately 2.2 %, with betamethasone-21-valerate being the major degradation 
product. No betamethasone was detected. BV also proved to be unstable under acidic 
conditions with again, betamethasone-21-valerate and betamethasone being the major 
degradation products. The substance remained stable under all other stress conditions 
investigated (see also Table 15 (b)). 
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Figure 36 Correlation between BV loss (blue line) and the corresponding increase of 
betamethasone 21 valerate (red line) over the pH range 1.2 - 8.2 
 
 
The results confirm that the rearrangement reaction is both acid and base 
catalysed but that the acyl group migration occurs much more readily under basic pH 
conditions. It also confirms that the acyl migration dominates over the hydrolysis 
reaction, i.e. that the acyl group migrates first to the 21 position and is then hydrolysed 
to betamethasone base. The above data is in good agreement with literature studies 
18
. 
Figure 36 shows that BV is relatively stable between pH 1 and 5 but that its stability 
decreases rapidly at pH values > 5. 
 
 General Conclusions from the Stress Testing 3.5.2.3
The results of stress-testing indicate that pH and temperature are likely to be critical 
factors with regard to the stability of BV and FA in any potential cream formulation       
(Figure 37 and Figure 38). The results also indicate that the developed analytical 
procedures are stability-indicating with regard to the two active substances since they 
are capable of detecting any loss of content of the active substances as well as any 
increase of likely degradation products in stressed samples. One indicator of the 
stability-indicating nature of an analytical procedure is the so called "mass-balance 
ratio", which is obtained by adding the content value of the API (in %) and the sum of 
all impurities (in % relative to the API). Ideally, if the content of the API drops by 5 %, 
then an equivalent 5 % increase of degradation products would be expected, which 
would provide a sum of 100 %. However, in reality 100 % is seldom reached and values 
between 95 - 105 % are generally considered acceptable. In the present case the mass-
balance ratios are acceptable. 
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Table 14 Assay and purity results from stress testing of FA 
FUSIDIC ACID 
HEMIHYDRATE 
RRT Response 
factors  
Control  Acid  Base  Oxidative  Daylight 
(3 days)  
UV-Light 
(254nm)  
Ultrasonic 
Bath 
  
Temp.105°C/ 
24h 
Stability 
in 
Solution 
(10 days) 
Assay (Content value, %) -- -- 97.64 97.80 92.57 96.63 98.02 97.46 97.57 88.83 94.91 
 
24,25-dihydro-24,25-dihydroxy- 
Fusidic acid (Imp. A) 
 
0.27 
 
-- 
 
<0.05 
 
0.091 
 
0.082 
 
0.050 
 
<0.05 
 
<0.05 
 
<0.05 
 
<0.05 
 
<0.05 
24,25-dihydro-24,25-dihydroxy- 
Fusidic acid 21,25-lactone (Imp. B) 
0.43 -- 0.079 <0.05 <0.02 0.150 0.090 0.095 0.090 0.079 0.091 
(24R)-24,25-dihydro-24,25- 
Dihydroxyfusidic acid 21,24-lactone (Imp. C) 
0.49 0.7 0.083 0.186 0.179 0.126 0.114 0.120 0.110 0.485 0.145 
(24S)-24,25-dihydro-24,25- 
Dihydroxyfusidic acid 21,24-lactone (Imp. D) 
0.54 0.7 0.099 0.144 0.081 0.142 0.116 0.120 0.117 0.425 0.154 
Imp. N 0.56 -- 0.052 <0.05 <0.05 0.060 0.058 0.124 0.058 <0.05 <0.05 
26-oxofusidic acid (Imp. F) 0.60 0.3 0.063 0.056 0.046 0.071 0.069 0.079 0.070 0.310 0.233 
3-didehdrofusidic acid (Imp. G) 0.83 -- 0.254 0.251 0.237 0.253 0.255 0.260 0.255 0.409 0.254 
11-didehydrofusidic acid (Imp. H) 0.86 -- 0.090 0.204 5.887 0.090 0.090 0.089 0.091 0.205 0.205 
16-epi-deacetylfusidic acid (Imp. I) 0.95 0.6 <0.05 <0.05 <0.05 <0.05 <0.05 <0.05 <0.05 <0.05 <0.05 
Deacetylfusidic acid 21,16-lactone (Imp. O) 1.14 0.6 0.042 0.098 0.281 <0.05 <0.05 <0.05 <0.05 0.623 0.077 
9,11-anhydrofusidic acid (Imp. L) 1.17 -- 0.072 0.083 0.073 0.074 0.074 0.072 0.074 0.942 0.070 
11-deoxyfusidic acid (Imp. M) 1.27 -- <0.05 <0.05 <0.05 <0.05 <0.05 <0.05 <0.05 0.245 <0.05 
Single unknown (max.) 0.28 -- 0.087 0.080 0.067 0.086 0.056 0.057 0.056 0.105 0.084 
 
Sum of unknown impurities (%) -- -- 0.138 0.193 0.067 0.192 0.159 0.161 0.159 0.218 0.142 
 
Sum of all impurities (%) 
 
-- 
 
-- 
 
1.23 
 
1.64 
 
7.40 
 
1.56 
 
1.35 
 
1.12 
 
1.02 
 
3.94 
 
1.37 
 
 
Mass Balance Ratio (%) 
 
-- 
 
-- 
 
98.87 
 
99.45 
 
100.22 
 
98.32 
 
99.37 
 
98.58 
 
98.59 
 
92.77 
 
96.28 
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Table 15 (a) Assay and purity results from stress testing of BV 
BETAMETHASONE-17-
VALERATE 
RRT Response  
factors  
Control             Acid               
1.0 M                     
Acid         
0.01 M            
Base            
1.0 M           
Base            
0.1 M         
Base             
0.01 M        
Base             
0.001 M          
Oxidative  
Assay -- -- 99.04 1.22 100.32 
C
o
m
p
le
te
 D
eg
ra
d
at
io
n
 
0.00 2.50 99.24 98.89 
Betamethasone, % 0.30 1.154 <0.05 57.340 <0.05 70.329 10.178 <0.05 <0.05 
Betamethasone-21-valerate, % 1.35 0.930 0.942 42.483 0.092 0.884 92.723 2.208 0.933 
Sum of unknown impurities, % -- -- <0.05 <0.05 <0.05 11.318 <0.05 <0.05 0.316 
Sum of all impurities, % -- -- 0.94 99.82 0.09 82.53 102.90 2.20 1.24 
Mass balance Ratio (%) -- -- 99.98 101.04 100.41 82.53 105.40 101.44 100.13 
 
 
 
Table 15 (b)  Assay and purity results from stress testing of BV 
BETAMETHASONE-17-
VALERATE 
RRT Response 
 factors  
 
UV-Light  
(254nm)  
Ultrasonic  
Bath  
Temp. 
105 °C 
/ 24h  
Solution 
Stability  
(8 days) 
Daylight                       
 (8 days) 
Assay -- -- 99.25 98.53 99.51 98.88 99.63 
Betamethasone, % 0.30 1.154 <0.05 <0.05 <0.05 <0.05 0.207 
Betamethasone-21-valerate, % 1.35 0.930 0.451 1.302 0.375 0.284 0.307 
Sum of unknown impurities, % -- -- <0.05 <0.05 <0.05 <0.05 <0.05 
Sum of all impurities, % -- -- 0.45 1.30 0.38 0.28 0.51 
Mass balance Ratio (%) -- -- 99.70 99.83 99.89 99.16 100.14 
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Figure 37 Stress testing of FA – results 
 
 
 
 
Figure 38 Stress testing of BV – results 
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A primary aim of the work in this chapter was to develop an analytical procedure which 
could be employed for the stability-indicating analysis of the content of the active 
substances betamethasone 17-valerate and fusidic acid hemihydrate as well as the 
preservative compounds potassium sorbate, methyl paraben und propyl paraben in 
candidate formulations of a developmental hydrophillic cream. One of the main 
challenges encountered in developing such a procedure was the difference in polarity 
between the 5 analytes of interest. Potassium sorbate is the potassium salt of sorbic acid 
and is highly water soluble. In contrast, the more lipophilic compounds betamethasone-
17-valerate and fusidic acid hemihydrate are practically insoluble in water but are 
soluble in high polarity organic solvents, such as acetonitrile and ethanol. The challenge 
was to develop a procedure which would allow sufficient extraction of both the 
hydrophilic and hydrophobic analytes but without extracting large quantities of the 
hydrophobic matrix components of the cream, since these usually collect at the HPLC 
column-inlet frit or adsorb onto the stationary phase. This can cause problems with 
backpressure, peak shape as well as with retention time, since the irreversible adsorption 
of matrix components will inevitably have an influence on the chemical interactions 
between the analyte and the stationary phase. 
 Another aspect of the work was to develop a selective HPLC procedure for the 
purity analysis of the active substances in the cream preparations. The main challenge 
here was to develop a procedure which could separate the 2 active substances as well as 
2 known degradation products of betamethasone valerate and 15 known impurities of 
fusidic acid. A suitable separation was achieved by beginning isocratically for the first 
20 minutes, allowing for the elution of hydrophilic components, and then increasing the 
proportion of the organic phase to 92 % in order to elute the more hydrophobic analytes.  
The procedure also needed to be sensitive enough to analyse impurities at low 
concentrations, which proved to be a problem for betamethasone 17-valerate due its low 
concentration in the cream (1.2 mg/g). Optimisation of the sample preparation 
procedure was viewed to be the most efficient way to increase sensitivity. By increasing 
the concentration of analytes in the sample solution 5 fold, a suitable level of sensitivity 
was obtained.  
 Both of the developed analytical procedures were checked for selectivity, 
sensitivity, reproducibility, accuracy and robustness. Both procedures were found to be 
 Discussion and Conclusions 3.6
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fit-for-purpose and sufficiently robust to be suitable for application in a routine quality 
control laboratory. 
 A final aspect of the work in this chapter was the performance of stress testing of 
the drug substances in order to elucidate possible degradation pathways for these 
substances in the finished product and to demonstrate the stability-indicating nature of 
the developed procedures. It has been shown that both APIs are labile under extreme pH 
conditions and at elevated temperature. Betamethasone 17-valerate was shown to be 
unstable under both strong acidic and basic pH conditions, being substantially less 
stable with regard to basic conditions than acidic. The required pH for optimum stability 
was found to be approximately 3.5. Fusidic acid was also found to be unstable under 
strong acidic and basic conditions, being less stable at lower pH than at higher pH. The 
pH optimum with regard to stability lay at ca. 4.2. The calculated mass-balance values 
from these experiments demonstrate that both analytical procedures are stability-
indicating. 
 The analytical procedures must be validated according to the relevant ICH 
guidelines 
19
 for the parameters, selectivity, linearity, precision, accuracy, sensitivity 
and robustness. This has been addressed in Chapter 4. 
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 CHAPTER 4 – Validation of Analytical Procedures 4
 
Current legislation governing the licencing of new pharmaceutical products requires that 
analytical procedures used for quality control- and stability testing of these products are 
validated before the drug product application can be approved. The process of 
validation may be described as the verification, through appropriately designed 
analytical experiments, that an analytical procedure is suitable for its intended purpose. 
In Europe, relevant validation characteristics are defined in ICH guideline Q2R1 – 
Validation of Analytical Procedures: Text and Methodology 
1
, which was published in 
its revised format in November 2005. According to this guideline, typical validation 
characteristics which should be considered include: Accuracy, Precision, Selectivity, 
Limit of Detection, Limit of Quantitation, Linearity and Range. System suitability and 
Robustness are 2 further parameters which are generally considered important for 
validation. Each of the validation characteristics can be defined as follows: 
 
The Selectivity of an analytical method can be defined as the ability of the method to 
accurately measure the analyte or analytes of interest without interference from other 
components of the sample solution, e.g. solvent, matrix or other analyte components. 
 
Figure 39  Insufficient selectivity (a) vs. sufficient selectivity (b) 
 
System suitability, as the name suggests, is the experimental confirmation that 
the analytical system to be employed during the validation study is suitable to perform 
the required task. Testing system suitability usually involves multiple injections of a 
suitable standard solution and analysis of the precision of both the retention times and 
peak areas of all resulting chromatograms. Accuracy, (sometimes termed Recovery), 
can be defined as a measure of the closeness of the obtained result to an agreed 
 Introduction 4.1
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theoretical value. Precision, on the other hand, is defined as the closeness of the 
measured results to each other, i.e. the scatter between multiple measurements of the 
same homogenous sample. An analytical procedure may be accurate but have a low 
precision, or vice-versa. In an ideal situation a procedure should be both accurate and 
precise (Figure 40). 
 
 
Figure 40 Definition of accuracy and precision in analytical measurements 
 
The Limit of Detection (LOD) is the lowest concentration of analyte which can 
be detected by the analytical system. It is normally defined as the concentration of 
analyte required to provide a signal-noise-ratio of 3, where the signal- and noise heights 
are defined as H and h (Figure 41) and the signal-to-noise-ratio is 2H/h. The Limit of 
Quantitation (LOQ) is the lowest concentration of analyte which can be accurately 
quantified by the analytical system. It is normally defined as the concentration of 
analyte required to provide a signal-to-noise-ratio of 10. The Linearity of an analytical 
procedure describes the degree to which a linear relationship exists between the 
concentration of the analyte and the recorded response. It is usually expressed in the 
form of the correlation coefficient, r, which ranges from 0 to 1, where a correlation 
coefficient of 1.000 indicates a perfect linear relationship with a positive slope. Some 
analytical procedures may not show a linear relationship between analyte concentration 
and response, e.g. biological immunoassays 
2
. 
 
Figure 41  Signal (H) to Noise (h) Ratio for determination of LOD and LOQ 
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Non-linear processes may however show linear like behaviour over narrow 
concentration ranges, leading to the misinterpretation of the concentration/response 
model as being linear. It is therefore important to check the residual values from the 
linearity experiment for any obvious trends. This is performed by generation of a 
residual plot, which is a scatter plot of the individual differences between the values 
predicted by the best-fit-line and the actual observed values. If the analytical procedure 
is truly linear then the residuals should be distributed randomly about 0, as in Figure 42 
(a) below. 
 
 
Figure 42 Residual distributions: random (a), non-random (b + c) 
 
The Robustness of an analytical procedure is a measure of the ability of the 
procedure to remain unaffected by small changes to the chromatographic conditions. It 
provides an indication of how the method is likely to perform in the laboratory on a 
day-to-day basis where human, technical and environmental variation come into play. 
Examples of changes to the chromatographic conditions include increasing or 
decreasing the column temperature or the percentage of organic modifier in the mobile 
phase. The goal of the analytical chemist is to develop a procedure which is not 
significantly influenced by minor changes to the chromatographic conditions, or if the 
method is affected that these effects are known and documented. Procedures lacking 
robustness may cause problems during routine analysis leading to reduced sample 
through-put and increased analysis costs. 
 
The purpose of the work in this chapter is to demonstrate the validity of the analytical 
procedures developed in Chapter 3 for use in the stability-indicating HPLC analysis of 
betamethasone-17-valerate and fusidic acid hemihydrate in developmental cream 
formulations. The procedures will be validated according to current ICH guidelines for 
 Aim 4.2
 97 
the parameters selectivity, linearity, precision, accuracy, sensitivity and robustness 
within the appropriate concentration range for each analyte. 
 
Before validation of any analytical procedure, it is first necessary to define suitable 
acceptance criteria for each of the parameters to be validated. The selection of suitable 
criteria will depend on several factors, the most important of which will include: (i) the 
concentration level of the analyte in the sample, (ii) the required specification for the 
analyte in the drug product and (iii) the nature of the analytical procedure, e.g. assay by 
HPLC or “loss on drying” test by gravimetric analysis. 
 In order to set appropriate acceptance criteria it is also essential to have a basic 
understanding of the statistical concepts surrounding the probability distribution of 
analytical measurements. In general, it is to be expected that the results of analytical 
measurements will demonstrate a normal distribution around a certain mean value 
(Figure 43), although there are some methods, e.g. microbiological assays,  where this is 
not the case. The normal distribution is described by the equation 
3
 :  
 
y =  
1
σ√2π
e
-(x-μ)2
2σ2  
Where, 
y  = vertical height on a point on the normal distribution 
x  = point on the horizontal axis 
σ = standard deviation of the data 
µ = mean of the data distribution 
e = exponential constant, 2.71828… 
π = 3.14159… 
 
Using this equation it can be shown that in a normally distributed population of 
values, 68 % of the values will lie with ± 1 standard deviation and 95 % will lie within ± 
2 standard deviations of the population mean (1.96 to be exact). This must be 
considered when setting acceptance criteria. Otherwise, the precision of the analytical 
procedure may not be compatible with the product specification. If for example, the 
content of a drug substance in a tablet is defined as 100 % and the specification for that 
substance is 95 – 105 %, then it is obvious that it would make no sense to employ a 
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procedure which has a standard deviation (precision) of 5 %, since a large number of the 
measured values would lie outside the specification just by chance alone, despite the 
fact that the content of drug substance in the tablet batch was acceptable.  
The normal distribution assumes a sufficiently large sample size and can 
generally be applied as a model when sample sizes are close to or above n = 60. During 
routine analysis and method validation, however, it is not feasible to perform 60 or 
more separate measurements of a sample. Usually a maximum of 6 measurements are 
made. Since a sample size of 6 is considerably lower than 60, it is statistically unsafe to 
presume that the arithmetic mean of 6 values represents the true mean of the entire 
sample population. To compensate for this lack of confidence in the mean, a variant of 
the normal distribution model, the t-distribution, is instead used. The mean is then 
reported together with its associated confidence interval which varies depending on 
sample size. If the sample size is low the mean is reported with a wide confidence 
interval indicating that the confidence that the calculated mean represents the true mean 
is lower than if the sample size were high, where the mean value would have a narrower 
confidence interval. At a sample size of approximately 60 the t-distribution resembles 
the normal distribution. In precision and accuracy experiments all mean values should 
be reported with their corresponding confidence intervals. 
 
 
Figure 43 Normal distribution curve 
 
 
On consideration of the above points, the acceptance criteria described in Table 16 were 
set for the validation of the assay and purity methods. 
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Table 16 Validation specifications for the assay and purity methods 
 
Validation Parameter Specification Assay Method 
 
Specification Purity Method 
Range 
 
50 – 150 % 0.1 – 8.0 % 
Selectivity No interferences from placebo, solvent, matrix or related 
substance components. Peak purity demonstrated by DAD 
analysis 
No interferences from placebo, solvent, matrix or related substance 
components.  
Precision 
- Repeatability 
- Intermediate precision 
            
RSD ≤ 2 %       
RSD ≤ 2 %       
 
 
RSD ≤ 10 % 
RSD ≤ 10 % 
Accuracy 
- Mean value 
- RSD of all values 
API                       Preservatives 
98.0 – 102.0 %      97.0 – 103.0 % 
≤ 2.5 %                ≤ 3.5 % 
 
90 – 110 % 
≤ 15 % 
 
Linearity r ≥ 0.995 
Residuals show no trend 
y-intercept passes through “0” 
r ≥ 0.995 
 
Sensitivity 
- LOQ 
 
Not relevant 
 
≤ 0.1 % 
 
Robustness The following changes will be made to the chromatographic 
conditions and any effects noted: 
 
 Column temperature ± 5 °C 
 Mobile phase flow rate ± 0.2 ml/Min. 
 Acetonitrile in mobile phase A ± 10 ml/L 
 Methanol in mobile phase A ± 10 ml/L 
 Detector wavelength ± 2 nm 
 Mobile phase B at start of gradient ± 4 % 
 
The following changes will be made to the chromatographic conditions 
and any effects noted: 
 
 Column temperature ± 5 °C 
 Mobile phase flow rate ± 0.2 ml/Min. 
 Acetonitrile in mobile phase A ± 20 ml/L 
 Methanol in mobile phase A ± 20 ml/L 
 Buffer in mobile phase A ± 20 ml/L 
 Detector wavelength ± 2 nm 
 Mobile phase B at start of gradient ± 5 % 
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 Selectivity  4.4.1
The selectivity of the analytical method for each of the analyte components was 
demonstrated by measuring the following solutions on the chromatograph: 
 Solvent , comprising of acetonitrile/purified water (50:50 v/v) 
 Placebo (without actives and preservatives) 
 Fusidic acid hemihydrate identification standard 
 Betamethasone-17-valerate identification standard 
 Potassium sorbate identification standard 
 Methyl paraben identification standard 
 Propyl paraben identification standard 
 Mixed standard solution 
 Betamethasone-17-valerate/Fusidic acid cream, lot: 110101, stored under 
ambient conditions 
 Betamethasone-17-valerate/Fusidic acid cream, lot: 110101, stored under 
accelerated conditions (40°C/75 % RH) for 9 months 
 Betamethasone-17-valerate/Fusidic acid cream, lot: 110101, stored under 
stress conditions (Light stress - exposure to daylight for 3 days) 
 Betamethasone-17-valerate/Fusidic acid cream, lot: 110101, stored under 
stress conditions (Oxidative stress – exposure to air for 3 days) 
 
The stressed samples were analysed in order to demonstrate the selectivity of the 
analytical method for the analytes of interest in the presence of possible degradation 
products and matrix components. The stressed conditions chosen, i.e. 9 months at 
40°C/75 % relative humidity, as well as 3 days exposure to light and to air, were 
considered to be ‘worst-case’ since the product is highly unlikely to be exposed to such 
conditions during manufacture, transport or long-term storage (the product is stored 
protected from air and light in aluminium tubes). 
Analysis of the resulting chromatograms demonstrates that there are no apparent 
interferences from either the solvent, placebo, preservative or related substance 
components. 
The purity of each of the relevant analyte peaks was further examined using a diode-
array detector, whereby UV-spectra (190 nm – 400 nm) were recorded and compared 
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across the whole of the analyte peak. Using this technique, co-eluting impurities are 
detected as differences in the recorded spectra. The purity graph consists of a single 
trace that represents the peak purity index for each point (Figure 44). The peak purity 
analysis demonstrated that each of the analyte peaks was pure, indicating that there are 
unlikely to be co-eluting impurities. It should be noted that this technique can only be 
considered to be an estimate of the peak purity and may not be suitable for detecting co-
eluting impurities present in low concentrations and/or having very similar spectral 
properties to the main peak, e.g. structurally related compounds.  However, the 
combination of this technique and visual examination of real chromatograms provides a 
reasonable level of certainty that the examined analyte peaks are pure. 
 
 
Figure 44 Example of a peak purity measurement output 
 
Linearity of the detector response for potassium sorbate 
The determination of the linearity of the detector response for potassium sorbate was 
performed over 8 concentration levels within the range 46 % to 153 % of the normal 
standard solution concentration (20 µg/ml = 100 %). The solutions were prepared by 
diluting a stock standard.  
 
 
 
 
Datafile Name:Std_KS_0101.lcd
Sample Name:Std_KS_0101
Sample ID:Std_KS_0101
4,3 4,4 4,5 4,6 4,7 4,8 4,9 5,0 5,1 min
-0,6
-0,5
-0,4
-0,3
-0,2
-0,1
0,0
0,0
25,0
50,0
75,0
100,0
125,0
150,0
175,0
mAU
Peak
Zero Line
Purity Curve
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Table 17 Linearity data – potassium sorbate  
Concentration 
level 
Average PA Conc. (µg/ml) Conc. (%) 
1 612907 9.201 46.01 
2 818408 12.268 61.34 
3 1027464 15.335 76.68 
4 1219448 18.402 92.01 
5 1428276 21.469 107.35 
6 1634448 24.536 122.68 
7 1818586 27.603 138.02 
8 2025814 30.670 153.35 
 
 
Figure 45 Linearity of the detector response for potassium sorbate with 95 % confidence interval 
 
 
Figure 46 Plot of the residuals versus calibration point 
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Linearity of the detector response for MP, PP, BV and FA 
The linearity experiments for the remaining analytes were performed analogous to the 
experiment for potassium sorbate. The correlation coefficient, r, for each of the linearity 
experiments meets the acceptance criterion of ≥ 0.995. The scatter plots of the residuals, 
i.e. the difference between the values predicted by the best fitting line and the actual 
observed values, show that they are spread about zero with no definitive trend. This 
indicates that the best-fitting line is a good fit for the observed data and is strong 
evidence that the relationship between concentration and detector response is a linear 
one. The calculated confidence interval for each of the y-intercepts contains the point 
“0”, indicating that the y-intercept passes through the origin. The use of a single-point 
calibration during routine analysis is therefore justified. 
 
 Precision 4.4.3
The analysis of method precision was performed on 2 separate days, whereby 6 test 
solutions were prepared on each day by a different analyst and measured using a 
different HPLC machine and reagents, e.g. mobile phase. The intermediate precision 
was assessed by statistically comparing the data sets from both days. The calculated rsd 
values from both the repeatability and intermediate precision experiments meet the 
prescribed criterion of ≤ 2 %. The precision of the analytical method is considered to be 
satisfactory.   
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Table 18 Intermediate precision 
Sample No. 
Content (mg/g) 
Potassium 
sorbate 
Methyl 
paraben 
Propyl 
paraben 
Betamethasone 
17-valerate 
 
Fusidic acid 
Hemihydrate 
 
D
a
y
 1
 
A
n
a
ly
st
 1
 
H
P
L
C
 1
 
1 1.73959 0.80609 0.16150 1.23536 19.89318 
2 1.74070 0.80541 0.16185 1.23488 19.88125 
3 1.74443 0.80481 0.15984 1.23180 19.84768 
4 1.76891 0.80963 0.16169 1.24056 20.05848 
5 1.75867 0.80986 0.16159 1.24120 20.00365 
6 1.76984 0.80795 0.16040 1.23551 19.99061 
D
a
y
 2
 
A
n
a
ly
st
 2
 
H
P
L
C
 2
 
7 1.77157 0.82353 0.16475 1.25067 20.10262 
8 1.76523 0.82114 0.16533 1.25356 20.14918 
9 1.77287 0.82315 0.16359 1.25168 20.11890 
10 1.76646 0.82039 0.16340 1.25576 20.18444 
11 1.76934 0.82122 0.16408 1.24959 20.08537 
12 1.76190 0.81571 0.16302 1.25877 20.23292 
m.v. 1.76079 0.81407 0.16258 1.24494 20.04569 
s.d. 0.01228 0.00747 0.00170 0.00939 0.12419 
rsd, % 0.70 0.92 1.05 0.75 0.62 
Confidence (95%) 0.00780 0.00475 0.00108 0.00596 0.07890 
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Figure 47  Linearity plots for (a) methyl paraben, (b) propyl paraben, (c) betamethasone 17-valerate, (d) fusidic acid hemihydrate 
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Table 19 Summary of data from the repeatability experiment  
Sample No. 
Content (mg/g) 
Potassium     sorbate Methyl paraben Propyl paraben Betamethasone-17-valerate Fusidic acid hemihydrate 
1 1.73959 0.80609 0.16150 1.23536 19.89318 
2 1.74070 0.80541 0.16185 1.23488 19.88125 
3 1.74443 0.80481 0.15984 1.23180 19.84768 
4 1.76891 0.80963 0.16169 1.24056 20.05848 
5 1.75867 0.80986 0.16159 1.24120 20.00365 
6 1.76984 0.80795 0.16040 1.23551 19.99061 
m.v. 1.75369 0.80729 0.16115 1.23655 19.94580 
s.d. 0.01393 0.00217 0.00082 0.00362 0.08320 
rsd, % 0.79 0.27 0.51 0.29 0.42 
Confidence (95%) 0.01462 0.00228 0.00086 0.00380 0.08731 
 
Table 20 Summary of statistical data from linearity experiments 
Substance y = mx + c r r 2 Residuals 
Concentration 
Range, % 
Concentration 
Range, µg/ml 
95 % confidence interval 
of y-intercept 
  Lower confidence limit 
Upper confidence 
limit 
Potassium sorbate y = 65680x + 13804 0.9999 0.9999 No trend 46.1 – 153.4 9.2 – 30.7  - 3140 30749 
Methyl paraben y = 47190x + 7311 0.9992 0.9984 No trend 45.0 – 150.1 3.6 – 12.0 - 8149 22770 
Propyl paraben y = 39561x + 1108 0.9992 0.9985 No trend 46.7 – 155.8 0.75 – 2.49 - 1565 3781 
Betamethasone-17-valerate y = 24520x + 2978 0.9998 0.9997 No trend 45.0 – 150.0 5.5 – 18.2 - 2508 8465 
Fusidic acid hemihydrate y = 6896x + 20841 0.9998 0.9996 No trend 44.3 – 147.8 88.7 – 295.6 - 7218 48900 
 107 
 Accuracy 4.4.4
The accuracy (recovery rate) of the analytical method was demonstrated by preparing 9 
solutions comprising of placebo spiked with each analyte at 50 %, 100 % and 150 % 
concentrations. Three solutions were prepared at each concentration level. The 
measured content values of these solutions were then compared to the theoretical value 
(spiked amount) in order to determine the percentage recovery. The percentage-
recovery values were used to calculate the mean recovery value, standard deviation, 
relative standard deviation and confidence intervals for the mean (95 %). 
 
Table 21 Data from the accuracy experiment 
Sample No. % Recovery 
 
Potassium 
sorbate 
Methyl- 
paraben 
Propyl- 
paraben 
Betamethasone 
17-valerate 
Fusidic acid 
hemihydrate 
50 % - 1 101.78 102.89 102.24 98.98 98.59 
50 % - 2 102.97 102.59 101.43 99.53 98.21 
50 % - 3 102.17 103.20 102.51 101.42 100.58 
100 % - 1 101.37 102.48 101.37 100.57 98.16 
100 % - 2 101.90 100.18 98.81 100.93 98.81 
100 % - 3 103.46 100.26 99.75 100.77 98.43 
150 % - 1 101.93 100.79 100.19 101.03 99.34 
150 % - 2 102.41 100.30 99.33 102.11 100.14 
150 % - 3 103.66 101.60 100.81 101.38 99.17 
m.v. 102.41 101.59 100.72 100.75 99.05 
s.d. 0.78 1.23 1.29 0.97 0.85 
rsd, % 0.77 1.21 1.28 0.96 0.86 
Confidence (95 %) 0.60 0.95 0.99 0.74 0.65 
 
 
The recovery and rsd values for potassium sorbate, methyl paraben and propyl 
paraben meet the specifications of 97.0 – 103.0 % for the mean recovery and ≤ 3.5 % 
for the rsd value. The acceptance criteria were set under consideration of the release 
specifications for the 3 components which is 90 – 110 % in each case. The recovery and 
rsd values for betamethasone-17-valerate and fusidic acid hemihydrate meet the 
specifications of 98.0 – 102.0 % for the mean recovery and ≤ 2.5 % for the rsd value. 
The acceptance criteria were set under consideration of the release specification for the 
2 components which is 95 – 105 % in each case. The accuracy of the analytical method 
is considered acceptable.  
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 Robustness 4.4.5
Two approaches were taken to the analysis of method robustness. The first approach 
involved an analysis of the stability of the sample and standard solutions over a fixed 
time period, whilst the second approach involved an analysis of the effects of changes 
of the mobile phase composition and system parameters on the chromatography and 
overall performance of the method.  
 
 4.4.5.1 Stability of the sample and standard solutions 
The stability of the sample and standard solutions was analysed over a period ranging 
from 0 to 47 hours, while stored in darkness, e.g. the vial compartment of the HPLC at 
25 ºC.  
 
Table 22 Stability of solutions – Potassium sorbate 
Time [h] Sample 1 Sample 1 Standard 1 Standard 2 
0 1173397 1152873 1349187 1330137 
5 1175022 1154385 1349764 1329214 
9 1177216 1158589 1353369 1334547 
14 1179516 1160979 1355412 1336915 
19 1181037 1161760 1357758 1339205 
23 1182162 1164788 1359775 1341063 
28 1184383 1165120 1360362 1343507 
33 1186804 1167379 1364901 1344529 
37 1189244 1170600 1365825 1349926 
42 1190644 1171464 1371741 1352831 
47 1191725 1172458 1372808 1354715 
m.v. 1180966 1165538 1360082 1341508 
s.d. 10797 6183 8073 8615 
rsd 0.91 0.53 0.59 0.64 
% Deviation  
over 47 hours 
+ 1.56 + 1.70 + 1.75 + 1.85 
 
The peak area plots of each of the analytes from the sample and standard 
solutions show no degradation trend over the 47 hour test period. Instead, the values 
appear to increase with time. This increase of peak area over time has been observed in 
all samples and standards and the rate of increase in both the sample and standard 
solutions appears to be similar. The increase of peak area can therefore most likely be 
attributed to normal system drift. Since both the sample and standard solutions show 
similar trends, there is unlikely to be a significant effect on assay results. The peak area 
values of any relevant degradation products of the active substances did not increase 
significantly over the measurement period, indicating that the APIs did not degrade 
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appreciably. The sample and standard solutions are considered to be stable for up to 47 
hours when stored in darkness at 25 °C. 
 
 4.4.5.2 Robustness of the HPLC method 
In order to investigate if the analytical method was robust enough to withstand small 
changes to the make-up of the mobile phase as well as adjustments to the instrument 
set-up parameters, several modifications/adjustments were made to both and the results 
were recorded. The changes that were studied were as follows:  
 
o The column-oven temperature was adjusted by ± 5 ºC. 
o The mobile phase flow rate was adjusted by ± 0.2 ml/min 
o The volume of methanol in mobile phase A was adjusted by ± 10 ml/L 
o The detector wavelength was adjusted by ± 2 nm 
o The proportion of mobile phase B at the beginning of the gradient run was 
adjusted by ± 4 % 
 
The quality of the chromatography obtained after these changes was monitored with 
the aid of a solution prepared from a sample which had been stressed under the 
conditions of 50 °C/75 % RH for 8 weeks and contained all of the relevant degradation 
products of betamethasone-17-valerate and fusidic acid hemihydrate. A review of the 
resulting chromatograms led to the following conclusions: 
 
 An increase of the column-oven temperature by 5 °C leads to a shortening of the 
retention times of all peaks and to a reduction of the resolution between the 
potassium sorbate and methyl paraben peaks. A reduction of the column-oven 
temperature by 5 °C has the opposite effect.  
 
 An increase of the flow-rate by 0.2 ml/min. leads to a shortening of the retention 
time of all peaks. A decrease of the flow-rate by 0.2 ml/min. leads to a lengthening 
of the retention time of all peaks. In both instances the resolution between the 
potassium sorbate and methyl paraben peaks remains largely unaffected.  
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 Increasing/decreasing the volume of methanol in mobile phase A by ± 10 ml/L has 
no significant effect on the chromatography. The resolution between potassium 
sorbate and propyl paraben remains unaffected. 
 
 In order to evaluate the effect of small changes of wavelength on the content results, 
an assay test was performed on a sample of Betamethasone-17-valerate/Fusidic acid 
cream and the content values were calculated at 238 nm, 240 nm and 242nm.  
 
Table 23 Robustness of the assay method to wavelength changes 
Compound 
Name 
Assay value 
at 238 nm 
(mg/g) 
Assay value 
at 240 nm 
(mg/g) 
Assay value 
at 242 nm 
(mg/g) 
Potassium sorbate 1.7594 1.7593 1.7595 
Methyl paraben 0.8040 0.8037 0.8040 
Propyl paraben 0.1656 0.1657 0.1655 
Betamethasone-17-valerate 1.2375 1.2394 1.2384 
Fusidic acid 20.1866 20.0818 20.0926 
 
As demonstrated by the above results, varying the wavelength by ± 2 nm has no 
significant effect on the assay results. The analytical method is deemed to be robust 
with respect to minor changes of wavelength. 
 
 An increase of the proportion of mobile phase B at the beginning of the gradient by 
4 % (82 % -> 86 %) leads to a lengthening of the retention times of the early eluting 
peaks. The resolution between the potassium sorbate and methyl paraben peaks 
increases considerably from 2.4 to 3.3. A decrease of the proportion of mobile phase 
B at the beginning of the gradient by 4 % (82 % -> 78 %) leads to a shortening of 
the retention times of the early eluting peaks and to a reduced resolution between the 
potassium sorbate and methyl paraben peaks from 2.4 to 1.4. 
 
The resolution between the critical peak pair of potassium sorbate and methyl 
paraben is dependent on a number of factors such as the proportion of organic modifier 
in the mobile phase and the steepness of the gradient program. The resolution between 
these peaks will affect the quantitative results due to possible integration errors when 
the peaks are not fully resolved. Consequently, it will be specified as a system 
suitability criterion for routine analysis that the resolution between these 2 peaks must 
be greater than 1.5. 
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Figure 48 Graphical representation of the effect of changes of the analytical parameters on the 
resolution between the critical pair KS and MP. Green indicates an increase, and red a decrease of 
resolution between both peaks 
 
 
 Methodology  4.5.1
The analytical procedure for the determination of the purity of betamethasone-17-
valerate and fusidic acid hemihydrate in the developmental cream was validated for 
selectivity, linearity, precision, accuracy and robustness according to ICH guideline Q2 
(R1) in a similar fashion to the assay method. Additionally, the sensitivity of the 
procedure as well as the response factors for each of the impurities were evaluated. The 
response factors for betamethasone and betamethasone-21-valerate were calculated by 
dividing the slope of the best-fitting line from the linearity experiment of each impurity 
with the slope obtained for the best-fitting line of the betamethasone-17-valerate (API) 
linearity experiment. The response factors for the impurities of fusidic acid 
monohydrate were taken directly from the EP 7.3 monograph for the drug substance. 
 
 Results 4.5.2
The results of the validation experiments are provided in Figure 25 - Figure 28Table 28. 
The analytical procedure has been demonstrated to be selective, linear, precise, accurate 
and robust within the investigated concentration range. The procedure can be considered 
fit-for-purpose. 
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Table 24 Impurity response factors 
Impurity/Active 
Response  
Factor 
Betamethasone-17-valerate 1.000 
Betamethasone-21-valerate 0.930 
Betamethasone 1.154 
Fusidic acid 1.000 
3-Didehydrofusidic acid 1.074 
(24R)-24,25-dihydro-24,25-dihydroxyfusidic acid 21,24-lactone 1.429 
(24S)-24,25-dihydro-24,25-dihydroxyfusidic acid 21,24-lactone 1.429 
26-Oxofusidic acid 3.333 
16-epideacetylfusidic acid 1.667 
Deacetylfusidic acid 21,16-lactone 1.667 
 
The aim of the work in this chapter was to demonstrate that the analytical procedures 
developed in Chapter III are fit-for-purpose, i.e. to demonstrate that the procedures are 
capable of performing the task for which they were designed. In the case of the assay 
procedure, it has been shown that the method is capable of a selective separation of the 
active- and preservatives compounds without interference from the excipient or solvent 
components of the cream preparation, sample or mobile phase. The suitability of the 
procedure to accurately and precisely determine the content of the analytes of interest 
has been demonstrated through appropriately designed experiments, the results of which 
adhere to well established and accepted pharmaceutical industry standards.  It has been 
demonstrated that there is a linear correlation between the analyte concentration and the 
detector response. The use of a single point calibration (single concentration) for 
quantitation is justified, since the 95 % confidence interval of the y-intercept of the best-
fit line contains the value "zero". This indicates that the y-intercept is not significantly 
different from "zero" and it can therefore be presumed that the regression line goes 
through the origin. 
 In Chapter III a separate procedure was also developed for the analysis of the 
purity of the drug substances in formulations candidates. This procedure was validated 
in an analogous fashion to the assay procedure, with additional experiments being 
performed for the determination of the limits of detection and quantitation. As 
previously discussed, the sensitivity of the purity procedure proved to be suboptimal 
during development due to the low concentration of the glucocorticoid in the candidate 
 Discussion and General Conclusions 4.6
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cream formulations (1.2 mg/g). The sensitivity was increased by increasing the analyte 
concentration in the sample solution. An increase of the injection volume was not 
feasible due to constraints of the analytical equipment and the requirement for the 
method to be capable of being operated on all HPLC machines within the laboratory. 
During validation the limits of detection and quantitation were determined and found to 
be below the required reporting threshold of (0.1 %). 
 In conclusion, the analytical procedures have been demonstrated to be fit-for-
purpose and may be employed in the analysis of formulation candidates of the 
developmental cream. This is the subject of Chapter V. 
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Table 25 Summary of the statistical data from linearity experiments 
Substance y = mx + c r r 
2
 Residuals 
Concentration 
Range, % 
Concentration 
Range, µg/ml 
95 % confidence interval 
of y-intercept 
  Lower confidence limit Upper confidence limit 
Betamethasone y = 92932x + 8269 0.9999 0.9999 No trend 0.09 – 8.71 0.05 – 5.3  6392 10146 
Betamethasone-21-valerate y = 75300x - 514 0.9999 0.9999 No trend 0.06 – 5.82 0.04 – 3.5 -1276 248 
Betamethasone-17-valerate y = 80537x + 895 0.9999 0.9999 No trend 0.09 – 8.68 0.05 – 5.3 -354 2145 
3-didehydrofusidic acid y = 23072x + 3252 0.9999 0.9999 No trend 0.06 – 6.05 0.6 – 60.5 -7015 511 
Fusidic acid hemihydrate y = 29387x + 8134 0.9999 0.9999 No trend 0.08 – 7.84 0.8 – 78.4 -671 16893 
*Specification: r > 0.995 
 
Table 26 Summary of the data from the repeatability experiment  
Sample No. 
Content (%) 
Betamethasone-
21-valerate 
3-didehydrofusidic 
acid 
16-epideacetylfusidic acid-
21,16-lactone 
16-epideacetyl-
fusidic acid 
Sum of all impurities 
Betamethasone valerate 
Sum of all 
impurities Fusidic 
acid 
1 19.193 0.433 0.333 0.376 19.367 3.296 
2 19.197 0.428 0.334 0.378 19.372 3.298 
3 19.110 0.425 0.332 0.376 19.297 3.390 
4 19.162 0.429 0.331 0.384 19.343 3.324 
5 18.976 0.422 0.327 0.382 19.161 3.304 
6 19.113 0.426 0.329 0.384 19.300 3.322 
m.v. 19.125 0.427 0.331 0.380 19.307 3.322 
s.d. 0.082 0.004 0.002 0.004 0.078 0.035 
rsd, % 0.43 0.92 0.75 0.98 0.41 1.06 
Confidence (95%) 0.086 0.004 0.003 0.004 0.082 0.037 
*Specification: rsd ≤ 10 % 
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Table 27 Summary of the data from the intermediate precision experiment (intra-laboratory precision) 
Sample No. 
Content (%) 
Betamethasone-
21-valerate 
3-didehydrofusidic 
acid 
16-epideacetylfusidic acid-
21,16-lactone 
16-epideacetylfusidic 
acid 
Sum of all impurities 
Betamethasone valerate 
Sum of all 
impurities    
Fusidic acid 
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1 19.193 0.433 0.333 0.376 19.367 3.296 
2 19.197 0.428 0.334 0.378 19.372 3.298 
3 19.110 0.425 0.332 0.376 19.297 3.390 
4 19.162 0.429 0.331 0.384 19.343 3.324 
5 18.976 0.422 0.327 0.382 19.161 3.304 
6 19.113 0.426 0.329 0.384 19.300 3.322 
D
ay
 2
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st
 2
 
H
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 2
 
1 19.945 0.447 0.325 0.419 20.283 3.489 
2 18.966 0.435 0.300 0.404 19.323 3.435 
3 18.946 0.429 0.304 0.401 19.273 3.298 
4 19.452 0.440 0.317 0.401 19.778 3.371 
5 20.178 0.454 0.326 0.427 20.529 3.637 
6 20.296 0.453 0.332 0.417 20.633 3.540 
m.v. 19.379 0.435 0.324 0.396 19.638 3.392 
s.d. 0.483 0.011 0.011 0.018 0.534 0.112 
rsd, % (*) 2.5 2.5 3.5 4.6 2.7 3.3 
Confidence (95%) 0.307 0.007 0.007 0.012 0.339 0.071 
*Specification: rsd ≤ 10 % 
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Table 28 Summary of the data from the accuracy experiment      
Sample No. 
% Recovery 
Betamethasone- 
21-valerate 
Betamethasone 
Betamethasone- 
17-valerate 
Fusidic acid 3-didehydrofusidic acid  
0.1 % - 1 93.14 83.94 86.62 104.71 95.73  
0.1 % - 2 97.55 74.74 90.72 105.55 102.12  
0.1 % - 3 98.90 95.35 91.98 105.27 94.48  
1 % - 1 108.30 111.86 100.72 100.01 98.18  
1 % - 2 111.50 109.40 103.70 100.88 100.40  
1 % - 3 112.98 110.63 105.07 103.03 103.87  
8 % - 1 111.76 111.40 103.94 102.12 104.79  
8 % - 2 111.01 111.00 103.24 101.56 104.47  
8 % - 3 112.80 112.16 104.91 103.02 105.46  
m.v. (*) 106.44 102.27 98.99 102.91 101.06  
s.d. 7.70 14.19 7.16 1.96 4.10  
rsd, % (**) 7.2 13.9 7.2 1.9 4.1  
Confidence (95%) 5.92 10.91 5.50 1.51 3.15  
*Specification: average recovery value 90 – 110 %, **rsd ≤ 15 % 
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CHAPTER 5 
 
Formulation factors affecting the isomerisation rate of 
betamethasone 17-valerate in a developmental hydrophilic cream 
- A HPLC and microscopy based stability study 
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Betamethasone is a synthetic corticosteroid with anti-inflammatory properties which is 
employed in the treatment of inflammatory skin disorders such as eczema and psoriasis 
1,2
. Topical application of betamethasone base is not feasible since only 12 – 14 % of the 
administered dose of the drug is absorbed through the skin 
3
. To help improve local 
bioavailability the substance is normally administered in the form of one of its esters, 
such as betamethasone-17-valerate (BV) or betamethasone-17,21-dipropionate, which 
have increased lipophilic nature allowing for better penetration of the drug molecule 
across the lipid membranes of the skin 
4,5
. BV is one of the more potent and commonly 
used esters of betamethasone and is available in several marketed products for topical 
use, such as Betnovate
® 
Cream (GlaxoSmithKline) for monotherapy, or together with 
clioquinol in Betnovate
TM
-C (GlaxoSmithKline) for combinational therapy of 
inflammatory skin-conditions with mild secondary infections.  
The formulation of BV into a suitably stable vehicle is often problematic. The 
substance is susceptible to an acid and base catalysed isomerisation in aqueous and 
semi-solid formulations resulting in an acyl group migration from position C-17 to the 
more stable C-21 position of the steroid ring system 
6
 (Figure 49). This isomerisation 
process is of significant clinical relevance since betamethasone-21-valerate 
demonstrates only ≈ 1/15th of the potency of its 17-valerate counterpart 5. In order to 
guarantee the safety and efficacy of drug products containing BV, the rate of 
isomerisation must be kept to a minimum. 
In a highly regulated environment such as the pharmaceutical industry, the 
stability of pharmaceutical preparations is ensured through extensive analytical testing. 
The data generated through this testing is used as a basis for justifying the shelf-life of a 
pharmaceutical product. In a clinical setting such as in a hospital pharmacy, however, 
physicians often like to prescribe dilutions of topical corticosteroids in order to reduce 
possible side-effects associated with their use, such as skin atrophy and pigmentation 
loss 
5
. Very often, such dilutions do not undergo the same rigorous analysis as the 
original product and the short- or long-term stabilities of these dilutions may not be 
known. The practice of dilution of marketed corticosteroids is widespread and appears 
in principle to be justified, since numerous studies have shown that the relationship 
between concentration and activity of topically applied glucocorticoids is non-linear 
5,7
, 
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with much weaker dilutions often demonstrating similar activity to the undiluted 
original product in vasoconstriction assays 
2,7–9
. However, due to the lack of stability 
data there may be potential issues regarding the safety and efficacy of such dilutions. 
 
 
Figure 49 Schematic of the isomerisation of betamethasone 17-valerate 
 
Previously published studies on this topic have demonstrated that the dilution of 
semi-solid formulations containing BV can affect the stability of the drug substance. It 
has been shown that the choice of diluent plays a crucial role with regard to the 
isomerisation process. For example, 1:4 dilutions of Betnovate
®
 in Unguentum Merck 
and white soft paraffin were stable over 12 months 
5
, whereas dilutions in Emulsifying 
Ointment showed 50 % degradation within several hours 
10
. Many of the published 
studies offered little explanation as to why the diluent was influencing the isomerisation 
rate 
5,6,9–11
. In most cases, the increased rate of isomerisation was attributed to an 
increased pH of the diluted preparation, without consideration of other factors.  
Boonsaner et al 
8
 studied the stability of betamethasone 17-valerate in Beeler’s Basis 
and Cold Cream
®
 and came to the conclusion that the degradation rate cannot be solely 
dependent on the pH alone but that other unknown factors must be involved. It was 
demonstrated that preparations with similar pH values can show very different 
stabilities. No conclusive evidence was provided as to what these unknown factors may 
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have been. During the early stages of formulation development it became apparent that 
other factors not related to the pH were affecting the isomerisation rate of BV in the 
initial trial formulations. Since the above mentioned literature studies did not provide a 
plausible explanation with regard to the isomerisation process in semi-solid dosage 
forms, it was necessary to study this process more extensively. 
The primary aim of the research described in this chapter was to investigate which 
formulation factors influence the isomerisation rate of BV in a model hydrophilic 
cream. Different variables, such as, (i) the types and concentrations of excipients;  (ii)  
the influence of oxidative processes and (iii) the effect of trace metals, were  
investigated. It was intended that the information gained through these studies would 
then be used to develop a stable, marketable topical medication containing both BV and  
FA for the treatment of inflammatory skin disorders with secondary infections. 
  
  Initial trial batches 5.3.1
The necessary excipients for the manufacture of the cream were chosen based on the 
knowledge and expertise of the responsible formulation chemists as well as on 
regulatory requirements. An overview of these components is presented in Table 29. 
A number of trial formulations were prepared with different quantities of the 
excipients Stearate-20 (S-20), Cetylstearyl alcohol (CSA) and Hydroxypropylmethyl 
cellulose (HPMC), the proportions of which are also provided in Table 29. These trial 
formulations were the first test formulations which were physically stable enough to be 
placed on long-term and accelerated stability studies, i.e. the respective oil-in-water 
(O/W) emulsions demonstrated no significant phase separation. The batches were 
labelled 18I, 18II, 19 and 20 (see Table 29). In contrast to the other formulations, 
variant 18I contained the antioxidant alpha-tocopherol, which was added to investigate 
if oxidative processes were likely to affect the stability of the drug substance. The 
quantities of all other ingredients of the cream as well as the manufacturing procedure 
and equipment were identical for all batches. In each case, the pH was adjusted to 5.0 ± 
0.2 and the active pharmaceutical ingredients were initially present in suspended form 
in each of the cream formulations. 
 Aim 5.2
 Results 5.3
 122 
The stability of each of the trial formulations was determined by HPLC analysis 
12,13
 after storage for 1 month under real-time (25 °C/60 % RH) and accelerated (40 
°C/75 % RH) stability conditions. The results indicated that variant 20 was markedly 
more stable than any of the other variants with regard to the isomerisation rate (Figure 
50 a). Variants 18I, 18II and 19 contained approx. 3 % - 4 % betamethasone-21-valerate 
after storage for 1 month at 25 °C/60 % RH. This level of degradation was considered 
unacceptable since this quantity of impurity would normally be expected to appear after 
24 – 36 months storage in a comparable pharmaceutical product. Furthermore, current 
guidelines 
14,15
 require that the content of the drug substance should lie between 95 – 
105 % or, if justified, between 90 – 105 % of the label claim throughout the shelf-life of 
the product. The above results indicated that, in variant 18 for example, the API would 
have been completely degraded after 36 months, if the isomerisation had continued at a 
linear rate.  
 
Table 29 Formulations of the first experimental batches 
  Var. 18I with tocopherol 
 
Var. 18II 
 
 
Var. 19 
 
 
Var. 20 
 
Article Description 
Proportion 
in % mass 
Proportion 
in % mass 
Proportion 
in % mass 
Proportion 
in % mass 
1 
Macrogolstearylether-20  
(S-20) 
5.0000 5.0000 5.0000 3.6500 
2 
Cetylstearyl alcohol  
(CSA) 
5.0000 5.0000 5.0000 6.3500 
3 Paraffin, liquid 21.8800 21.8800 21.8000 21.8800 
4 White Vaseline  9.8200 9.8200 9.8200 9.8200 
5 Water, purified 21.5050 21.5050 11.5060 18.0000 
6 Methyl paraben 0.1000 0.1000 0.1000 0.1000 
7 Propyl paraben 0.0200 0.0200 0.0200 0.0200 
8 Potassium sorbate 0.2500 0.2500 0.2500 0.2500 
9 Water, purified 15.0000 15.0000 25.0000 18.5050 
10 Citric acid-monohydrate 0.1000 0.1000 0.1000 0.1000 
11 
Hypromellose  
(HPMC) 
1.0000 1.0000 2.0000 0.5000 
12 Paraffin, liquid 13.3000 13.3000 13.3010 13.3010 
13 Fusidic acid 0.5H2O 2.4000 2.4000 2.4000 2.4000 
14 Betamethasone 17-valerate  0.1214 0.1214 0.1214 0.1214 
15 Paraffin, liquid 4.5000 4.5000 5.0000 5.0000 
16 Tocopherol, alpha- 0.0004 0.0000 0.0000 0.0000 
 
The data also seemed to indicate that reducing the quantity of HPMC to 0.50 % 
may slow the rate of isomerisation, whereas in contrast, increasing the quantity of 
HPMC from 1.00 % to 2.00 % did not affect the stability of BV. Decreasing the 
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quantity of S-20 to 3.65 % in combination with an increase of CSA to 6.35 % may also 
slow the rate of isomerisation. As evident by a comparison of the data from variants 18I 
and 18II, the addition of alpha-tocopherol to the formulation has no effect on the rate of 
isomerisation. It was therefore concluded that oxidative degradation processes are 
unlikely to play a role in the observed degradation of BV in the investigated hydrophilic 
formulation. 
 
 Optimisation I 5.3.2
 Methodology 5.3.2.1
Despite the encouraging data from variant 20, the stability of the first trial batches 
proved to be unacceptable, requiring optimisation of the formulation. Further 
experimental batches were manufactured and subjected to stability studies/HPLC 
analysis in a similar fashion to the initial formulations. The compositions of these 
optimised formulations are provided in Table 30. Some of the optimisation steps 
included (i) varying the concentrations of S-20 and HPMC; (ii) use of an alternative 
emulsifier, Macrogolstearylether-21 (S-21); (iii) addition of disodium edetate in order to 
remove metal contaminants; as well as the addition of the API to the aqueous phase of 
the cream rather than the oil phase (iv). 
 
 Effect of S-20, CSA and HPMC concentrations 5.3.2.2
The data generated after 5 months real time storage and 1 month accelerated storage is 
presented in Figure 50 (c/d) and demonstrates that increasing the content of HPMC 
from 0.50 % to 1.00 % increases the isomerisation rate. In contrast, a reduction of the 
quantity of S-20 from 5.00 % (variant 18II) to 2.14 % (variant 14) coupled with an 
increase of the quantity of CSA from 5.00 % (variant 18II) to 7.86 % (variant 14) 
appeared to slow the rate of isomerisation. Replacing S-20 with Macrogolstearylether-
21 (S-21) also appeared to slow the rate of isomerisation, whereas suspending the API 
in the aqueous phase of the cream (as opposed to the oil phase) did not improve 
stability. 
HPMC is present in the formulation as a thickening agent which in theory should 
not affect the stability of BV. However, according to the Technical Handbook for 
METHOCEL Cellulose Ethers from the DOW chemical company 
16
, Methocel (HPMC) 
also possesses emulsifying properties and can act as a surfactant in solution. It was 
therefore considered possible that HPMC may help to increase the solubility of BV in 
the aqueous phase of the cream, leading to an increased rate of isomerisation. Despite 
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being theoretically possible, it seemed unlikely that an increase of the content of HPMC 
by 0.50 % could lead to such a dramatic increase of the isomerisation rate from 10 % 
(0.50 % HPMC) to 35 % (1.00 % HPMC) after 1 month storage.  Furthermore, the data 
from the initial trial batches did not support this hypothesis, since variant 19 contained 
2.00 % HPMC and did not show such as marked increase of isomerisation as compared 
to variant 18. After further review of the formulations and analytical data it was noticed 
that variant 18 with 1.00 % HPMC had a pH value of 6.0 in contrast to the other 
variants which had pH values of 5.0 ± 0.2. Since it was known from the studies of 
Bundgaard and Hansen 
17
 that the kinetics of the transesterification of BV to the 21-
valerate ester in aqueous solution is pH dependent, it was considered likely that the shift 
in pH from 5 to 6 was responsible for the increased isomerisation rate. Repeat 
experiments confirmed this hypothesis. When the pH of the cream was kept constant the 
concentration of HPMC had no influence on the isomerisation rate. Experiments in 
aqueous media later showed that the pH increases with increasing HPMC concentration. 
 
 Effect of disodium edetate, S21 and O/W phase 5.3.2.3
Literature studies indicate that the presence of trace metals in pharmaceutical 
preparations can cause degradation of glucocorticoids 
18,19
. For this reason the influence 
of the chelating agent disodium edetate on the degradation rate of BV was investigated 
(variant 18 with EDTA). The results showed little improvement in stability as compared 
to variant 18 without EDTA, e.g. variant 18 with 0.5 % HPMC. It could be concluded 
that metal ions are unlikely to influence the isomerisation rate of BV in the cream. 
Likewise, the suspension of the API in the aqueous phase did not significantly influence 
the isomerisation rate, indicating that the presence of water alone is not sufficient to 
initiate the isomerisation process. This was perhaps to be expected since BV is 
practically insoluble in water
 20
. This observation, however, confirmed that the API 
must be in solution for the isomerisation to take place and, furthermore, that some 
component of the cream must be enhancing the solubility of the initially suspended BV 
crystals in the aqueous phase of the cream. Since it had been observed that a reduction 
of the concentration of S-20 leads to an increased stability, it was suspected that this 
emulsifying compound was aiding the dissolution of the suspended BV crystals into the 
aqueous phase of the drug formulation.  
In the initial experiments, replacing S-20 with S-21 appeared to decrease the 
isomerisation rate of BV. The chemical structures of S-20 and S-21 differ in the number 
of oxyethylene (-OC2H4) groups attached to the stearic acid chain. Both substances have 
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very similar HLB values (Hydrophilic-Lipophilic-Balance) of 15.2 and 15.5
 
according 
to the   manufacturer 
21
, indicating that they are likely to show very similar solubilities 
in aqueous solution. The HLB value is a measure of the relative hydrophilicity or 
lipophilicity of a surfactant and higher values indicate increased water solubility. Due to 
the similarity of the HLB values it would be expected that both substances would 
influence the stability of the cream formulation to a similar extent. Repeat experiments 
could not confirm the initial observation and it was finally concluded that no major 
differences exist between these substances with regard to their influence on the 
isomerisation process. Due to commercial and regulatory considerations, however, S-21 
was employed in all further experiments. 
 
 Optimisation II 5.3.3
The results of the initial and optimisation I experiments demonstrated that reducing the 
content of S-20/21 from 5.00 % (variant 18) to 3.65 % (variant 20) and further to 2.14 
% (variant 14) significantly slowed the rate of isomerisation. In order to investigate this 
effect in more depth, further trial formulations were produced containing less S-21 and 
with varying quantities of CSA. The goal was to find the optimum concentration of 
these components which would provide the lowest rate of isomerisation without 
compromising the physical stability of the cream. The proportions of liquid paraffin and 
Vaseline were also adjusted with the aim of optimising the physical stability of the 
preparation. The accelerated stability studies demonstrated that maximum physical- and 
chemical stability was achieved with 1.5 % S-21 and 5.5 % CSA (variant 36, Figure 52 
a/b)). Reducing the S-21 concentration to 1.00 % did not appear to bring further 
improvement. Stability studies of the final formulation (variant 36) which were 
performed under real time conditions showed no apparent increase of betamethasone-
21-valerate content after 1 month and < 3 % increase after a period of 36 months 
storage.              
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 (a)  
 
   (c)  
 
 (b)  
 
   (d) 
Figure 50 Graphs showing the stability data of the initial- (a/b) and optimised trial formulations (c/d) at 25 °C (upper graphs) and 40 °C (lower graph). Displayed results are 
an average of n=2 measurements 
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Table 30 Quantities of S-20, CSA and HPMC in the optimised test formulations  
 
 Var. 14 Var. 14 with warming Var. 18 with 
0.5 % HPMC 
Var. 18 with  
1.0 % 
HPMC 
Article Proportion 
in mass % 
Proportion 
in mass % 
Proportion 
in mass % 
Proportion 
in mass % 
Macrogolstearylether-20/21 
(S-20/21) 
2.14 2.14 5.00 5.00 
Cetylstearyl alcohol 
(CSA) 
7.86 7.86 5.00 5.00 
Hypromellose 
(HPMC) 
0.50 0.50 0.50 1.00 
  Var. 18 with 
0.1 % Na2EDTA 
Var. 18 
with Steareth-21 
Var. 18 
API in H2O 
 
Article Proportion 
in mass % 
Proportion 
in mass % 
Proportion 
in mass % 
Macrogolstearylether-20/21 
(S-20/21) 
5.00 5.00 5.00 
Cetylstearyl alcohol 
(CSA) 
5.00 5.00 5.00 
Hypromellose 
(HPMC) 
1.00 1.00 2.00 
 
 Confirmational study 5.3.4
As previously mentioned, optimisation of the concentrations of S-21 and CSA resulted 
in an increased chemical stability of BV, whilst optimisation of the proportions of 
Vaseline and liquid paraffin lead to an increased physical stability of the cream 
preparation. In order to demonstrate definitively that the reduction of the concentration 
of the emulsifier gives rise to the increased stability of BV, and not, for example, the 
adjustment of the Vaseline and paraffin quantities, the concentration of S-21 in 
optimised variant 36 was again increased from 1.5 % to the initial concentration present 
in variant 18, i.e. 5.00 %. The concentrations of all other components of the cream 
remained equivalent to the optimised variant 36. The HPLC stability results confirmed 
unequivocally that an increase of the concentration of the primary emulsifier, S-21, 
leads to an increase of the isomerisation rate.  
 
 Effect of pH on the isomerisation rate  5.3.5
The effect of pH on the isomerisation rate of BV was investigated in both aqueous 
solution and in the cream preparation itself. The substance is stable in aqueous solution 
at pH values between 1.2 and 4.2 with an optimum of approx. 3.2 in this experiment. 
This is in good agreement with the reported literature value of 3.5 
11
. Above pH 4.2 the 
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rate of isomerisation increases gradually, then increasing very rapidly above pH 6.2.  
Complete isomerisation of BV was observed after 48 hours at pH 8.2 (see section 3.5). 
 A similar trend was observed in the cream preparation (Figure 52 (c)). At pH 
values between 2.7 and 5.3 the drug substance is relatively stable, although some 
degradation still occurs. At higher pH values, e.g. > 6,  the isomerisation rate increases 
very rapidly giving rise to complete isomerisation within 1 month at pH 7.6 and 
40°C/75 % RH. A pH range of between 5.0 ± 0.5 was chosen for the cream since this 
range is a compromise between skin tolerability and drug stability. Lower pH values are 
generally considered too acidic for topical treatment (in particular for the treatment of 
damaged skin where the healing process may be affected by the pH 
22
) and higher pH 
values would compromise the stability of the API, as demonstrated by the analytical 
results. 
 Experiments in liquid paraffin 5.3.6
During manufacture, BV is suspended in liquid paraffin before being added to the rest 
of the ingredients during the last stage of the process. In order to confirm that the 
isomerisation only occurs when an aqueous medium is present, the stability of BV in 
liquid paraffin was investigated by stressing under conditions which were known to 
give rise to isomerisation in aqueous solution. No isomerisation was observed, 
indicating that water is necessary for this process to occur. Since the API crystals are 
initially suspended in the cream, the BV must first dissolve into the aqueous 
(continuous) phase of the O/W emulsion for isomerisation to occur. This hypothesis was 
further investigated by experimentation in aqueous solution. 
 
 Effect of excipients on the aqueous solubility of BV 5.3.7
Since it was known that water is necessary for the isomerisation to occur, it seemed 
plausible to suggest that the cream preparation might be stabilised by decreasing the 
quantity of water in the formulation. However, from the very beginning of the 
formulation development process it had been decided that the finished formulation 
should contain between 60 – 70 % water, in order to ensure that the required physico-
chemical properties of the drug product were achieved. Furthermore, in a hydrophilic 
cream the quantity of water is likely to be vastly in excess of the minimum quantity 
required to dissolve the API in the presence of emulsifier. Small reductions of the water 
quantity are therefore highly unlikely to influence the isomerisation rate. More 
significant reductions of the water quantity would result in the manufacture of a cream 
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with different physico-chemical characteristics as required. This is not preferred since 
such characteristics, e.g. viscosity, are considered to influence the in-vitro and in-vivo 
release rates of drug substances from cream matrices 
23
. For this reason a reduction of 
the water content of the formulation was not further pursued. The most feasible option 
available was to try to reduce the solubility of the drug substance through modification 
of the quantities of non-aqueous excipient components in the cream matrix. 
 
 Effect of S-21 concentration on the solubility and  5.3.8
  stability of BV  
The relationship between the isomerisation rate of BV and the concentration of S-21 
was investigated over the range 0.0 % - 1.0 % of S-21. The influence of pH was 
removed by adjusting the pH of all solutions to 5.3 ± 0.2 during preparation. The 
solubility of BV was measured by HPLC using the purity procedure developed in 
Chapter 3. Figure 51 shows how the solubility of BV increases with increasing 
concentration of S-21. In contrast, the rate of isomerisation does not increase 
proportionally. This is because of the relatively favorable pH of 5.3 which prevents a 
rapid isomerisation from occurring (section 5.3.5). It was concluded that S-21 increases 
the solubility of BV in aqueous media, suggesting that the increased emulsifier 
concentration also leads to an increased solubility of BV in the drug product 
formulation.  
 
 
Figure 51  Effect of emulsifier concentration on the solubility and isomerisation rate of 
betamethasone-17-valerate in aqueous solution at pH 5.3. Displayed results are an average of n=2 
measurements
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      (a) 
 
 
 
      
 
 
 
 (c) 
     (b) 
Figure 52 Stability data from round II of optimisation, (a) 2 months at 25 °C/60 % RH, (b) 1 month at 40 °C/75 % RH, (c) demonstrates the influence of pH on the 
isomerisation rate of BV in the cream formulaton. Displayed results are an average of n=2 measurements
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 Effect of variation of both S-21 concentration and pH  5.3.9
The effect of simultaneously varying both S-21 concentration and pH was investigated 
by preparing samples in the same fashion as in section 5.3.8, the only difference being 
that appropriate buffers were employed over the pH range 3.2 to 7.2. Buffers were 
required due to the need to achieve accurate pH values over the specified range. The 
results (Figure 53) demonstrate that at higher pH values, e.g. 7, and low concentrations 
of S-21, the rate of isomerisation remains low, indicating that the BV must be 
solubilised into solution before the isomerisation can take place. At lower pH values, 
e.g. pH 3, and higher concentrations of S-21, the rate of isomerization remains low, 
indicating that the isomerization only takes place when the pH conditions allow. The 
results indicate that the BV must first be solubilised into the aqueous phase where the 
rate of isomerization is then pH dependent. This means that in the cream formulation 
higher concentrations of emulsifier more rapidly solubilize the BV thus increasing the 
overall concentration of drug substance present in the aqueous phase. Whether the BV 
then isomerizes is solely dependent on the pH of the surrounding matrix. 
 
 
Figure 53 Effect of both pH and emulsifier concentration on the isomerisation rate of BV in 
aqueous solution (pH 3.2 – 7.2). Displayed results are an average of n=2 measurements 
 
 
 Effect of Ethoxy-Chain Length of the Emulsifier on the 5.3.10
  Isomerisation rate  
Since the initial experimental data had suggested a correlation between the HLB value 
of the emulsifier (which is determined primarily by the ethoxy-chain length) and the 
rate of transesterification of BV, it was decided to investigate this effect further. Test 
formulations containing mixtures of emulsifiers with different ethoxy chain lengths 
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were manufactured and the stability of BV in these formulations was investigated over 
time. The compounds steareth-10 (S-10), S-21 and steareth-100 (S-100) were chosen for 
this purpose. Test batches were prepared by adding a further 3.5 % of each of the 
chosen emulsifiers to variant 36 which already contained 1.5 % of S-21. The batches 
were subjected to stability studies and tested at intervals of 1, 2, 3 and 6 months. 
The following mixtures were prepared: 
 
- Cream product with 1.5 % S-21 and 3.5 % S-10  HLB ≈ 13 
- Cream product with 5.0 % S-21     HLB ≈ 15 
- Cream product with 1.5 % S-21 and 3.5 % S-100  HLB ≈ 18 
- Cream product with 1.5 % S-21     HLB ≈ 15 
 
The results presented in Table 31 and Figure 54 show that the addition of a 
further 3.5 % of emulsifier leads to a marked increase of the isomerisation rate. There 
does, however, not appear to be a relationship between the HLB value of the emulsifier 
mix and the isomerisation rate. If, as hypothesised, an increase of the HLB value of the 
emulsifier results in a reduction of the isomerisation rate (this is what the initial data 
seemed to suggest), then it would be expected that the steareth-10 mixture would show 
the highest rate of isomerisation (HLB ≈ 13) and the steareth-100 mix the lowest (HLB 
≈ 18). This is not the case. It appears that the overall mass of emulsifier incorporated 
into the formulation is more important than its HLB value, as demonstrated by the very 
similar isomerisation rates observed for each of the macrogolstearylether variants. Note: 
all variants had pH values of 5.0 ± 0.2, ensuring that none of the results were affected by 
the pH. 
 
Table 31 Effect of the ethoxy chain length of the emulsifier on the isomerisation rate of BV 
Emulsifier Mixture % betamethasone-21-valerate 
Storage period (40 °C/75 % RH) 
 
0 
months 
1 
month 
2 
months 
3 
months 
6 
months 
1.5 % S-21 / 3.5 % S-10 0.0 5.45 9.98 12.01 27.40 
5.0 % S-21 0.0 5.19 7.89 10.07 25.29 
1.5 % S-21 / 3.5 % S-100 0.0 5.99 10.71 13.51 31.90 
1.5 % S-21 0.0 1.60 3.77 5.91 12.24 
 133 
 
Figure 54 Effect of the ethoxy chain length of the emulsifier on the isomerisation rate of BV         
in BV/FA cream stored at 40 °C/ 75 % RH. Displayed results are an average of n=2 measurements 
 
 
   Microscopy  5.3.11
The effect of modifying the concentration of emulsifier on the isomerisation rate was 
also examined by microscopy. This technique allowed for the direct observation of any 
dissolution phenomena of the suspended BV crystals in real time. One drawback of this 
technique, however, was that the BV employed in the cream formulation was 
micronised (particle size distribution of 90 % < 5 µm) which made the observation of 
these minute crystals difficult in such a complex matrix. This problem was overcome by 
employing non-micronised BV which had a particle size distribution of 90 % < 110 µm, 
thus making the observation of the dissolution of the crystals considerably easier. One 
batch of each of variant 18 (the least stable variant) and variant 36 (the most stable 
variant) were prepared with non-micronised BV and placed on stability for 1 year under 
accelerated conditions (40 °C/75 % RH). The microscopic profiles and chemical 
stability of the creams were analysed after 1, 2, 3, 6, 9 and 12 months.  
The micrographs presented in Figure 55 demonstrate that the BV crystals in 
variant 18 (with 5 % S-21) dissolve over time. After 12 months storage at 40 °C/75 % 
RH there are no visible crystals remaining in the cream. The data from the chemical 
analysis also indicates that the BV has significantly degraded under these conditions. In 
contrast, the BV crystals in variant 36 remain largely unchanged, a well-defined crystal 
structure being present throughout the entire study.  The isomerisation rate of BV is also 
much lower in variant 36 than in variant 18, as shown by the chemical data. This 
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confirms the hypothesis that increasing the concentration of emulsifier leads to a more 
rapid dissolution of the suspended crystals. 
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Figure 55 Micrographs and chemical data of BV crystals in variants 36 (top) and 18 (bottom) 
after storage at 40 °C/75 % RH (x 40, polarisation) 
 
 
The current study has demonstrated that the pH of the pharmaceutical vehicle is not the 
only factor to be considered when formulating BV into semi-solid drug products. The 
stability of BV in such products may be influenced by the concentration of the 
emulsifier to such a degree, that either practically no isomerisation occurs throughout 
the shelf-life, or alternatively, that complete isomerisation occurs within a number of 
hours. An increased concentration of S-20 or S-21 has been shown to enhance the 
solubility and isomerisation rate of BV in the aqueous phase of a hydrophilic cream. 
Maximum chemical stability was achieved at a concentration of ≤ 1.5 % (w/w) of this 
substance in the preparation. The data suggests that the co-emulsifier, CSA, does not 
play a significant role in the isomerisation process. Overall, the factors influencing the 
rate of isomerisation of suspended BV in a hydrophilic cream can be summarised as 
follows (Figure 56): 
 
 Discussion and Conclusions 5.4
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 It is necessary that BV is dissolved in aqueous solution in order for the 
isomerisation to take place. Transesterification will not occur to a significant 
extent in a non-aqueous environment, e.g. a fatty, anhydrous ointment. 
 At high concentrations of emulsifier such as S-20 or S-21 (e.g. 5 %) and higher 
pH values (e.g. > 6) there is a rapid rate of isomerisation. 
 At high concentrations of emulsifier such as S-20 or S-21 (e.g. 5 %) and lower 
pH values (e.g. < 4) there is a moderate rate of isomerisation which is pH 
dependent. 
 At low concentrations of emulsifier (e.g. 1 %) and higher pH values (e.g. > 6) 
there is a moderate rate of isomerisation which appears to be mainly dependent 
on the solubility of the API in the aqueous phase. 
 At low concentrations of emulsifier (e.g. 1 %) and lower pH values (e.g. < 4) 
there is a slow rate of isomerisation, since very little BV is dissolved in the 
aqueous phase and the quantity which is dissolved isomerises at a slow rate due 
to the low pH. 
 
In order to optimise the stability of BV in a hydrophilic cream suspension, both the 
concentration of emulsifier and the pH value should be kept as low as possible. It seems 
reasonable to hypothesise that the instabilities observed on dilution of BV creams with 
emulsifying ointment and other emulsifier containing diluents in previous studies 
9,10
 
may have been due to an increased solubility of BV in the aqueous phase. This study 
demonstrates that the concentration of emulsifier chosen for a topical vehicle containing 
BV is likely to be of critical importance when developing a stable formulation. Equally, 
the diluent used for diluting marketed corticosteroid preparations must be chosen with 
care, taking not only pH but also emulsifier concentration into account. Based on the 
observed mechanism, it seems plausible that the findings are also relevant for other 
topically formulated C-17 esterified glucocorticoids, although this remains to be 
confirmed. In the case of Betamethasone/Fusidic acid cream a stable formulation was 
obtained with 1.5 % S-21. The complete formulation of the final cream is presented in 
Table 32. It should be noted that for reasons of intellectual property the manufacturing 
process for the cream cannot be disclosed. Fusicutan
®
 plus Betamethason cream (Figure 
57) came to market in Germany, Austria, Poland and Croatia in early 2017. The 
application for a Europe-wide market authorisation is in progress.  
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Figure 56 Schematic of the effect of emulsifier concentration and pH on the isomerisation rate of 
BV in a hydrophilic cream 
 
 
Figure 57 Fusicutan
®
 plus Betamethason Cream which came to market in early 2017 
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Table 32 Final formulation of Fusicutan
®
 plus Betamethason Cream 
 
Article 
Proportion in mg/g 
Cream 
Macrogolstearylether-21 (S-21) 15.000 
Cetylstearyl alcohol (CSA) 55.000 
Paraffin, liquid 318.636 
White Vaseline  215.000 
Water, purified 365.290 
Methyl paraben 0.800 
Propyl paraben 0.160 
Potassium sorbate 2.500 
Citric acid-monohydrate 1.000 
Hypromellose (HPMC) 5.000 
Fusidic acid hemihydrate 20.400 
Betamethasone 17-valerate  1.214 
Σ 1000.000 
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CHAPTER 6 
 
Polymorphism in Commercial Sources of the Antibiotic Fusidic 
acid –  A Study of its Effects on the Stability of the Drug 
Substance and its Release Rate from a Marketed Topical Drug 
Product 
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Pharmaceutically active substances often exist in a number of different crystalline 
forms. The existence of two or more crystalline forms of the same substance, which 
have different arrangements and/or conformations of molecules in their respective 
crystal lattices, is known as polymorphism 
1,2
. Differences in crystal structure may also 
arise due to incorporation of water (termed hydration) or solvent molecules (termed 
solvation) into the crystal lattice of a drug substance, a state known as 
pseudopolymorphism 
3,4
.  Apart from existing in several crystalline states, drug 
substances can also exist in an amorphous state, which differs from the crystalline state 
in that there is no long range order of molecules within a lattice structure. 
 As mentioned above, crystalline substances show long range order of the 
molecules within the crystal lattice. Thus, crystals may be considered as being made up 
of numerous repetitions of a single 3-dimensional structure, or unit cell 
5
. Lattice theory 
describes the 3-dimensional packing of molecules within a unit cell and according to 
this theory; any individual crystal may be classified as belonging to one of seven 
possible crystal classes, which are: cubic, tetragonal, orthorhombic, monoclinic, 
triclinic, hexagonal and trigonal 
5
. Each class is defined by the relationships between the 
individual dimensions, a, b and c, and the individual angles, α, β and γ, of the unit cell 5 
(Figure 58). 
 
Figure 58 Example of a triclinic unit cell [6] 
 
 Further to the assignment to a particular crystal class, a crystal may also be 
designated to one of 14 Bravais lattices, and further to one of the 230 individual space 
groups which exist 
7
. Consequently, lattice theory allows for a complete description of 
the relative positions and symmetries of atoms and/or molecules in a unit cell. Since 
polymorphs of the same substance differ in how the molecules are packed within the 
 CHAPTER 6 - Polymorphism in Commercial Sources of Fusidic acid 6
 Introduction 6.1
  
142 
unit cell, two forms of the same substance may belong to completely different crystal 
classes and/or space groups.   
 Due to differences in lattice structures and energies, different polymorphs of the 
same substance may vary in their physical properties, such as stability, solubility, 
melting point, density, hardness as well as optical and electrical characteristics 
8–10
. It is 
these differences that make polymorphism such an important aspect in drug product 
development. One high-profile case of crystal polymorphism, involving the HIV 
protease inhibitor, ritonavir, (marketed as Norvir
®
 in liquid and capsule form by Abbott 
Laboratories), was reported in the late 1990’s. New polymorphs of the drug substance 
were only detected after the already marketed product began failing dissolution testing 
11,12
. It was subsequently discovered that a polymorphic conversion of the drug 
substance in the capsule preparation during storage was responsible for the failed 
dissolution results. This discovery eventually led to the removal of the capsule dosage 
form from the market 
11
. In total, five crystal forms of ritonavir were subsequently 
discovered. Micrographs of Forms III and IV are presented in Figure 59. The above case 
exemplifies the importance of polymorphism in pharmaceutical development and it is 
the goal of the development chemist to select the most stable polymorph of a substance 
for incorporation into the intended drug product. This can be challenging since many 
polymorphs are metastable and their stability may be dependent on several factors, such 
as the drug product formulation as well as the environmental and chemical conditions 
present during manufacture and storage. 
 During the manufacture of a drug product, the active drug substance may be 
subjected to both thermal and mechanical stress, which can result in conversion of the 
 
Figure 59 Photomicrographs of different polymorphs of ritonavir, a HIV protease inhibitor (a = 
Form III, b = Form IV) [11] 
 
desired polymorphic form to a less desirable form, or to the generation of amorphous 
material within the bulk substance. This is highly undesirable since the presence of a 
different polymorph could alter the efficacy of the drug product. The presence of 
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significant quantities of amorphous material in the bulk substance can also influence the 
stability of the product, since amorphous materials tend to be more soluble and less 
stable than their crystalline equivalents. Examples of stress factors encountered during 
the manufacture of drug products include: drying, homogenizing, milling, grinding, wet 
granulating and compaction.  
 Often, drug substances must be micronized before they can be incorporated into 
drug products. Micronisation is a mechanical process for reducing the particle size of 
bulk drug substances in order to improve their homogeneity and bioavailability in the 
finished drug product. This is normally performed by jet-milling or grinding. Both of 
these processes are highly energetic and can lead to polymorphic interconversion, 
particularly, if the drug product is present in a metastable form. The grinding of the 
antibiotic substance chloramphenicol palmitate is an example of such a process, where 
it was observed that Form B converted to the less therapeutically desirable form A 
during grinding 
13
. Further examples of process related polymorphic conversions 
include the conversion of Form II of the neuroleptic drug substance chlorpromazine 
hydrochloride 
13
  to Form I during wet granulation; the conversion of the monohydrate 
Form C of the barbiturate phenobarbital to the anhydrous Form B during drying at 45 
°C 
13
; as well as the conversion of the needle-like α-Form of the non-steroidal anti-
inflammatory piroxicam to the cubic β-Form during the compaction stage of tabletting 
13
.  
 It has been well documented that polymorphs of the same drug substance can 
possess different stabilities and/or solubility properties, which may lead to variations in 
local- and/or systemic bioavailability 
14–17
. Drug substances which show differences in 
stability between their respective polymorphs include: Fenretinide, where Form I was 
shown to be more stable than Form II at all temperatures between 4 °C and 80 °C 
18
; 
Enapril maleate, where in contrast to form I,  form II was shown to be unsuitable for 
tablet production 
19
; and furosemide where form II was found to be more photolabile 
than form I 
20
. The above examples demonstrate that polymorphism is a complex theme 
which can present significant problems when a pharmaceutical manufacturer needs to 
change supplier of an active pharmaceutical ingredient (API) or add a second supplier in 
order to ensure a constant supply of a particular drug substance. In such cases, it must 
be ensured that the alternative drug substance is of the same polymorphic form as the 
original, which necessitates characterisation studies of the crystalline structure, 
solubility and in-vitro-release properties of the API from the drug product, as well as the 
performance of suitably designed stability studies 
1,3,21
.  
  
144 
 FA is known to demonstrate polymorphism, with 4 crystalline forms (I – IV) 
described to-date in relevant literature 
22–24
. Despite the fact that FA has been on the 
market for several decades 
25
, polymorphism in this substance has only been 
documented in more recent times and to-date no relevant data has been published with 
regard to the release rate of different polymorphs of FA from topical pharmaceutical 
formulations. This is surprising given the strict legislative requirements with regard to 
the use of different polymorphic drug forms in pharmaceutical products 
26,27
.  
The goal of the current study is to investigate polymorphism in commercial sources of 
fusidic acid and to assess its effects on the stability of the bulk drug substance and its  
in-vitro release from the topical pharmaceutical dosage form developed in Chapter 5. 
This information is of critical importance when considering whether FA from different 
commercial sources can be used interchangeably in the developed drug product without 
significant implications for the safety and efficacy of the product. The study will also 
investigate the influence of micronisation on the stability of the drug substance. 
Fusidic acid was purchased from Ercros SA (Madrid, Spain, Manufacturer A), Joyang 
Laboratories (Jiangsu, China, Manufacturer B) and OJSC Biosintez (Penza, Russia, 
Manufacturer C). Gradient grade methanol and acetonitrile were purchased from VWR 
International GmbH (Darmstadt, Germany). Purified water was obtained from the in-
house purification system at mibe GmbH Arzneimittel (Brehna, Germany). Phosphoric 
acid (85 % m/m, analysis grade, d = 1.71 g/ml) was purchased from Merck (Darmstadt, 
Germany). All cream samples were provided by mibe GmbH Arzneimittel (Brehna, 
Germany). 
 The materials and methods employed for measurement of the intrinsic 
dissolution and In-vitro release rate are described in sections 2.3 and 2.4. XRPD 
experiments were performed as described in section 2.2. All stability studies were 
performed in Binder KBF 720 stability chambers (Binder Inc., USA) according to ICH 
Guideline Q1A 
28
. FTIR analysis was performed on a Perkin-Elmer SpectrumOne 
spectrophotometer (Perkin-Elmer, Massachusetts, USA) 
 
 
 
 Aim 6.2
 Materials and Methods  6.3
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 FTIR, XRPD and Microscopic Analysis 6.4.1
The characterisation of FA has been described in several patents 
23,24
 as well as in 
mainstream scientific literature 
22
. Extensive data has been published, including FTIR- 
spectra and XRP diffractograms of each of the polymorphic forms of FA discovered to 
date.  The most significant differences between the FTIR spectra of these forms are 
observed in the region 1650 cm
-1
 to 1750 cm
-1
. Form I shows a single stretching band at 
≈ 1720 cm-1, whilst form II shows a band at  ≈ 1720 cm-1 and an additional stretch at ≈ 
1697 cm
-1
. Form III shows two very distinct bands at approx. 1748 cm
-1
 and 1688 cm
-1
. 
A comparison of the literature data with the FTIR data of FA from the commercial 
samples shows that FA from Manufacturer A is of Form III, FA from Manufacturer C is 
of Form I and that FA from Manufacturer B comprises predominantly of Form III but is 
not of pure crystalline form. It contains significant quantities of either Form I or Form 
II, which can be seen by the presence of an extra absorption band at ≈ 1720 cm-1 (Figure 
60). 
Powder X-Ray diffraction analysis of FA from manufacturers A, B and C (Figure 
62) demonstrates that A and B are of similar crystal form (form III), since both 
diffractograms are comparable for all significant reflexes. In contrast, the diffractogram 
of FA from Manufacturer C shows significant differences to A and B and is comparable 
with the literature data for Form I. The XRPD data agrees with the results of the FTIR 
analysis. Scanning electron micrographs of FA from each of the manufacturers show 
differences in morphology (Figure 62). FA from Manufacturer A and B comprises of 
flat, irregularly shaped particles whilst FA from Manufacturer C comprises of 
predominantly spherical particles. 
 
 Stability Studies 6.4.2
Stability studies of micronised and non-micronised FA from each manufacturer were 
performed according to the relevant ICH Guidelines with a view to investigating if the 
polymorphic modification of FA influences the stability of the bulk drug substance 
during storage. It should be noted that the particle size distributions of FA from each 
manufacturer were comparable. Samples comprising of 5 g of drug substance stored 
under a nitrogen atmosphere in a suitably sealed polyethylene bag, which was further 
packaged in a heat sealed aluminium sachet, were placed on stability under the 
conditions of 5 ± 3 °C, 25 °C/60 % relative humidity (RH), 30 °C/65 % RH and 40 
°C/75 % RH for 24, 24, 12 and 6 months, respectively. 
 Results 6.4
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The results (Figure 61 a, b and c) demonstrate that the stability of FA is 
temperature dependent. The greatest stability is observed at 5 ± 3 °C with the stability 
decreasing with increasing temperature. No significant difference in stability was 
observed between polymorphic Form I (Manufacturer C) and Form III (Manufacturers 
A and B) under ICH conditions. However, the data showed that micronisation of the 
API has a negative effect on the stability of FA, as demonstrated by the higher levels of 
impurities observed as compared to the non-micronised material. This is likely due to 
the reduction of the particle size and corresponding significant increase of the specific 
surface area of the substance after micronisation. XRPD and FTIR analysis confirmed 
that the polymorphic form of FA does not change during micronisation or storage. 
 
 Stress tests 6.4.3
The results of the ICH stability studies showed that there are no significant differences 
in stability between polymorphic forms I and III under the chosen conditions. This 
however was no guarantee that there are no differences in the intrinsic stabilities of the 
different modifications under other conditions. In order to examine this further, the 
effect of humidity and light were investigated under stress conditions. Light and 
humidity were chosen as stress factors because experience had shown that these factors 
give rise to degradation in FA. The photo-stability of FA was examined according to 
ICH guideline Q1B, whereby the samples were illuminated with 1.2 million lux hours at 
an energy of 200 watt hours/m
2
. The humidity test was performed by placing FA in an 
open container and storing at 60 % relative humidity for 6 months. The results of both 
tests indicated that FA from Manufacturer B was significantly less stable under these 
conditions than FA from either of the two other manufacturers (Figure 61 d). This 
instability may be due to the fact that this product does not consist of a pure 
polymorphic form, but of a mixture of two or more forms. The further investigation of 
this point was beyond the scope of this work. 
  
147 
 
 
Figure 60 FTIR spectra of FA from manufacturers A (black), B (red) and C (blue) demonstrating major differences, particularly in the region 1600 cm
-1
 to 1800cm
-1
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Figure 61 Results of stability studies on FA at 5 °C /24 months (a), 25 °C/60 % RH/24 months, 40 °C /75 % RH/6 months as well as under photolytic stress conditions as 
described in ICH Q1B(Manufacturer A = 432-M - 463-M; Manufacturer B = 140101FA - 131213FA; Manufacturer C = 89113 - 831113) 
(A) (B) 
(C) (D) 
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Figure 62  X-ray powder diffractograms and scanning electron micrographs of FA from 
Manufacturer A (micronised, form III), B (non-micronised, form III) and C (non-micronised, form I) 
showing differences amongst manufacturers 
 
 Intrinsic Dissolution Rate 6.4.4
The solubility properties of FA from each of the three manufacturers were compared by 
measuring the intrinsic dissolution rates of samples from each manufacturer according 
to Ph. Eur. 2.9.29 using the rotating cylinder apparatus. Samples were taken at 10, 20, 
30, 40, 50 and 60 minute intervals and the cumulative release rate in mg was plotted 
against time. The intrinsic dissolution rate (mg/min/cm
2
) was calculated as the slope of 
(A) 
(B) 
(C) 
(B) 
(C) 
(A) 
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the best-fitting line (mg/min) of this plot divided by the surface area of the drug 
substance (= 0.5 cm
2
). The measured release rates were 0.42, 0.36 and 0.30 mg/min/cm
2
 
for manufacturers A, B and C, respectively (Figure 63, Table 33). Statistical analysis of 
the data showed no significant difference between the IDR profiles of FA from the 
different manufacturers, indicating that the samples have comparable intrinsic 
dissolution rates (see appendix 2 for an example of the statistical analysis procedure). 
 
 
Figure 63 Intrinsic dissolution data – plot of cumulative release versus time. Displayed values are 
an average of n=6 measurements 
 
Table 33 Intrinsic dissolution rates of FA from manufacturers A, B and C 
 
slope unit Slope/Surface area unit 
Manufacturer A (Ercros) 0.1809 mg/min 0.36 mg/min/cm
2
 
Manufacturer B (Joyang) 0.2120 mg/min 0.42 mg/min/cm
2
 
Manufacturer C (OJSC) 0.1494 mg/min 0.30 mg/min/cm
2
 
Surface area of disc = 0.5 cm2 
     
 
 In-Vitro-Release Profile from Fusicutan® plus  6.4.5
  Betamethason Cream 
The results of the intrinsic dissolution tests indicated that the investigated samples show 
comparable dissolution rates in the model system used for this test. This data provides 
useful clues about the comparability of the solubility properties of the measured 
samples. It can however not easily be extrapolated to the release rate of the drug 
substance from a semi-solid drug product. In semi-solid systems the drug substance is 
very often suspended, with only a fraction of the total quantity of drug substance being 
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dissolved in solution. In order to compare the release rates of drug substances from such 
preparations an in-vitro penetration test is often employed. One of the most commonly 
employed versions of such a test uses a vertical diffusion cell, or Franz cell, comprising 
of a jacketed, vertical diffusion cell connected by appropriate tubing to a heated 
reservoir of fluid which is continuously pumped around the system to ensure a constant 
temperature of 32 °C,  thus mimicking the temperature at the external skin surface 
(Figure 64) 
 
Figure 64 Franz Cell Apparatus (Vertical Diffusion Cell) 
 
Figure 65  In-vitro-release profiles of FA from Fusicutan
® 
plus Betamethasone cream 
 
In order to demonstrate the discriminatory power of the procedure, i.e. the ability 
of the procedure to detect differences in the release rates of API from different cream 
formulations, a batch of cream was prepared which contained non-micronised fusidic 
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acid. The release rate for this batch was significantly slower than for the batches which 
contained micronised material. The slower release rate can be attributed to the larger
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Table 34  Example calculation spreadsheet for the statistical comparison of the intrinsic dissolution rates (part I) 
 
STATISTICAL EVALUATION OF INTRINSIC DISSOLUTION DATA (related to  Wilcoxon Rank Sum/Mann-Whitney Rank Test) 
                 
                 
                 Product 1 Time t1/2 Cumulative Release [mg] 
        [Minutes] [Minutes] Cell 1 Cell 2 Cell 3 Cell 4 Cell 5 Cell 6 Mean s.d. 
      Joyang 20 4.47 8.930 8.040 9.340 8.340 7.980 8.860 8.582 0.498 
      Ch: 140102FA 30 5.48 12.730 10.880 12.910 11.340 12.190 12.340 12.065 0.728 
        40 6.32 16.330 16.250 18.360 17.260 18.900 15.690 17.132 1.166 
        50 7.07 17.100 17.840 18.860 17.400 18.810 20.260 18.378 1.068 
        60 7.75 19.660 20.130 22.610 21.440 21.710 23.670 21.537 
         slope 3.409 3.533 3.686 3.699 3.780 3.851 3.660 
         R
2
 0.987 0.984 0.968 0.970 0.966 0.967 
          sd 0.743 0.902 1.088 1.286 1.636 0.792 
        
                 
                 Product 2 Time t1/2 Cumulative Release [mg] 
        [Minutes] [Minutes] Cell 1 Cell 2 Cell 3 Cell 4 Cell 5 Cell 6 Mean s.d. 
      OJSC 20 4.47 8.530 8.400 8.430 9.430 8.270 8.170 8.538 0.415 
      Ch: 891113 30 5.48 12.790 11.770 12.940 14.250 11.600 11.150 12.417 1.038 
        40 6.32 15.530 14.680 15.180 16.480 14.550 14.610 15.172 0.681 
        50 7.07 18.310 17.510 19.410 20.270 17.830 18.450 18.630 0.942 
        60 7.75 20.800 19.920 20.560 21.690 20.190 20.410 20.595 
         slope 3.699 3.614 3.672 3.697 3.683 3.727 3.682 
         R2 0.998 0.991 0.985 0.965 0.965 0.967 
          s.d. 0.281 0.346 0.616 0.267 0.572 0.351 
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Table 34  Example calculation spreadsheet for the statistical comparison of the intrinsic dissolution rates (part I) 
 
T/R ratios RS1 RS2 RS3 RS4 RS5 RS6 
          TS1 0.9216 0.9432 0.9283 0.9221 0.9257 0.9148 
          TS2 0.9550 0.9774 0.9620 0.9555 0.9592 0.9479 
          TS3 0.9965 1.0199 1.0038 0.9971 1.0010 0.9891 
          TS4 1.0001 1.0236 1.0074 1.0006 1.0045 0.9927 
          TS5 1.0218 1.0458 1.0292 1.0224 1.0263 1.0142 
          TS6 1.0411 1.0655 1.0487 1.0417 1.0457 1.0334 
          
                 Results: 
                
                 The eighth and twenty-ninth ordered individual ratios are the lower and upper limits of the  
       90% confidence interval for the ratio of the median in-vitro release rates (slopes) of test-  
        and reference products.  
            
                 8th T/R ratio = 
 
0.9549776 lower limit 
            29th T/R ratio = 
 
1.0263347 upper limit 
            
                 In terms of percentage. this corresponds to  95.50 to 102.63 % 
          
                 Because this 90% confidence interval falls/does not fall within the limits of 75% to 133.33% 
         
                 the test product has passed 
 
at Stage 1. 
             
                 Conclusion: 
                
                 Based on the above results the intrinsic dissolution rate of the Test product 1 
           is similar to the intrinsic dissolution rate of the Test product 2. 
           
                 Table 35 Example calculation spreadsheet for the statistical comparison of the intrinsic dissolution rates (part II) 
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particle size of the FA crystals. This indicates that the analytical procedure is capable of 
discriminating between batches which exhibit different release rates. Figure 65 shows 
the results of the in in-vitro diffusion test. A statistical analysis of the release rates of 
FA from each of the test batches of cream (Table 34) was performed using a non-
parametric confidence interval procedure related to the Mann-Whitney rank test 
29
. The 
release rates were not significantly different according to this test. 
The goal of the studies performed in this chapter was to investigate polymorphism in 
commercial sources of fusidic acid and to assess its effects on the stability of the bulk 
drug substance and its in-vitro release from the topical pharmaceutical dosage form 
developed in Chapter 5. The results indicate that there are at least two polymorphic 
forms of fusidic acid currently available on the commercial market. FTIR and XRPD 
experiments have confirmed that 2 of the 3 manufacturers which were investigated 
produce FA of form III, although manufacturer B does not appear to produce 
polymorphic pure product. FTIR analysis showed a band at ≈ 1720 cm-1, which is 
characteristic of either form I or II. The third manufacturer was found to produce FA of 
form I.  
 Under refrigerated, real-time and accelerated- stability conditions the API from 
all three sources was found to have a comparable stability when packaged under an 
atmosphere of nitrogen in an air-tight, light protective container. The stability of FA 
was found to be temperature dependent with the greatest stability being observed at 5 
°C ± 3 °C. Under stress conditions the API from manufacturer B (form III) was found to 
be significantly less stable than either of the other sources. This could possibly be due to 
the lack of polymorphic purity observed in samples from this manufacturer. This issue 
was, however, beyond the scope of the study and was not pursued further. 
The intrinsic dissolution rate of each of the drug substance samples was 
determined according to Ph. Eur. 2.9.29. Statistical analysis of the resulting dissolution 
data did not suggest a significant difference between the solubilities of each of 
measured samples. This was in agreement with previous literature studies. In order to 
demonstrate that polymorphic forms I and III show no significant difference with regard 
to their release rate from the drug product (which could lead to differences in the in-vivo 
bioavailability of the drug substance) their diffusion rates from the marketed topical 
product Fusicutan
®
 plus Betamethason (developed in Chapter 5) were analysed and 
found to be statistically comparable. The data indicates that polymorphic forms I and III 
 Discussion and conclusions 6.5
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have similar solubility properties and are therefore likely to demonstrate a similar in-
vivo bioavailability. Overall, it can be concluded that forms I and III can be used 
interchangeably in the drug product without affecting the safety or efficacy of that 
product. This means that each  of the manufacturers investigated in this study may be 
established as a second supplier, ensuring that the drug product can still be produced 
and marketed even if one of these suppliers ceases its production of FA over the coming 
years.   
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CHAPTER 7 
In-vitro-Release and Antimicrobial Efficacy Studies of  
Electrospun Poly(caprolactone) Membranes containing the Drug 
Substances Fusidic Acid and Betamethasone 17-valerate as well 
as the Novel Low Molecular Weight Gelator FMOC-OH-C18 
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 CHAPTER 7 – In-vitro Release Studies of Electrospun Fibers 7
As already discussed in Chapter 1, atopic dermatitis (also termed “atopic eczema”) is a 
complex genetic skin disorder linked to a defect in a gene known as FLG, which is 
responsible for the production of filaggrin, a dermal protein involved in maintaining 
intactness and structural stability of the skin-barrier 
1–3
. In diseased skin the absence of 
filaggrin can lead to barrier defects which expose the immune cells of the dermis to 
external antigens, resulting in an inflammatory response which is characterised by the 
typical atopic dermatitis related symptoms, such as itching and swelling. The first line 
of treatment for atopic dermatitis is topical therapy, including the application of 
emollients, keratolytics, topical vitamin D analogues as well as topical corticosteroids 
4–
6
. Due to the allergic component of the disease it is often advantageous to cover the 
affected area with a wet or dry dressing to avoid contamination by foreign antigens and 
microbes, which may exacerbate the symptoms or cause secondary infection 
7–9
. Such 
occlusive dressings also have the added advantage of not having to be applied several 
times daily, as with for example, a topical cream.  Additionally, a dressing may help to 
stop the wound from drying out, which is an important factor for successful healing 
10
. 
 
 Electrospinning for Biomedical Applications  7.1.1
In the past decade several studies have investigated the possibility of incorporating drug 
substances, such as antibiotics, into wound dressings 
11–14
. One of the most novel types 
of experimental dressing comprises of membranes manufactured from drug loaded 
ultra-thin fibers produced by electrospinning 
15,16
. Electrospinning is a simple and cost-
effective procedure involving application of a high voltage electric field to a drop of 
fluid, usually comprising of a mixture of a polymer such as Polylactide (PLA) or 
poly(caprolactone) (PCL, Figure 66) in a suitably volatile solvent. Application of the 
electric field causes the solution to become charged which in turn leads to droplet 
deformation (Taylor-cone formation). This results in the ejection of a charged jet from 
the tip of the cone which accelerates towards the counter electrode, leading to the 
formation of continuous fibers 
17,18
. A schematic of the electrospinning set-up used in 
the current study is presented in Figure 67.  
 Electrospun fibres have huge potential for use in biomedical applications, 
including tissue engineering and as bioresorbable wound dressings 
15–17,19,20
. One 
particularly interesting potential use of electrospun microfibers is in the topical- and 
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systemic delivery of drug substances. Electrospun fibres have a large surface area 
allowing for relatively high drug loading capacities and have the added advantage of 
 
 
Figure 66 Chemical structure of poly(caprolactone) 
 
 
being modifiable, i.e. fibre thickness, solubility and pore size may be modified allowing 
for a tailored release rate of the drug substance.  Examples of electrospun fibres as drug 
delivery systems include the incorporation of the antibiotic Gentamicin into polylactide-
based ultrathin fibres for the treatment of musculoskeletal infections 
21,22
; the 
manufacture of fusidic acid and rifampicin co-loaded PLGA nanofibers for the 
prevention of orthopaedic implant associated infections 
23
 as well the production of 
dexamethasone encapsulated coaxial electrospun PCL/Poly(ethylene oxide) hollow 
microfibers for inflammation regulation 
24
. 
 
Figure 67 Schematic of the electrospinning apparatus used in the current study 
 
 Aim 7.1.2
In this study the feasibility of incorporating the synthetic glucocorticoid BV and the 
antibiotic compound FA into electrospun PCL fibres as a potential topical therapy for 
infected atopic dermatitis will be investigated. The morphological, physicochemical, in-
vitro-release- and antimicrobial properties of the resulting electrospun fibres will be 
examined. Additionally, the influence of the incorporation of a novel gelator, Fmoc-
OH-C18 (General Procedures 
O
O
n
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Figure 68), on the morphology and manufacturability of the fibres, as well as on their 
drug release properties will be studied. Fmoc-OH-C18 is an N-Fmoc-L-serine lipoamino 
acid which can function as a low molecular weight gelator (LMWG), having the ability 
to form gels in a range of organic solvents of different polarity, including ethanol 
25
.  
 
Figure 68 Chemical structure of FMOC-OH-C18  
 
 Reagents 7.2.1
Fusidic acid and Betamethasone 17-valerate were both of Ph. Eur. Quality and 
purchased from Ercros SA (Madrid, Spain) and Crystal pharma (Valladolid, Spain), 
respectively. Fmoc-OH-C18 was synthesised according to the procedure of Ramos et al  
25
. Gradient grade methanol and acetonitrile as well as HPLC grade chloroform and 
ethanol were purchased from VWR International GmbH (Darmstadt, Germany) and 
Sigma Aldrich (Darmstadt, Germany). Purified water was obtained from the in-house 
purification system at mibe GmbH Arzneimittel (Brehna, Germany). Phosphoric acid 
(85 % m/m, analysis grade, d = 1.71 g/ml) was purchased from Merck (Darmstadt, 
Germany). Porafil
®
 membranes made from regenerated cellulose and having a porosity 
and diameter of 0.45 µm and 25 mm were purchased from Macherey-Nagel (Düren, 
Germany). Poly(caprolactone) (Mn 70.000 – 90.000) was purchased from Sigma-
Aldrich (Darmstadt, Germany). Electrospun fibers were manufactured according to the 
procedure described in section 2.6. 
 
 Instrumentation  7.2.2
Differential scanning calorimetry experiments were performed on a DSC Auto Q20 
from TA Instruments equipped with TA 40 Refrigerated Cooling System (TA 
Instruments, Delaware, USA). The evaluation of thermograms was performed using the 
TA Instruments Universal Analysis 2000 software. Samples were measured by 
O
O
NH
NH
OH
O
CH3
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equilibrating the sample for 5 minutes at 25 °C after which the temperature was ramped 
to 170 °C at 10 °C/Min. After holding at this temperature for 1 minute the sample was 
cooled to -30 °C at a rate of -35 °C/Min., held for 5 minutes at this temperature and then 
reheated to 250 °C at 10 °C/Min. Scanning electron micrographs were obtained using a 
Hitachi 3200N SEM instrument (Hitachi, Tokyo, Japan). In-vitro penetration studies as 
well as the associated HPLC measurements were performed according to the procedures 
described in section 2.4.  The samples used in the experiment were cut from the original 
membranes described in section 2.6.2. 
 
 
Figure 69 Example HPLC Chromatogram showing the BV and FA peaks 
 
 Morphology 7.3.1
Figure 71 shows the morphology of the respective electrospun fibres after single 
loading with 5 %, 10 %, 15 % and 20 % of each drug substance. The scanning electron 
micrographs show significant bead formation which may be dependent on drug loading, 
since bead formation appears to be more frequent at lower loading percentages. The 
formation of homogenous, bead-free fibres was not possible at any of the drug loading 
concentrations. The addition of 0.15 % of the gelator FMOC-OH-C18 had a profound 
effect on the morphology of the resulting fibres. Figure 72 shows release curves and 
SEM images which compare the fibre morphology of electrospun co-loaded membranes 
prepared both with- and without the gelator. In the absence of the gelator it is not 
possible to effectively spin the solution into acceptable fibres and massive bead 
formation occurs. The presence of the gelator in the initial mixture, in contrast, results 
Datafile Name:STD_MS_Fusi Plus_2_01.lcd
Sample Name:STD_MS_Fusi Plus_2_01
0,0 0,5 1,0 1,5 2,0 2,5 3,0 3,5 4,0 4,5 5,0 5,5 6,0 6,5 7,0 7,5 8,0 8,5 9,0 9,5 10,0 10,5 11,0 11,5 12,0 12,5 13,0 13,5 14,0 14,5 min
0
1
2
3
4
5
6
7
8
9
10
11
mV
Detector A 235nm 
B
e
ta
m
e
th
a
s
o
n
/3
,0
6
6
F
u
s
id
in
s
ä
u
r
e
/8
,0
9
2
 Results  7.3
  
164 
in morphologically homogenous fibres with a diameter of ca. 2 µm. No bead formation 
was observed.  
 DSC 7.3.2
All membranes displayed a melting peak at 58 °C which could be associated with the 
melting of PCL. After quench cooling and recrystallisation a doublet peak was observed 
for PCL at ca. 54 °C in all samples. There was no evidence of thermal events due to 
either of the drug substances. Due to the rapid loss of solvent during electrospinning the 
drug substances are unlikely to have time to crystallise and are most likely present in an 
amorphous state. The addition of the gelator had no effect on the appearance of the 
thermogram.  
 In-Vitro-Release – Membrane Permeation Study 7.3.3
The results of the membrane permeation study of mono drug-loaded membranes show a 
typical burst release of the drug substance over the first 30 minutes of the test (Figure 
71); followed by a tailing off over the remaining 150 minutes. After 180 minutes the 
drug substances are completely released from membranes with 5 % - 15 % drug 
loadings. The compositions of the different fibers are provided in Table 36. At 20 % 
drug loadings the drug substance was not completely released after 180 minutes and 
consequently, the measurement time was increased to 300 minutes with sampling 
intervals of 60 minutes for all subsequent studies. As demonstrated by Figure 72 the 
addition of the Fmoc gelator to co-loaded fibres does not significantly affect the release 
rates of either of the drug substances. These fibres also show typical release profiles 
with an initial burst followed by a slow tailing off. Both drug substances are completely 
released after 300 minutes. 
 
Figure 70 In-vitro membrane diffusion apparatus (a), Single Franz-Cell set-up (b) and membranes 
after analysis (c) 
 
 
 
In-vitro Diffusion Apparatus 
(c) (b) 
(a) 
PCL Membranes after Analysis Franz-Cell 
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Table 36 Composition of the electrospun membranes employed in the in-vitro  release test 
 
Label Concentration of FA 
in polymer solution  
Composition Label Concentration of BV 
in polymer solution  
Composition 
A 5 % (w/w) 50 mg FA 
dissolved in 2 ml 
Ethanol + 2 ml of 
PCL solution 
comprising of  1 g 
PCL + 7.5 ml 
CHCl3 + 2.5 ml 
Ethanol 
E  5 % (w/w) 50 mg  BV 
dissolved in 2 ml 
Ethanol + 2 ml of 
PCL solution 
comprising of  1 g 
PCL + 7.5 ml 
CHCl3 + 2.5 ml 
Ethanol 
B 10 % (w/w) 100 mg FA 
dissolved in 2 ml 
Ethanol + 2 ml of 
PCL solution 
comprising of  1 g 
PCL + 7.5 ml 
CHCl3 + 2.5 ml 
Ethanol 
F 10 % (w/w) 100 mg BV 
dissolved in 2 ml 
Ethanol + 2 ml of 
PCL solution 
comprising of  1 g 
PCL + 7.5 ml 
CHCl3 + 2.5 ml 
Ethanol 
C 15 % (w/w) 150 mg FA 
dissolved in 2 ml 
Ethanol + 2 ml of 
PCL solution 
comprising of  1 g 
PCL + 7.5 ml 
CHCl3 + 2.5 ml 
Ethanol 
G 15 % (w/w) 150 mg BV 
dissolved in 2 ml 
Ethanol + 2 ml of 
PCL solution 
comprising of  1 g 
PCL + 7.5 ml 
CHCl3 + 2.5 ml 
Ethanol 
D 20 % (w/w) 200 mg FA 
dissolved in 2 ml 
Ethanol + 2 ml of 
PCL solution 
comprising of  1 g 
PCL + 7.5 ml 
CHCl3 + 2.5 ml 
Ethanol 
H 20 % (w/w) 200 mg BV 
dissolved in 2 ml 
Ethanol + 2 ml of 
PCL solution 
comprising of  1 g 
PCL + 7.5 ml 
CHCl3 + 2.5 ml 
Ethanol 
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Figure 71 Release profiles and scanning electron micrographs of electrospun fibres with 5 %, 10 %, 15 % and 20 % loadings of 
FA (a-d) and BV (e-h). The displayed results are the average of n=6 measurements 
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.  
 
 
 
 In-Vitro Release – Agar Diffusion Test 7.3.3.1
The pieces of electrospun membranes containing FA (B, C and D in Figure 73) show 
clear inhibition zones around them, whereas the control samples do not (A, E and F). 
The diameters of the observed inhibition zones (Hemmhof) are provided in Table 38. 
The size of the inhibition zones observed for the electrospun fibers B, C and D do not 
differ visually from each other, which suggests a similar antibacterial activity. 
Additionally, the size of the inhibition zone of sample D does not differ from that of 
sample C, indicating that the presence of the Fmoc gelator does not affect the release of 
FA from the electrospun membrane. This confirms the results of the in-vitro permeation 
study which also showed a similar release rate for membranes with and without the 
gelator. The results demonstrate that the bioactivities of electrospun fibres containing 
FA are similar to those observed for solutions with an equivalent concentration of pure 
FA. This can be observed by comparing the plates P1 and P2 with plate P3 in Figure 73. 
Figure 72 Comparison of drug release profiles of FA (panel A) and BV (panel C) with and 
without the addition of FMOC-OH-C18. Micrographs B and D show the morphology of fibres 
manufactured with (D) and without (B) the Fmoc gelator. The compositions of the respective fibers 
are equivalent to Product C and D in Table 37. The displayed results are an average of n=6 
measurements 
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Overall, the results indicate that fusidic acid is released from the electrospun 
membranes at a sufficient rate and to a sufficient extent as to ensure an adequate 
antibacterial activity. 
 
Table 37 Composition of the electrospun membranes employed in the agar diffusion test 
 
Quantity of FA (µg) in the portion of 
membrane used for the experiment 
 
Composition of polymer solution used for electrospinning 
Control A 
Quantity of Fusidic acid: 0 µg 
 (CONTROL 1) 
1.5 mg Fmoc-OH-C18 + 1 ml Ethanol + 2 ml PCL Solution (1 g PCL 
+ 7.5 ml chloroform + 2.5 ml Ethanol) 
 
Product B 
Quantity of Fusidic acid = ca. 230 µg 
10 % FA (100 mg in 1 ml chloroform) 
0.60 % BV (6 mg BV in 1 ml chloroform) 
89.4 % PCL solution (8 ml of PCL solution made with 1 g of PCL, 
7.5 ml chloroform, 2.5 ml ethanol) 
 
Product C 
Quantity of Fusidic acid = ca. 450 µg 
20 % FA (200 mg in 1 ml chloroform) 
1.21 % BV (12.1 mg BV in 1 ml chloroform) 
78.79 % PCL solution (8 ml of PCL solution made with 1 g of PCL, 
7.5 ml chloroform, 2.5 ml ethanol) 
 
Product D 
Quantity of Fusidic acid = ca. 380 µg 
20 % FA (200 mg in 1 ml chloroform) 
1.21 % BV (12.1 mg BV in 1 ml chloroform) 
0.15 % JRO gelator 4 (1.5 mg Fmoc-OH-C18) in 1 ml Ethanol) 
78.64 % PCL solution (8 ml of PCL solution made with 1 g of PCL, 
7.5 ml chloroform, 2.5 ml Ethanol) 
 
Control E  
Quantity of Fusidic acid: 0 µg 
(CONTROL 2) 
PCL solution (99.85 %) and JRO gelator 4 (0.125 % Fmoc-OH-C18) 
 
 
 
Table 38 Results of the Agar Diffusion Test showing the diameter of the resulting inhibition zone 
(Hemmhof) in mm for each sample 
 
Sample  
Name 
Hemmhof 
[mm] 
Comparable 
with sample 
Hemmhof 
[mm] 
Sample 
Name 
Hemmhof 
[mm] 
Comparable 
with sample 
Hemmhof 
[mm] 
G 26.17 B 28.88 K 22.33 B 28.88 
H 27.75 D 30.02 L 23.72 D 30.02 
I 29.20 C 31.87 M 24.32 C 31.87 
        
    N 14.90 < B 28.88 
    O 19.79 < D 30.02 
    P 23.36 < C 31.87 
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A Control – Membrane with Fmoc-OH-C18/ without FA D 
PCL Membrane with BV/with Fmoc-OH-C18/          
equivalent to 380 µg FA 
K 50 µl FA solution equivalent to 200 µg FA 
B 
PCL Membrane with BV/without Fmoc-OH-C18/ 
equivalent to 230 µg FA 
E Control – Membrane with Fmoc-OH-C18/ without FA L 50 µl FA solution equivalent to 350 µg FA 
C 
PCL Membrane with BV/without Fmoc-OH-C18/ 
equivalent to 450 µg FA 
F Blank – Filterpaper without FA M 50 µl FA solution equivalent to 450 µg FA 
F Blank – Filterpaper without FA G 
Filter paper immersed in FA solution / equivalent to 
200 µg FA 
N 50 µl FA solution equivalent to 0.25 µg FA 
G 
Filter paper immersed in 25 µl FA solution / equivalent 
to 200 µg FA 
H 
Filter paper immersed in FA solution / equivalent to 
350 µg FA  
O 50 µl FA solution equivalent to 2.5 µg FA 
H 
Filter paper immersed in 25 µl FA solution / equivalent 
to 350 µg FA  
I 
Filter paper immersed in FA solution / equivalent to 
450 µg FA 
P 50 µl FA solution equivalent to 25 µg FA 
I 
Filter paper immersed in 25 µl FA solution / equivalent 
to 450 µg FA 
Q Control – Filter paper with buffer pH 6.0 / without FA R Control – buffer pH 6.0 / without FA 
 
Figure 73 Demonstration of the bioactivity of FA released from the drug-loaded electrospun membranes against on example strain b - 
Staphylococcus aureus ATCC 6538 
 
P1 P2 P3 
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 Figure 74   Plot of the log reduction of the bacterial count versus time – Method A. Sample 
descriptions are provided in 2.7 
 
Figure 75 Plot of the log reduction of the bacterial count versus time – Method B. Sample 
descriptions are provided in 2.7 
 
 Antimicrobial Efficacy 7.3.3.2
At clinically relevant concentrations fusidic acid works primarily as a bacteriostatic 
agent, i.e. it prevents growth but doesn’t directly kill the bacteria. However, at higher 
concentrations it may also work bactericidal. The agar diffusion test provides useful 
information about the release rate and inhibitory action of an antibiotic but it doesn’t 
allow any conclusion to be drawn about the mode of inhibition. As described in section 
2.7.1, two methods (A & B) were used to evaluate the antimicrobial efficacy. The 
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results of both methods show a drop of bacterial count of approximately 1 decimal log 
reduction. This indicates that FA is functioning predominantly bacteriostatically, and 
not bactericidal, at the investigated concentration. In order to be considered to have a 
bactericidal effect, FA would have to demonstrate a minimum of 3 decimal log 
reductions over 2 days (Ph. Eur. 5.1.3 cutaneous use), which is equivalent to an 
approximate 100 times greater efficacy than observed. The blank (parafilm) and control 
samples also showed a log reduction of the bacterial count which was comparable to 
that observed for the membranes which contained FA. It might be expected that the 
bacterial count in these samples should have increased as compared to the membranes 
containing FA. The lack of bacterial growth in these samples may possibly be attributed 
to innate antimicrobial attributes of parafilm and polycaprolactone filaments or due to a 
disturbance of the micro environment required for the bacteria to propagate. This 
phenomenon would need to be investigated in further experiments.  
 
The aim of the work in this chapter was to investigate the feasibility of incorporating the 
antibiotic FA and the glucocorticoid BV into electrospun fibres for use as an occlusive 
bandage in the treatment of infected atopic dermatitis. It has been demonstrated that it is 
possible to produce electrospun fibers loaded with clinically relevant concentrations of 
both drug substances. Membranes were produced containing 20 % (w/w) and 1.21 % 
(w/w) of FA and BV, respectively. The effects of the addition of the novel gelator   
Fmoc-OH-C18 on morphology, manufacturability, in-vitro release and antimicrobial 
efficacy of the resulting fibers have been investigated. In-vitro membrane permeation 
studies have demonstrated that both drug substances are released in a rapid initial burst 
and that the addition of the gelator does not significantly influence the drug release rate. 
It has been shown that the addition of the Fmoc gelator has a profound effect of the 
morphology of the resulting fibers. Massive bead formation was observed in the 
absence of the gelator. It is considered possible that the gelator induces a change of the 
viscosity and/or surface tension of the polymer solution which in turn affects its 
spinability. This phenomenon has been described in the literature 
39
. This would suggest 
that a critical surface tension is required in order for fibers to be drawn from the 
solution.  This hypothesis would need to be tested further. Antimicrobial efficacy 
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studies have demonstrated that FA is released adequately from the electrospun fibers 
and that the resulting membranes have an efficacy against the chosen test organisms 
similar to that of a solution of equal concentration of the pure substance.                                             
 Based on the initial experimental results it appears plausible that a drug loaded 
bandage containing FA and BV for the treatment of atopic dermatitis could be 
manufactured by electrospinning. Significant further development work is however 
needed before a proper conclusion can be drawn. The work in these studies only 
investigated the in-vitro efficacy of the antibiotic in the fibres, but did not address the 
efficacy of the glucocorticoid. Although the in-vitro membrane permeation studies 
indicate a good release of BV, further tests would be necessary. It would need to be 
shown, in an animal model for example, that the quantity of steroid released is sufficient 
to give rise to the desired anti-inflammatory response. This could be performed using a 
suitably designed vasoconstriction assay. Furthermore, the effects of manufacturing 
variables, e.g. voltage, needle gauge size, solution flow rate, solution viscosity, surface 
tension, etc. on the morphology and drug release rates of spun fibers needs to be 
thoroughly investigated, so that the process is completely characterised. Only then 
would it be possible to conclude whether the process is reproducible, i.e. whether fibers 
with a consistent drug content, fibre thickness, etc., can be produced which also release 
the drug substances at a suitable and reproducible rate. In summary, the process would 
need to be fully understood and validated before pre-clinical trials could be considered. 
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The aim of the research performed in this thesis was initially described at the end of 
chapter 1. The first goal was to develop and validate analytical procedures to enable the 
stability-indicating analysis of the drug substances and preservatives of interest in 
formulation candidates.  Novel procedures for the analysis of both content and purity 
were developed and their validity and suitability for the analyses of BV, FA and 
respective preservatives in cream matrices has been demonstrated. 
 As planned, the developed procedures were employed to study formulation 
factors affecting the isomerisation of betamethasone 17-valerate in semi-solid 
pharmaceutical formulations. It has been demonstrated that both pH and emulsifier 
concentration are critical with regard to this process. With the help of both microscopy 
and HPLC experiments it was possible to show that increasing the concentration of 
emulsifier leads to an increase of the solubility of BV in the aqueous phase of the oil-in-
water cream. It was shown that after dissolution the rate of isomerisation is then 
dependent on the pH of the surrounding matrix. If the pH is low (< 5) then a lower rate 
of isomerisation is observed than if the pH were higher (>5). It could be shown that the 
rate of isomerisation can be kept to a minimum by optimising both pH and emulsifier 
conditions. Maximum stability can be obtained at pH values below 4 and emulsifier 
concentrations below 1.5 % (w/w). The data gathered through these studies was used to 
develop a stable cream product which began being marketed in early 2017. 
 A further goal of the work in this thesis was to investigate the prevalence of 
polymorphism in commercial sources of FA and to compare the solubilities- and in-vitro 
release rates of any polymorphs observed. This was necessary since the existence of 
polymorphism may affect the bioavailability of a drug substance from a drug product 
due to solubility differences between different polymorphic forms. It was demonstrated 
that Form I and Form III are currently available on the commercial market. 
Measurements of the intrinsic dissolution rates of both forms indicated that they have 
comparable solubilities. In-vitro membrane permeation studies indicate that both 
polymorphic forms demonstrate a similar bioavailability from the developed topical 
cream. It could be concluded that both polymorphic forms are bioequivalent and can be 
used in semi-solid pharmaceutical preparations. 
 The final aspect of this research involved investigating the plausibility of 
incorporating BV and FA into electrospun poly(caprolactone) fibers for use as an 
 General Conclusions 8
  
177 
occlusive bandage for the treatment of infected atopic dermatitis. The study results 
suggest that both drug substances can be incorporated into electrospun fibers in a 
clinically relevant concentration and that the use of a medicated occlusive bandage 
could present an alternative to current topical treatments. In-vitro release studies have 
indicated that both BV and FA are released in a short initial burst followed by a longer 
tailing off phase. It has been demonstrate through agar-diffusion testing that the 
antibiotic activity of FA released from the electrospun membranes is equivalent to a 
similar concentration of the pure substance, indicating that FA is released at a sufficient 
rate from the fibers as to ensure an effective antibacterial activity. Based on the initial 
experimental results it appears plausible that a drug loaded bandage containing FA and 
BV for the treatment of atopic dermatitis could be manufactured by electrospinning. As 
described in Chapter 7, significant further development work is needed before a proper 
conclusion can be drawn.  
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